

Coinfection dynamics of experimentally challenged channel catfish (*Ictalurus punctatus*)

by

Allison Lauren Wise

A thesis submitted to the Graduate Faculty of
Auburn University
in partial fulfillment of the
requirements for the Degree of
Master of Science

Auburn, Alabama

May 6, 2023

Polymicrobial, aquaculture, channel catfish, *Flavobacterium covae*, *Edwardsiella ictaluri*, virulent *Aeromonas hydrophila*

Copyright 2023 by Allison Lauren Wise

Approved by

Timothy J. Bruce, Chair, Assistant Professor, School of Fisheries, Aquaculture and
Aquatic Sciences

Benjamin R. LaFrentz, Research Scientist, USDA-ARS Aquatic Animal Health
Research Unit

Anita M. Kelly, Extension Professor, School of Fisheries, Aquaculture, and Aquatic
Sciences

Mark R. Liles, Professor, Department of Biological Sciences

Abstract

Catfish farming is the largest sector of the U.S. aquaculture industry and is of paramount economic importance for Southern U.S. agriculture. Maintaining and improving catfish health is a primary concern for producers, and bacterial pathogens can cause large-scale losses in production ponds. *Edwardsiella ictaluri*, *Aeromonas hydrophila*, and *Flavobacterium columnare* are the most predominant bacterial pathogens causing mortality within catfish production facilities. Interestingly, disease outbreaks resulting in high mortalities may also be coupled with multiple pathogens. Bacterial coinfections may often go unreported or misdiagnosed, resulting in a lack of proper mitigation for the coinfective effectors. Bacterial coinfections may increase the severity of the constituent pathogens along with grossly increasing mortality, thus creating economic losses. To assess and characterize the effects of bacterial coinfections, two pathogen challenge trials were conducted to compare in vivo virulence and fish immune responses resulting from exposure to single and coinfective bacteria. Trial results emphasize the importance of evaluating coinfections and demonstrate dramatic increases in mortality when two pathogens are combined, even at half-doses. The synthesis of these mortality and health metrics will aid fish health diagnosticians and channel catfish producers in developing therapeutants and prevention methods to control bacterial co-infections better.

Acknowledgments

I would like to thank Guillaume Cacot, Courtney Harrison, Crystal Lodi, Abdulmalik Oladipupo, Uthpala Padeniya, and James Tuttle for trial support with the in vivo experiments. I would also like to thank Dr. Lester Khoo and Tingbi Xu for their contributions to the literature review of bacterial coinfections in catfish. I am also thankful for the guidance from Dr. Matt Griffin on aspects of the experimental methodology. Additionally, I thank my committee for their advice and contributions to my projects. Lastly, I thank those who helped support my research at the E.W. Shell Research Station, School of Fisheries, Aquaculture, and Aquatic Sciences, at Auburn University.

Table of Contents

| | |
|---|----|
| Abstract..... | 2 |
| Acknowledgments | 3 |
| List of Tables | 10 |
| List of Figures | 11 |
| List of Abbreviations | 17 |
| Chapter 1: A Review of Bacterial Coinfections in Farmed Catfish: Components, Diagnostics, and Treatment Directions List of Abbreviations..... | 18 |
| 1.1 Abstract | 19 |
| 1.2 Catfish culture in the southern United States | 20 |
| 1.3 Bacterial pathogens commonly observed in catfish culture | 22 |
| 1.4 Bacterial coinfections..... | 34 |
| 1.5 Diagnostic summary of recent bacterial coinfections in Alabama and Mississippi | 40 |
| 1.6 Future directions for bacterial coinfection mitigation and research | 42 |
| 1.7 References | 48 |
| Chapter 2: Infection Dynamics of Experimental <i>Edwardsiella ictaluri</i> and <i>Flavobacterium covae</i> Coinfection in Channel Catfish (<i>Ictalurus punctatus</i>) | 60 |
| 2.1 Abstract | 61 |
| 2.2 Introduction | 62 |
| 2.3 Materials and Methods | 65 |

| | |
|--|-----|
| 2.4 Results | 72 |
| 2.5 Discussion | 76 |
| 2.6 References | 81 |
| Chapter 3: Coinfection of Channel Catfish (<i>Ictalurus punctatus</i>) with Virulent | |
| <i>Aeromonas hydrophila</i> and <i>Flavobacterium covae</i> exacerbates mortality | |
| 3.1 Abstract | 94 |
| 3.2 Introduction | 95 |
| 3.3 Materials and Methods | 98 |
| 3.4 Results | 106 |
| 3.5 Discussion | 109 |
| 3.6 References | 114 |
| Chapter 4: Future Coinfection Research in Catfish | |
| 4.1 Future Research | 162 |
| 4.2 Conclusion | 162 |

List of Tables

Table 1 (Mississippi State University - College of Veterinary Medicine Aquatic
Research & Diagnostic Laboratory - Stoneville, MS Polymicrobial Cases from 2016-
2020 Disease Diagnosis as a Percentage of Total Case Submissions) 45

Table 2 (Alabama Fish Farming Center Polymicrobial Cases from 2016-2020 Disease
Diagnosis as a Percentage of Total Case Submissions)..... 46

Table 3 (Description of treatment groups, including which bacterium was
administered, volume, and final dose for challenged channel catfish.) 121

List of Figures

- Figure 1: Cumulative percent mortality due to single infections of *E. ictaluri* and *F. covae* and coinfections from both pathogens over the entirety of the trial (21 days). Each treatment group had three tanks (n=3). Bars represent the standard error of the mean for each day. 88
- Figure 2: Images depict catfish with clinical signs due to (A) co-infection with *E. ictaluri* first, then *F. covae* 48 h post-initial inoculation, exhibiting both saddleback lesions, discoloration, and external hemorrhaging (B) infection only with *E. ictaluri*, exhibiting ocular and fin hemorrhaging and exophthalmia. 88
- Figure 3: Images depict catfish with clinical signs due to (A) co-infection with *F. covae* first, then *E. ictaluri* 48 h post-initial inoculation, or (B) infection only with *F. covae*. 89
- Figure 4: Cumulative percent mortality from Trial B due to single infections of *E. ictaluri* or *F. covae* and co-infections from both pathogens over the entirety of the trial (11 days). Each treatment group had three tanks (n=3). Bars represent the standard error of the mean for each day..... 89
- Figure 5: Lysozyme activity ($\mu\text{g mL}^{-1}$) in sera from sampled fish at 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in activity between treatment time periods, and lowercase letters represent significance within treatment groups. Error bars represent the standard error of the mean for each treatment group. 90

Figure 6: Lysozyme activity ($\mu\text{g mL}^{-1}$) in sera from sampled fish at 21 days post-challenge. Each treatment group was conducted in triplicate (n=3). Error bars represent the standard error of the mean for each treatment group. 90

Figure 7: *il8* expression (fold-change) was evaluated from extracted anterior kidneys 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Error bars represent the standard error of the mean for each treatment. 91

Figure 8: *il1 β* expression (fold-change) was evaluated from extracted anterior kidneys during 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment. 91

Figure 9: *tnfa* expression (fold-change) was evaluated at 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment. 92

Figure 10: *tgfb-1* expression (fold-change) was evaluated from extracted anterior kidneys during 2, 4, and 7 days post-challenge. Each treatment group was assessed in triplicate (n=3). Bars represent the standard error of the mean for each treatment. 92

Figure 11: Graphic depicting experimental design to assess full and half doses of both single and coinfective treatment groups 122

Figure 12: Cumulative percent mortality due to single infections of virulent *Aeromonas hydrophila* and *Flavobacterium covae* and coinfections from both pathogens throughout the trial (96 h). Each treatment group had three tanks (n=3). Bars represent the standard error of the mean for each day 123

Figure 13: Lysozyme activity (mg mL⁻¹) in sera from sampled fish at 6, 12, 24, 48, and 96 hours post-challenge. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in activity between treatment time periods (6, 12, 24, 48, 96 hpc), and lowercase letters represent significance within treatment groups. Coinfected groups at 48 and 96 hpc are not included due to no surviving fish. Error bars represent the standard error of the mean for each treatment group 123

Figure 14: *illb* expression (fold-change) was quantified from RNA extractions of anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment 124

Figure 15: *il8* expression (fold-change) was quantified from RNA extractions of anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between

| | |
|--|-----|
| treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment | 125 |
| Figure 16: <i>mfa</i> expression (fold-change) was quantified from RNA from anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment | 126 |
| Figure 17: <i>tgfb</i> expression (fold-change) was quantified from RNA from anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment | 127 |
| Figure 18: Images document catfish with clinical signs due to singly infected vAh: ocular hemorrhaging and hemorrhaging of all fins (A) and <i>F. covae</i> ; skin discoloration, frayed fins, and damaged operculum (B) | 128 |
| Figure 19: Images documenting catfish with clinical signs due to coinfection with <i>F. covae</i> and vAh during early-stage infection (12 hpc). Image (A) depicts discoloration of deceased fish (saddleback lesion), and (B) depicts mild and external hemorrhaging in fins and operculum..... | 129 |
| Figure 20: Images documenting catfish with clinical signs due to coinfection with <i>F. covae</i> and vAh during later-stage infection (36 hpc)..... | 130 |

Figure 21: The bacterial load (log copy number) of treatment groups challenged with *F. covae* (ALG-00-530) and vAh (ML09-119). The log of the copy number corresponds to 5 ng of input DNA for each sample. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment 131

List of Abbreviations

| | |
|------|--|
| BHIA | Brain heart infusion agar |
| BHIB | Brain heart infusion broth |
| cDNA | Complementary deoxyribose nucleic acid |
| CPM | Cumulative percent mortality |
| DNA | Deoxyribonucleic acid |
| DPC | Days post challenge |
| HPC | Hours post challenge |
| ESC | Enteric septicemia in catfish |
| MAS | Motile <i>Aeromonas</i> septicemia |
| MSA | Modified Sheih agar |
| MSB | Modified Sheih broth |
| PCR | Polymerase chain reaction |
| qPCR | Quantitative polymerase chain reaction |
| RNA | Ribonucleic acid |
| RPM | Revolutions per minute |
| TSA | Tryptic soy agar |
| TSB | Tryptic soy broth |
| US | United States |
| vAh | Virulent <i>Aeromonas hydrophila</i> |

Chapter 1:

Literature Review

This manuscript has been published:

Wise, A.L.; LaFrentz, B.R.; Kelly, A.M.; Khoo, L.H.; Xu, T.; Liles, M.R.; Bruce, T.J.
A Review of Bacterial Co-Infections in Farmed Catfish: Components,
Diagnostics, and Treatment Directions. *Animals* **2021**, *11*, 3240,
doi:10.3390/ani11113240.

1.1 Abstract

Catfish production is a major aquaculture industry in the United States and is the largest sector of foodfish production. As producers aim to optimize production yields, diseases caused by bacterial pathogens are responsible for high pond mortality rates and economic losses. The major bacterial pathogens responsible are *Edwardsiella ictaluri*, *Aeromonas* spp., and *Flavobacterium columnare*. Given the outdoor pond culture environments and ubiquitous nature of these aquatic pathogens, there have been many recent reports of co-infective bacterial infections within this aquaculture sector. Co-infections may be responsible for altering disease infection mechanics, increasing mortality rates, and creating difficulties for disease management plans. Further, proper diagnoses of primary and secondary pathogens are essential in ensuring the correct treatment approaches for both antimicrobials and chemical applications. A thorough understanding of the interactions and infectivity dynamics for these warmwater bacterial pathogens will allow for the adoption of new prevention and control methods. This review aims to provide an overview of co-infective pathogens in catfish culture, along with present diagnostic case data from both Mississippi and Alabama to better define prevalence for these multiple-species infections.

1.2 Catfish culture in the southern United States

Aquaculture provides safe and sustainable fish crop for consumers, supplying approximately 490,041 tonnes of total aquaculture production per year in the United States. Of this total, 65 percent of production originates from finfish alone. Most common production species include catfish, trout, salmon, and tilapia [1]. Catfish farming is the largest aquaculture industry within the United States, producing half a billion dollars per year. Nearly, 300 million pounds of channel and hybrid catfish are produced annually, making it substantially larger than any other aquaculture industry. Production of freshwater catfish is dominated by the southeastern region of the United States. Top regions of production include Mississippi, Alabama, and Arkansas [2]. The Mississippi Delta's economy relies heavily on the revenue generated through the catfish industry and Mississippi's catfish industry produced \$223,972,000 in annual sales with Alabama producing \$98,763,000.

Catfish typically inhabit freshwater streams but are also found in brackish muddy waters, lakes, and ponds, which allows for them to be relatively tolerant to culture in the Southern United States. The optimal growth temperature for channel catfish is around 29.4°C and environmental temperatures can dictate appetite (increased temperatures lead to increased feed consumption to a limit, which in turn may influence growth mechanics). Freshwater catfish are primarily produced in ponds dug into the earth and the pond types often include levees and/or watershed designs [3].

Catfish culture systems differ between the two major catfish producing states in the U.S., with Alabama having mainly watershed ponds, while Mississippi has levee ponds or split-pond production systems with groundwater wells used to fill ponds. Initially, eggs are transferred to hatchery troughs following spawning. When eggs hatch, the fry are transported and placed into production ponds where they grow to fingerling sizes. Fingerlings are then subjected to grow-out and are harvested once a marketable weight (approximately 1½ lbs) is reached [4].

Though channel catfish are the most common catfish produced in the USA, production of hybrid catfish has been increased by producers due to higher survival rates, crop yields, resistance to certain pathogens, and health benefits [5,6]. Hybrids are produced by artificially breeding female channel catfish (*Ictalurus punctatus*) with male blue catfish (*Ictalurus furcatus*). Female channel catfish are injected with hormones to prompt ovulation and sperm is removed from male blue catfish and used to fertilize eggs. Inconsistent egg quality and poor hatchery conditions increase the difficulty of hybrid production and hybrid fry production costs [5]. However, genetic advances have been made resulting in the increased efficiency of hybrid fry production. Though hybrid catfish have presented traits of increased resistance to pathogens compared to channel catfish disease is still a concern for both [7]. Methods for controlling diseases have included, medicated feed, improved water quality, vaccines and genetic improvement [7]. For both channel and hybrid catfish, disease is a primary concern for farmers leading to further investigation into disease pathogens

and co-infections in order to mitigate the proper disease management and treatment practices. As such, an understanding of the primary disease mechanisms for common bacterial pathogens in catfish culture is essential to being able to discern dynamics related to bacterial co-infections.

1.3 Bacterial pathogens commonly observed in catfish culture

Due to the economic impact of the catfish industry in the southeastern United States, maintaining catfish health is the primary concern for most farmers. Overcrowding and elevated temperatures facilitate disease within the hatcheries and ponds, and results in high mortality rates along with profit declines due to mortalities as well as costs associated with treatment. The majority of disease-related deaths in the catfish industry originate from bacterial diseases. The most prominent being *Edwardsiella ictaluri*, *Flavobacterium columnare*, and *Aeromonas hydrophila* in channel catfish; 78.1% of production operations and 42.1% of ponds experience outbreaks of ESC and columnaris [8]. Each pathogen is responsible for causing substantial catfish mortalities and creating interruptions to production due to lost feeding time (growth) and mitigation with chemical or antibiotic treatment means (economic expenses). Extensive efforts from researchers have been devoted to the development of vaccines and other methods to reduce the losses caused by bacterial infections.

Losses mentioned due to each pathogen have been during single infections. Though often unreported, co-infections amongst these pathogens have increased mortality and created drastic economic losses. Within this sector, the mechanics and prevalence of these bacterial co-infections remain poorly documented. In order to properly diagnose and investigate co-infective factors involving these primary bacterial pathogens, it is important to comprehend disease etiology and current treatment options available. Improvements in treatment methods against single pathogen infections have increased over the years, yet many treatment effects have not been tested during mixed infections.

Edwardsiella ictaluri

Edwardsiella ictaluri is the causative pathogen of enteric septicemia (ESC) which is an extremely fatal disease. Approximately \$60 million dollars have been attributed to losses due to ESC [9] and up to 47 percent of cases each year are from ESC [10].

Edwardsiella ictaluri enters through the gut and passes from the stomach into the intestine. While passing through the epithelial barriers, propria macrophages engulf *E. ictaluri*. Typically, macrophages aid the host in resisting the pathogen, yet *E. ictaluri* has been observed within macrophage vacuoles, leading to the finding that it can survive within the macrophage and spread through the bloodstream [9]. Once in the bloodstream, the pathogen moves to the kidneys [10]. Clinical signs of ESC include petechial hemorrhaging around pectoral fins and belly, white pustules in the liver,

exophthalmia, distended abdomen related to ascites fluid, and cranial ulcerations. Fish can be seen swimming in spiral motions along with swimming at the surface due to a systemic infection and inflammation of the brain. Pathogen diagnosis includes isolating *E. ictaluri* from internal organs, kidney, or spleen, on tryptic soy agar with sheep blood. [10]. Environmental elements are key in facilitating infection.

Outbreaks are typically associated with prominent levels of stress, due to handling and confinement, and temperature. For infection to occur, the temperature must be within 22 °C- 28 °C range . Transmission takes place once an infected fish sheds the pathogen, thus allowing surrounding fish to ingest *E. ictaluri* [10]. This disease can manifest in catfish of varying size and age class, including fish that are of market size [9]. Although all ages of catfish can experience ESC, channel catfish fingerlings are most susceptible. Altogether, post-hatch losses due to disease typically arise from enteric septicemia [11]. ESC survivors possess immunity to the disease, rendering older catfish more resistant to reinfection. In addition to *E. ictaluri* infections in catfish, other related and pathogenic *Edwardsiella* spp. are also routinely isolated from catfish ponds, including *E. tarda* [12] and *E. piscicida* [13].

The management strategy and treatment for ESC often calls for feed medicated with antibiotics, including: sulfadimethoxine-orometoprim, and florfenicol. There are several limitations when using medicated feed to treat. Medicated feed is expensive and sick fish often refuse feed, thus rendering treatment ineffective [11]. Other methods include restricting feed to the catfish while temperatures are within ESC's

optimal growth range. However, this method also has some limitations. Though it slows the spread, it can reduce growth of catfish during production [11]. Early diagnosis of ESC is vital in order to treat infections appropriately and effectively. Recently, several investigations have aimed to discern mechanisms of virulence for *E. ictaluri*. Abdelhamed et al. (2017) identified the TonB transducing system as a virulence factor that is intertwined with ESC pathogenesis [14]. The role of lipopolysaccharides (LPS) in *E. ictaluri* virulence has also been investigated, with selected mutations related to LPS biosynthesis resulting in such modifications as altered biofilm formation abilities and motility [15]. An understanding of these virulence factors is of great importance for understanding the associated pathogenesis of ESC, and recently [16] identified differences in plasmids and virulence factors in *E. ictaluri* isolates from various fish species. Thus, the infectivity of *E. ictaluri* still remains a topic of research interest to more thoroughly define mechanisms of entry and host-pathogen interactions.

The development and introduction of ESC vaccines has been proven to decrease infection rates, but it does not eliminate threats of infection. Typically, ESC vaccines have been administered through immersion baths on catfish fry [11]. However, this method may not be the most effective as fry may not be immunocompetent. It has been documented that immunoglobulin responses cannot appear in channel catfish until 3 to 4 weeks post hatch [17]. Therefore, fingerling vaccination is likely the most

effective method. For catfish aquaculture, there are limited opportunities to vaccinate fingerlings using immersion delivery, therefore, effective oral vaccines are preferred.

Live *E. ictaluri* vaccines have received considerable attention due to the lack of immune response elicited from bacterin vaccines. Live vaccines have the ability to generate a multitude of immune responses, thus allowing higher protective abilities than the killed vaccines [18]. A live-attenuated oral vaccine has been developed to combat the pathogen. The vaccine strain (S97-773-340X2) was attenuated by passage on medium containing increasing concentrations of rifampicin, a method previously reported by Klesius and Shoemaker (1999) [19]. The effectiveness of the live-attenuated ESC vaccine was tested through the use of laboratory and experimental pond trials [20] and the results demonstrated significant increases in fingerling survival [21]. Commercial feed was diluted with the 340X attenuated isolate and administered to fingerling catfish orally [22]. Increased feed consumption of vaccinated fingerlings was documented along with a decrease in mortality due to disease compared to nonvaccinated fish [20]. In addition to survival, antibody responses were also measured. Vaccinated fish presented with an 18-fold increase in anti-*E. ictaluri* antibody levels when compared to nonvaccinated fish [20]. Antibody production is correlated to protective abilities against certain pathogens [23]. Elevated anti- *E. ictaluri* antibody levels present in vaccinated fish show an increase in immune response, demonstrating the vaccine's ability to hinder disease spread [20]. The results from the live-attenuated ESC vaccine experiments and pond trials indicated a

live-attenuated oral vaccine is proven to be an effective avenue to protect and immunize fingerling channel catfish [20].

In addition to vaccination, the use of hybrids has reduced the impact of *E. ictaluri* infections on the industry. Hybrid catfish have demonstrated considerable resistance to ESC, thus promoting their use to farmers and researchers. Blue catfish have also been shown to have a higher tolerance to ESC. Analyzing the resistance of multiple catfish species and families [24] has become increasingly important providing the possibility for farmers to raise hybrids by taking advantage of hybrids ability to have increased resistance to disease [9].

Virulent Aeromonas hydrophila

Historically, *A. hydrophila* has been considered a secondary pathogen in fish production, with cases of motile Aeromonad Septicemia (MAS) typically observed in fish that are stressed due to adverse environmental conditions or infection by a primary pathogen [25]. Fish with MAS can exhibit an array of symptoms, especially hemorrhaging and lesions that can progress to necrotic ulcers, and MAS is associated with high fish mortality [26]. It is common to co-isolate *A. hydrophila* and other pathogens from fish suffering from MAS symptoms, including such pathogens as *E. ictaluri*, *F. columnare* or *Vibrio parahaemolyticus* [27;28]. There is significant antigenic diversity among *A. hydrophila* strains, with 44 different O-antigen serotypes observed among mesophilic *A. hydrophila* strains [29], but more recent description of

A. hydrophila strains isolated from diseased fish are not commonly serotyped. The diversity of bacteria within the *A. hydrophila* complex that infect fish [30] and the ubiquitous presence of *A. hydrophila* within aquatic ecosystems particularly in biofilms and sediments [31] pose significant challenges for the generation of fish vaccines that are broadly protective against *A. hydrophila*.

A significant challenge for fish farmers has been the emergence of a hypervirulent pathotype of *A. hydrophila* causing MAS in farmed carp species in China first reported in 1989 [32], and in farmed catfish in the southeastern United States first reported in 2009 [33]. Fish infected with hypervirulent *A. hydrophila* (vAh) experience rapid onset of MAS disease and very high mortality. This virulent strain has been estimated to have caused greater than 12 million dollars in economic losses since the fish appearance in the U.S. industry [9,34].

The development of vaccines to protect farmed fish against *A. hydrophila* has been reported beginning in the 1970s. The strategies to vaccinate fish include the use of bacterins (inactivated cells), live-attenuated bacteria, and recombinant vaccines. *A. hydrophila* bacterins prepared by formalin- or heat-inactivation were reported to protect channel catfish [35], walking catfish (*Clarias batrachus* L.) [36], goldfish (*Carassius auratus*) [37], rainbow trout (*Oncorhynchus mykiss*) [38], carp (*Cyprinidae*) and loaches (*Misgurnus*) [39]. These bacterins triggered strong adaptive immune responses and have been shown to stimulate *A. hydrophila*-specific antibody titers and peroxidase activities in walking catfish [36], goldfish [37], and rainbow

trout [38]. Likewise, *A. hydrophila* bacterins have been observed to increase the expression of immune-related functions like IgM, IL-10 and lysozyme in carp and loaches [39].

The use of live-attenuated *A. hydrophila* vaccines can trigger more intense and prolonged immune responses by introducing avirulent bacteria by intraperitoneal injection [40], as has been demonstrated in common carp (*Cyprinus carpio L*) [41] and in Indian major carp species (*Catla catla*, *Labeo rohita*, *Cirrhinus mrigala*) [42]. The specific antibody titer in common carp was significantly increased by vaccination with live-attenuated *A. hydrophila* compared to fish that were vaccinated with formalin-killed vaccine [41]. For Indian carp species, vaccination with a hemolysin-negative *A. hydrophila* mutant induced significant protection (RPS >80%) and good agglutinating antibody response against virulent *A. hydrophila* [42].

Recombinant vaccines have been evaluated for their ability to protect rohu (*Labeo rohita*) [43], and American eel (*Anguilla rostrata*) [44] against *A. hydrophila*. *Escherichia coli* has been used overexpress pathogen genes, such as the outer membrane protein gene of *A. hydrophila*, which resulted in stimulation of IgM levels, lysozyme and significantly reduced fish cumulative mortality rates when challenged by *A. hydrophila* [43][44].

Experimental challenges with vAh strains isolated from US catfish result in significant mortality rapidly and the vast majority of fish that succumb to disease die within 24 hours [45]. The structure of the group 4 capsular polysaccharide and LPS-

associated O-antigen from a vAh strain isolated from a US catfish has a novel structure [46] unlike that of other *A. hydrophila* isolates from fish and a capsular polysaccharide-exporting mutant of the well-characterized catfish vAh isolate ML09-119 was observed to be attenuated in its virulence [47]. A catfish-derived vAh strain selected for resistance to two antibiotics demonstrated significant protection in channel catfish and Nile tilapia when IP-injected, resulting in 86-100% protection relative to naïve fish [48]. Attenuated vaccines to protect fish from vAh have been generated by selecting for antibiotic resistance [49], or by generating attenuated vAh via multiple gene deletions [50]. An attenuated vAh strain resistant to both novobiocin and rifampicin was used to vaccinate channel catfish by IP, resulting in 100% protection against the parent vAh strain with evidence for a strong antibody-mediated response and induction of Na(+)/K(+) ATPase α subunit, hepcidin, interleukin-1 β and lysozyme c within the anterior kidney in vaccinated fish relative to naïve fish [49]. In a study that deleted five vAh genes (*aerA*, *hly*, *ahp*, *alt* and *ast*) to produce an attenuated mutant strain, this was able to elicit a strong adaptive immune response in grass carp (*Ctenopharyngodon idella*), and yielded a RPS of 70 or 75% when fish were vaccinated by immersion and subsequently challenged by two different vAh strains, or a RPS of 75 or 85% when fish were vaccinated by intracelomic injection and challenged by vAh strains [50].

Besides using attenuated vAh strains, the extracellular proteins (ECPs) can serve as antigens that can elicit a protective response in channel catfish [51;52]. The

antiserum from the vaccinated fish agglutinated both vAh cells and more than 68 pathogenic proteins were recognized and aggregated by catfish IgM, including aerolysin and hemolysin. All channel catfish immunized with vAh ECP (2 micrograms) and Freund's adjuvant by intraperitoneal (IP) injection survived challenge whereas naïve fish injected with adjuvant alone all died within five hours [51]. Furthermore, ECP-immunized sera from channel catfish could be used to passively immunize channel catfish and provide an RPS of 85% by two days post-vaccination [52].

The infection of vAh significantly induced transcription of apolipoprotein A1 [53], chicken-type lysozyme [54], G-protein coupled receptor 18 [55], and goose-type lysozyme [56] in kidney, liver, and other tissues of channel catfish. These proteins were then expressed in the *E. coli* expression system and exhibited high lytic activity against the pathogen. The recombinant vaccines provided 100% protection to catfish two days after IP injection, and the protection remained at 77% - 100% two to four weeks post-vaccination when challenged by vAh AL09-71 [28,29,30,31] Similar approaches using recombinant expression of vAh-derived aerolysin, hemolysin [57], ATPase [58], fimbrial proteins [59], immunogenic outer membrane proteins [60], aerA (hemolytic and cytolytic factor) [61] were used to vaccinate channel catfish, resulting in 58% - 98% protection relative to naïve fish. Collectively, these studies demonstrate that multiple vaccination strategies can be effective in providing protection against vAh to farmed fish. Ultimately, the vaccination strategy adopted by

fish producers will need to provide long-lasting adaptive immunity and be cost-effective in order to be widely used. An important question to be addressed by future research is whether any of the vaccines developed to protect fish against vAh strains will provide immunity against other *A. hydrophila* types that are ubiquitous in aquatic ecosystems.

Flavobacterium columnare

Flavobacterium columnare is the causative agent of columnaris disease with a worldwide distribution. The disease was first described in the early 1900's in the state of Iowa (USA), in which a thorough investigation of the disease was conducted [62]. Examination of infected tissue under a microscope revealed the responsible bacterium tended to form columns or haystacks; thus, the names *Bacillus columnaris* and columnaris disease were proposed for the bacterium and disease, respectively [62]. *Bacillus columnaris* was first cultured in 1944 [63] on low nutrient media and was reclassified as *Chondrococcus columnaris*. The bacterium has been reclassified several times as *Cytophaga columnaris* [64], *Flexibacter columnaris* [65], and finally, as *F. columnare* [66]. Research has revealed a striking degree of genetic variation among isolates of *F. columnare*, and phylogenetic analyses has defined four distinct genetic groups within the species [67]. Not only do these groups differ at the genomic level, but also in host associations. Genetic group 1 isolates are predominantly

associated with disease in salmonids and genetic group 4 isolates are associated with disease in tilapia (*Oreochromis* spp.) aquaculture [67].

In the US catfish industry, columnaris disease is the second leading cause of mortality. In East Mississippi and West Alabama alone, yearly losses attributed to *F. columnare* range between 1.5 and 2.4 million pounds for each region [68] (Bill Hemstreet, Alabama Fish Farming Center, Greensboro, AL USA, personal communication). Mortalities in extreme cases have reached 90%, and in commercial ponds mortalities have reached 50-60% [9] resulting in \$30 million dollars in economic losses. Columnaris disease has a bimodal distribution with most cases occurring in the spring and fall, at a time when pond temperatures are changing; however, recent increases in cases during the summer months has been noted. Clinical signs include gill necrosis, fin rot, and skin lesions often with a yellowish color due to the pigmentation of *F. columnare*. Infections may be exclusively external, internal (systemic) or a combination of both [27]. Juvenile catfish are more susceptible to columnaris disease; however, disease may occur during any phase of commercial production. Diagnosis of columnaris disease is achieved by observation of clinical signs, presence of long slender gram-negative rods in wet mounts of affected tissues, and isolation of *F. columnare* colonies from tissues characterized as adherent to agar, yellowish in color, and rhizoid colony morphology. Of importance is the common documentation of co-infections upon examination of columnaris disease cases. Hawke

and Thune (1992) examined 99 bacterial disease cases in catfish and greater than 50% represented co-infections [27].

Effective and practical vaccination is highly desired by catfish producers to reduce the impact from columnaris disease. Early research evaluated simple formalin-inactivated bacterins administered by immersion that showed some beneficial effects including reduced mortality and antibiotic use [69]. Subsequent research resulted in the commercialization of a live-attenuated vaccine that showed good efficacy in the laboratory [70]. Efficacy under production conditions was variable and use of the vaccine by the catfish industry declined [71]. As such, several new vaccine platforms have been assessed as mitigation tools, with many focusing on the outer membrane proteins (OMPs) as important, antigenic regions [72]. Further, a recombinant vaccine (comprised of *F. columnare* chaperone protein DnaK) was evaluated by [73] and showed promise for vaccine efficacy. Similarly, a new live-attenuated vaccine has been tested under conditions similar to production and the results demonstrated a beneficial effect including lower food conversion ratios and larger average weight at harvest [74]. However, there are currently no effective and commercial vaccines available for use in the catfish industry; thus, prevention of columnaris disease relies heavily upon using good pond management practices to reduce risk factors such as stress, handling, and poor water quality. Epizootics can and will occur with these in place and require treatment using approved antibiotics or other compounds.

1.4 Bacterial coinfections

Co-infections are frequently seen in nature and arise when two or more pathogens infect one host. Infections can occur from two primary pathogens infecting the host concurrently or one pathogen can develop as a secondary infection [75]. Mixed infections have also made determining the primary cause of mortality exceedingly difficult, thus increasing treatment difficulties. Though co-infections are so frequent in typical fish environments, associated information is scarce. The environment plays a principal role by facilitating microorganisms which can lead to co-infection. Co-infections can exist between bacterial pathogens, viruses, and parasites, allowing for a wide range of clinical manifestations and complications for treatment regimens in pond environments [75].

Parasites are frequently seen in combination with bacterial pathogens. Researchers have investigated whether parasites can act as vectors for bacterial pathogens increasing infection rates along with mortality. Parasites are known to increase host susceptibility by creating portals of entry for potential bacterial pathogens resulting in high mortality and stress. However, their ability to act as vectors is unknown. *Bolbophorus damnificus* is a parasitic trematode responsible for mortalities in commercial ponds in Mississippi. When co-infections between *B. damnificus* and *E. ictaluri* occur mortality rates have been documented to increase dramatically [76]. *B. damnificus* could potentially create a portal of entry allowing

higher host susceptibility to ESC. Similarly, proliferative gill disease (PGD) could present a portal of entry for bacterial infections through damage and hemorrhaging of the gill in channel catfish. PGD is a result from a myxozoan parasite, *Henneguya ictaluri*, causing branchial inflammation and the breakdown of chondrocytes [77]. Exposure of hemorrhaged gills due to PGD could allow *A. hydrophila* or other bacterial pathogens a route of transmission into the host's blood system. This *Aeromonas* spp. infection, in combination with PGD, substantially increases mortality rates thus increasing economic losses [77]. Simultaneous infections amongst these pathogens facilitates increased exposure to bacterial infections. Similarly, although not reported in catfish species, a combination of *A. hydrophila* and *Epistylus* spp. cause "red sore disease" has also become of recent interest for fish disease diagnostics in freshwater systems [78]. *Ichthyophthirius multifiliis* (ich; white spot disease), a freshwater protozoan that causes high mortalities within the industry, has been investigated for its potential in acting as a vector for *E. ictaluri*. After investigation, evidence supported ich's ability to act as a vector, as researchers concluded transmission of bacterial diseases can be increased through parasitic vectors [79]. Yusoff et al. (2020) also reported *A. hydrophila* as a secondary pathogen to *Dactylogyrus* spp., attributing the external, parasite-yielded injuries to the bacterial sites of entry [80].

Information pertaining to dual bacterial infections is highly limited when compared to parasitic and bacterial co-infections. Bacterial co-infections are known to

cause drastic effects in increasing the extremity of other diseases along with grossly increasing mortality, changing host-susceptibility, and duration of infection [75].

Farmers frequently under report bacterial co-infections leaving little data related to outbreaks including diagnosis, immune response of host [75], and clinical signs.

Clinical signs arising from co-infections can be difficult to distinguish due to lack of information on which pathogen is responsible for which sign of infection. Other infectious agents occurring concurrently with primary pathogens are often characterized as secondary infections or opportunistic, resulting in most of the research to be focused on primary pathogen infections. Co-infections change fish susceptibility to a variety of pathogens [75] resulting in outbreaks causing high mortality. Interactions between the pathogens can lead to bacterial load variability, where loads can be either both suppressed, increased, or one potentially suppressed while the other is increased, although, extraordinarily little information is known about how loads are affected during co-infections. Competition between resources of the host is typical in co-infections; modifying immune activity against other pathogens can suppress or increase the immune response leading co-infections to be either synergistic or antagonistic affecting and altering the host-pathogen interactions [75]. Antagonistic effects allow the primary pathogen to obstruct the secondary pathogen while synergistic effects create immunosuppressive effects allowing both pathogens to infect the host increasing mortality.

The co-infective ability of bacterial fish pathogens warrants further investigation to better comprehend natural exposure in production systems. In cobia (*Rachycentron canadum*), *Vibrio harveyi* and *Photobacterium damsela* have been used in experimental co-infective challenges and differences in mortality were observed in fish receiving multiple pathogens when compared to some of the single-pathogen treatment groups [81]. In rainbow trout, a co-infective pathogen challenge with novel Family *Flavobacteriaceae* isolates also showed increased mortality when compared to single-isolate treatments [82]. Similarly, systemic infection and ulcerative dermatitis was observed within farmed barramundi (*Lates calcarifer*) and the cause was attributed to co-infection with *Streptococcus iniae* and *Shewanella algae* [83]. A co-infection of *Yersinia ruckeri* and *Pseudomonas fluorescens* was also found to have caused mortality rates of up to 40% across three rainbow trout production farms in Turkey [84]. *Cyprinus carpio* var. *koi* (koi carp) experienced high mortality rates in Tianjin breeding farms. Moribund koi carps were cultured and *A. veronii* and *V. cholerae* were isolated and identified for the first time in combination by Han et al (2021) [85]. Both pathogens presented similar clinical signs including lesions along the liver, intestine, and spleen. Fish also exhibited intestinal hemorrhaging. Research indicated additional studies should be conducted to further study pathogenicity. This work could aid in developing treatment along with future prevention methods [85]. A study conducted by Chandrarathna et al. (2018) examined the effects of co-infection in zebrafish [86]. *Aeromonas hydrophila* and *A. veronii* were identified as the

causative pathogens inducing mortality amongst zebrafish. Isolates presented to be multidrug resistant. Once challenged, single infections with the pathogens caused less mortality than the co-infections suggesting that mixed infections of *A. hydrophila* and *A. veronii* have a higher pathogenicity than single infections [86].

To assess the full extent of co-infection outbreaks more specifically within catfish production, studies must be conducted to quantify multiple pathogens effects on host mortality. *Pangasianodon hypophthalmus* (striped catfish) were observed to have encountered natural infections of *E. ictaluri* in Thailand. Researchers discovered striped catfish were experiencing co-infections of *F. columnare* and *E. ictaluri*. The investigation into the outbreak aimed to characterize both single and dual infections from each pathogen. Clinical signs from both *E. ictaluri* and *F. columnare* were consistent between naturally occurring infections and induced infections [87]. Researchers were able to fulfill Koch's postulates and provided data of molecular markers to better identify outbreaks in fish. Similarly, striped catfish were immersed with both *E. ictaluri* and *A. hydrophila*. Results indicated the co-infection caused 95% cumulative mortality while the single infection of *E. ictaluri* only had 80% and *A. hydrophila* 10%, thus suggesting that *A. hydrophila* acted as a secondary or opportunistic pathogen [88]. Grizzle and Kiryu (1993) also found that channel catfish that were displaying latent *A. hydrophila* infection following experimental challenge also exhibited infections with *Acinetobacter* spp., *Plesiomonas* spp., and *Pseudomonas* spp.) [25]. Nofal and Abdel-Latif (2017) also reported a variety of

mixed bacterial, and mixed bacterial-parasitic infections in African catfish, with the prominent bacterial pathogens *Vibrio* spp., *A. hydrophila*, and *E. tarda* recorded from the pond fish kills [89].

In 2017, researchers at the E. W. Shell Fisheries Center at Auburn University (Auburn, AL) observed chronic mortalities in channel catfish within an in-pond raceways system. Mortalities were deemed unusual due to outbreaks occurring at lower water temperatures and during periods of reduced feeding. After further investigation, three different bacterial pathogens were isolated, indicating a co-infection. Gram-negative bacteria *A. veronii* and *S. putrefaciens* were identified along with the gram-positive bacterium *S. parauberis*. Fish were exposed to pathogens in an attempt to identify the primary causative agent. Both *A. veronii* and *S. parauberis* were unsuccessful in inducing mortality, while exposure to high doses of *S. putrefaciens* induced signs of disease and low mortality rates (33%-50%). Researchers concluded infection with *A. veronii*, *S. parauberis*, and *S. putrefaciens* was a novel co-infection, and future investigations should be done to determine transmission and pathogenicity of *S. parauberis* and *S. putrefaciens* [90].

Immune responses associated with co-infections must be further studied in attempt to develop future avenues of treatment and prevention [75]. The mucosal surface of catfish is an important immune component to investigate during co-infections. Mucosal surfaces of channel catfish are the first line of defense against pathogens thriving in aquatic environments [91]. Investigating fish mucus's innate

immune defense mechanisms can lead to better understanding of how pathogens attach and enter the host along with the aiding in developing prevention methods. *Flavobacterium columnare* is a prime example of a bacterial pathogen being dependent on attaching to the mucosal surface of the host in order to cause infection. Most studies regarding this are focused primarily with the liver, spleen, and kidney immune factors, however, by examining the expression patterns within the mucus researchers can determine whether attached bacteria suppress host immune responses [92]. The immune response of the mucosal surfaces of channel catfish have also been investigated during *A. hydrophila* infections. Vital lectins and proteins were observed to be altered potentially enhancing the pathogen's ability to disrupt and adhere to the mucosal barrier [92]. Though studies have been conducted to determine single pathogen effects on mucosal surface of catfish, similar studies have not been conducted to document multiple pathogen's effects.

1.5 Diagnostic summary of recent bacterial co-infections in Alabama and Mississippi

While diagnostic case records are fraught with submission bias, they can still provide valuable insight into the disease prevalence in the catfish industry. Bacterial diseases are the most commonly diagnosed diseases for catfish case submissions (each case submission is a composite sample of fish collected from a single pond on a given day) at the Alabama Fish Farming Center (AFFC) in Alabama and the Aquatic

Research & Diagnostic Laboratory (ARDL) in Mississippi. In addition, Mississippi and Alabama are the top producing catfish states in the US, each having farms that produce channel catfish and hybrid catfish (♀ , *Ictalurus punctatus* \times ♂ , *I. furcatus*). The top prevalent co-infection patterns differ between these states, which may be a reflection of the different system types.

The AFFC records showed that cases of co-infection in Alabama were primarily the bacteria *F. columnare* and either *A. hydrophila* or various other *Aeromonas spp.*, which include *A. sobria*, *A. caviae*, and *A. veronii*. The next frequently recorded co-infections were between *E. ictaluri* and *F. columnare* (Table 2). However, the ARDL data revealed bacterial co-infections occurred more frequently among the two most commonly diagnosed bacterial diseases, ESC and columnaris disease (Tables 1 and 2). These co-infection trends are consistent year-to-year for the AFFC and ARDL from 2016 to 2020.

There are some consistent trends within the Alabama and Mississippi records. Channel catfish represent most of *E. ictaluri-F. columnare* co-infection cases and are at least twice, if not more, the number of hybrid catfish cases. Within these cases, it is difficult to assign with certainty which is the primary pathogen as each can cause disease by itself. While *F. columnare* is often thought to be secondary, columnaris disease is usually seen earlier in the year when the cooler temperatures are less conducive for *E. ictaluri* infections and may set the fish up for co-infections later. For *Edwardsiella piscicida*-columnaris disease co-infections, hybrid catfish represent the

majority of cases, but this is not unexpected since hybrid catfish are more susceptible to *E. piscicida* infections [93] but are more resistant to ESC [94] and columnaris disease [95]. However, this combination of bacterial diseases is much less common than *E. ictaluri-F. columnare* infections. Therefore, columnaris disease is likely a secondary infection based on the severity of *E. piscicida* lesions compared to the *F. columnare* lesions.

The ARDL data showed co-infections between *F. columnare-A. hydrophila* and *F. columnare-Aeromonas* spp. infections, the latter of which are cases where the species of *Aeromonas* could not be speciated by the BD BBLTM Crystal™ Enteric/Nonfermentor (Becton Dickinson and Company, Sparks, MD), were significantly lower than those reported in Alabama.

In 2017, there were five *Yersinia ruckeri* cases in hybrid catfish from one farm in Mississippi, one of which was a *Y. ruckeri*-columnaris disease co-infection. While typically considered a coldwater fish pathogen, *Y. ruckeri* can be occasionally seen in warmwater fish species, including catfish [96]. No *Y. ruckeri* co-infection cases were diagnosed in Alabama from 2016-2020.

1.6 Future directions for bacterial co-infection mitigation and research

A more comprehensive understanding of bacterial co-infections will present many new avenues for enhancements to fish health within catfish production. By further capturing mechanisms for infectivity and virulence and detailing predominant pathogens in diagnostic casework, treatment regimens may be more customized for enhanced efficacy. For instance, properly identifying primary and secondary pathogens will allow for the appropriate selection of antibiotic or chemical treatment means. As we have limited approved drugs for use in cultured fish species, judiciously administering antibiotics allows producers to retain treatment efficacy. Similarly, as we detail more information on the prevalence and dynamics of antibiotic sensitivity in aquaculture pathogens, the importance of profiling antibiotic susceptibility of multiple pathogen infections is clear. Additionally, if both the presence and role of co-infective pathogens is discerned, more rearing-related parameters (i.e., water quality, temperature, feed administration) may be manipulated to cater to the primary effector. Further discerning expanded treatment efficacy has major economic implications for catfish producers, as treating large ponds for diseases can be very expensive for chemical treatments (aside from medicated feed expenses).

With respect to research aims for co-infective bacterial pathogens, access to case diagnostic profiles (both on a small and meta-scale) will provide directions for strain selections that best characterize ongoing health concerns in production ponds. There is a need to establish more natural multi-pathogen *in vivo* challenge models that best

represent the role of both primary and secondary effectors. For instance, dose-concentration studies and timing of pathogen introductions during an *in vivo* challenge are important aspects of emulating natural conditions related to disease onset. From this data, further mechanism of infectivity and changes to pathogenesis during co-infection events can be discerned using molecular tools (i.e., gene expression and sequencing) and growth dynamics.

Further, the cross-protective ability of vaccines used in catfish culture is also of importance to multi-infection mitigation plans. Optimizing catfish vaccine to provide an expanded umbrella of protection will also potentially reduce bacterial co-infections through an enhanced immune system response and/or shared protective antibodies that are cross-reactive. Aside from chemical treatments and prophylactics, the ability to select genetic lines that are more disease resistant to selected bacterial pathogens would also be of benefit to catfish producers. Several catfish strains and types (i.e., genetic crosses or transgenics) have established evidence for some aspects of disease resistance, yet the expansion and determined scope of these resistance capabilities is of interest.

Co-infective bacterial pathogens in the catfish production sector are not well reported in the literature and warrant further investigation to fully characterize their pathogenesis in production systems. Through the advanced analysis of disease diagnostic data and expanded, targeted research aims, the role of co-infective bacterial pathogens may be further elucidated to better control pathogens in catfish aquaculture.

Tables

Table 1. Mississippi State University - College of Veterinary Medicine Aquatic Research & Diagnostic Laboratory - Stoneville, MS Polymicrobial Cases from 2016-2020 Disease Diagnosis as a Percentage of Total Case Submissions

| 2020 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
|---|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-------|-----|----|----|----|
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris; <i>Aeromonas hydrophila</i> | | | | | | | 1 | | | | | | 1 | 0.13 | 1 | | | |
| Columnaris; <i>Aeromonas</i> sp. | | | | | | 2 | | | | | | | 2 | 0.26 | 2 | | | |
| <i>Edwardsiella piscicida</i> : columnaris | | | | | 6 | 5 | | 2 | | 1 | | | 14 | 1.83 | 2 | 12 | | |
| Enteric septicemia of catfish; <i>Aeromonas hydrophila</i> | | | | | | | 1 | | | | | | 1 | 0.13 | 1 | | | |
| Enteric septicemia of catfish; columnaris | | | 2 | 11 | 11 | 11 | 4 | 67 | 45 | 7 | 2 | | 160 | 20.97 | 118 | 42 | | |
| Enteric septicemia of catfish; columnaris; <i>Aeromonas</i> sp. | | | | 1 | | | | | | | | | 1 | 0.13 | 1 | | | |
| Total cases: 763 | | | | | | | | | | | | | | | | | | |
| 2019 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris, <i>Aeromonas hydrophila</i> , | | | 1 | | | | | | | | | | 1 | 0.14 | 1 | | | |
| Columnaris, <i>Aeromonas</i> sp. | | | | | 2 | 1 | | | | | | | 3 | 0.42 | | 3 | | |
| <i>Edwardsiella piscicida</i> , columnaris, | | | | | 2 | 2 | 1 | | 2 | | | | 7 | 0.97 | 1 | 5 | 1 | |
| Enteric septicemia of catfish, columnaris | | | | | 10 | 8 | 22 | 26 | 27 | 17 | | | 110 | 15.26 | 84 | 26 | | |
| Total cases: 721 | | | | | | | | | | | | | | | | | | |
| 2018 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris, <i>Aeromonas</i> sp. | | | | | | | | 1 | | | | | 1 | 0.2 | | 1 | | |
| <i>Edwardsiella piscicida</i> (<i>tarda</i>), columnaris | | | | | 2 | 1 | | | | | | | 3 | 0.5 | | 3 | | |
| Enteric septicemia of catfish, <i>Aeromonas</i> sp. | | | | | | | | | | 1 | | | 1 | 0.2 | | 1 | | |
| Enteric septicemia of catfish, columnaris | | | | 1 | 6 | 2 | 8 | 41 | 14 | 13 | 1 | | 86 | 13.0 | 70 | 16 | | |
| Total cases: 660 | | | | | | | | | | | | | | | | | | |
| 2017 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris, <i>Aeromonas</i> sp | | | 2 | | 1 | | | | | | | | 3 | 0.3 | 3 | | | |
| <i>Edwardsiella piscicida</i> , columnaris, | | | 1 | 1 | 1 | 2 | | 1 | 4 | 1 | | | 11 | 1.3 | 1 | 10 | | |
| Enteric septicemia of catfish, columnaris | | | | 1 | 19 | 28 | 16 | 51 | 44 | 25 | 1 | 1 | 186 | 21.6 | 155 | 31 | | |
| Enteric septicemia of catfish, <i>Edwardsiella tarda</i> | | | | | | | | | | | 1 | | 1 | 0.1 | | 1 | | |
| <i>Yersinia ruckeri</i> , columnaris | | | 1 | | | | | | | | | | 1 | 0.1 | | 1 | | |
| Total cases: 861 | | | | | | | | | | | | | | | | | | |
| 2016 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris, <i>Aeromonas</i> spp. | | | | 1 | | | 1 | 1 | | | | | 3 | 0.4 | 1 | 2 | | |

| | | | | | | | | | | | | | | | | | | | | | |
|---|--|--|--|--|--|--|---|----|----|----|----|----|----|---|--|-----|------|----|----|--|--|
| <i>Edwardsiella piscicida</i> , columnaris | | | | | | | 1 | | 1 | 2 | 1 | 3 | 2 | 2 | | 12 | 1.6 | 1 | 11 | | |
| <i>Edwardsiella piscicida</i> , columnaris, <i>Aeromonas hydrophila</i> | | | | | | | | | | | 1 | | | | | 1 | 0.1 | | 1 | | |
| Enteric septicemia of catfish, <i>Aeromonas hydrophila</i> | | | | | | | | | | | | | 1 | | | 1 | 0.1 | 1 | | | |
| Enteric septicemia of catfish, columnaris | | | | | | | 2 | 13 | 10 | 11 | 21 | 28 | 23 | 1 | | 109 | 14.7 | 79 | 30 | | |
| Total cases: 744 | | | | | | | | | | | | | | | | | | | | | |

2

3
4

Table 2. Alabama Fish Farming Center Polymicrobial Cases from 2016-2020 Disease Diagnosis as a Percentage of Total Case Submissions

| 2020 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
|--|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-----|----|----|----|----|
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris; <i>Aeromonas hydrophila</i> | | 2 | 4 | 2 | 2 | 8 | | 2 | 3 | 2 | | | 25 | 8.4 | 22 | 3 | | |
| Columnaris; <i>Aeromonas</i> sp. | | | 2 | | | 5 | 3 | | 2 | | | | 12 | 4 | 11 | 1 | | |
| <i>Edwardsiella piscicida</i> : columnaris | | | | | | | 1 | | | | | | 1 | 0.3 | | 1 | | |
| Enteric septicemia of catfish; <i>Aeromonas hydrophila</i> | | | | 1 | | | | | | | | | 1 | 0.3 | 1 | | | |
| Enteric septicemia of catfish; columnaris | | | 5 | | 4 | 3 | 4 | 1 | 1 | 3 | | | 21 | 7 | 17 | 4 | | |
| Total cases: 306 | | | | | | | | | | | | | | | | | | |
| 2019 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris, <i>Aeromonas hydrophila</i> , | | | | 2 | 7 | 5 | 4 | 5 | 5 | | | | 28 | 9.8 | 23 | 5 | | |
| Columnaris, <i>Aeromonas</i> sp. | | | 5 | 10 | 1 | 1 | | 4 | | | | | 21 | 7.3 | 14 | 7 | | |
| <i>Edwardsiella piscicida</i> , columnaris, | | | | | | | 1 | | | | | | 1 | 0.3 | | 1 | | |
| <i>Edwardsiella piscicida</i> , <i>Aeromonas</i> spp. | | | | | | | 1 | | | | | | 1 | 0.3 | 1 | | | |
| Enteric septicemia of catfish, <i>Aeromonas hydrophila</i> | | | | | | | | 3 | | | | | 3 | 1 | 6 | | | |
| Enteric septicemia of catfish, <i>Aeromonas</i> spp. | | | | | | | | 10 | | | | | 10 | 3.5 | 4 | 2 | | 5 |
| Enteric septicemia of catfish, columnaris | | | | | | | 6 | 4 | 1 | | | | 11 | 3.8 | 8 | 3 | | |
| Total cases: 287 | | | | | | | | | | | | | | | | | | |
| 2018 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS |
| Columnaris, <i>Aeromonas hydrophila</i> , | | | 1 | | 2 | | | | | 1 | 1 | | 5 | 1.7 | 3 | 2 | | |
| Columnaris, <i>Aeromonas</i> sp. | | | 4 | 10 | 1 | 5 | | | | | | | 20 | 6.8 | 10 | 10 | | |
| <i>Edwardsiella piscicida</i> , columnaris | | | | 3 | 2 | | | | | | | | 5 | 1.7 | 1 | 4 | | |
| Enteric septicemia of catfish, <i>Aeromonas hydrophila</i> | | | | | | | | | | | | | 0 | 0 | | | | |

| | | | | | | | | | | | | | | | | | | | | | |
|--|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-------|-----|----|----|-----|----|--|--|--|
| Enteric septicemia of catfish, <i>Aeromonas</i> sp. | | | | | | | | | | | | | | | | 0 | 0 | | | | |
| Enteric septicemia of catfish, columnaris | | | | 1 | 1 | | | | | | | | | | | 2 | 0.7 | 2 | | | |
| Columnaris, <i>Pleisiomonas</i> sp. | | | | | | 1 | | | | | | | | | | 1 | 0.3 | 1 | | | |
| Total cases 296 | | | | | | | | | | | | | | | | | | | | | |
| 2017 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS | | | |
| Columnaris, <i>Aeromonas hydrophila</i> , | | | | 1 | 1 | 1 | | | 1 | 4 | | | 8 | 2.3 | 5 | 3 | | | | | |
| Columnaris, <i>Aeromonas</i> sp. | | 2 | 6 | 2 | 6 | | | | | | | | 16 | 4.5 | 10 | 6 | | | | | |
| <i>Edwardsiella piscicida</i> , Columnaris, | | | | | | | | | | 1 | | | 1 | 0.3 | | 1 | | | | | |
| Enteric septicemia of catfish, <i>A. hydrophila</i> | | | | | | | | | | | | | 0 | 0 | | | | | | | |
| Enteric septicemia of catfish, columnaris | | | | | | 1 | | | 3 | 1 | | | 5 | 1.4 | 5 | | | | | | |
| Enteric septicemia of catfish, <i>Edwardsiella tarda</i> , | | | | | | | | | | | | | | | | | | | | | |
| <i>Aeromonas</i> spp. | | | | | | | | | | | | | 0 | 0 | | | | | | | |
| Total cases 352 | | | | | | | | | | | | | | | | | | | | | |
| 2016 Polymicrobial Disease Diagnostic Cases | | | | | | | | | | | | | | | | | | | | | |
| Disease | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | % | CH | HY | BL | OS | | | |
| Columnaris, <i>Aeromonas hydrophila</i> , | | | | | 1 | 5 | | 3 | 3 | 1 | | | 13 | 2.8 | 6 | 7 | | | | | |
| Columnaris, <i>Aeromonas</i> spp. | | | 3 | 8 | 4 | | 1 | | | 2 | | | 18 | 3.9 | 16 | 2 | | | | | |
| <i>Edwardsiella piscicida</i> , columnaris | | | | | | | | | | | | | 0 | 0 | | | | | | | |
| Enteric septicemia of catfish, <i>Aeromonas hydrophila</i> | | | | | | 1 | | | | 1 | | | 2 | 0.4 | 2 | | | | | | |
| Enteric septicemia of catfish, Ccolumnaris | | | 1 | 1 | 1 | | | | | 11 | 1 | | 16 | 3.5 | 13 | 3 | | | | | |
| Enteric septicemia of catfish, <i>Aeromonas</i> spp. | | | | | | 2 | | | | | | | | 0 | 2 | | | | | | |
| <i>Streptococcus</i> spp., <i>Aeromonas hydrophila</i> | | | | | | | 1 | | | | | | | 0 | 1 | | | | | | |
| Columnaris, <i>Pleisiomonas</i> spp. | | | | | 1 | | | | | | | | | 0 | 1 | | | | | | |
| Total cases: 460 | | | | | | | | | | | | | | | | | | | | | |

5 1.7 References

- 6
- 7 1. FAO Fisheries & Aquaculture National Aquaculture Sector Overview - United States
- 8 of America Available online: http://www.fao.org/fishery/countrysector/naso_usa/en
- 9 (accessed on 11 June 2021).
- 10
- 11 2. National Agricultural Statistics Service Catfish Production 04/02/2019. *Arkansas*
- 12 **2018**, 10.
- 13
- 14 3. Wellborn, T.L. Channel Catfish: Life History and Biology. **2006**, 4.
- 15
- 16 4. Steeby, J.; Avery, J. Channel Catfish Broodfish and Hatchery Management. *Southern*
- 17 *Regional Aquaculture Center* **2005**, 8.
- 18
- 19 5. Lucy Towers Producing Better Catfish The Hybrid Way Available online:
- 20 <https://thefishsite.com/articles/producing-better-catfish-the-hybrid-way> (accessed on
- 21 27 September 2021).
- 22
- 23 6. Stone, N. Catfish Farming – Freshwater Aquaculture Available online:
- 24 <https://freshwater-aquaculture.extension.org/catfish-farming/> (accessed on 27
- 25 September 2021).
- 26
- 27 7. Dunham, R.A.; Elasad, A. Catfish Biology and Farming. *Annu Rev Anim Biosci*
- 28 **2018**, 6, 305–325.
- 29
- 30 8. Wagner, B.A.; Wise, D.J.; Khoo, L.H.; Terhune, J.S. The Epidemiology of Bacterial
- 31 Diseases in Food-Size Channel Catfish. *J Aquat Anim Health* **2002**, 14, 263–272.
- 32
- 33 9. Zhou, T.; Yuan, Z.; Tan, S.; Jin, Y.; Yang, Y.; Shi, H.; Wang, W.; Niu, D.; Gao, L.;
- 34 Jiang, W.; et al. A Review of Molecular Responses of Catfish to Bacterial Diseases
- 35 and Abiotic Stresses. *Front Physiol* **2018**, 9, 1113.
- 36
- 37 10. Hawke, J.P. Enteric Septicemia of Catfish. Southern Regional Aquaculture Center.
- 38 **2015**. Publication No. 477.
- 39
- 40 11. Wise, D.J.; Greenway, T.E.; Byars, T.S.; Kumar, G.; Griffin, M.J.; Khoo, L.H.;
- 41 Chesser, G.; Lowe, J. Validation of *Edwardsiella ictaluri* Oral Vaccination Platform
- 42 in Experimental Pond Trials. *J World Aquac Soc* **2020**, 51, 346–363.
- 43
- 44 12. Meyer, F.P.; Bullock, G.L. *Edwardsiella tarda*, a New Pathogen of Channel Catfish
- 45 (*Ictalurus punctatus*). *Appl Microbiol* **1973**, 25, 155–156.
- 46
- 47 13. Griffin, M.J.; Ware, C.; Quiniou, S.M.; Steadman, J.M.; Gaunt, P.S.; Khoo, L.H.;
- 48 Soto, E. *Edwardsiella piscicida* Identified in the Southeastern USA by GyrB
- 49 Sequence, Species-Specific and Repetitive Sequence-Mediated PCR. *Dis Aquat*
- 50 *Organ* **2014**, 108, 23–35.

- 51 14. Abdelhamed, H.; Lawrence, M.L.; Karsi, A. The Role of TonB Gene in *Edwardsiella*
52 *ictaluri* Virulence. *Front Physiol* **2017**, *8*, 1066.
53
- 54 15. Santander, J.; Martin, T.; Loh, A.; Pohlenz, C.; Gatlin, D.M.; Curtiss, R. Mechanisms
55 of Intrinsic Resistance to Antimicrobial Peptides of *Edwardsiella ictaluri* and Its
56 Influence on Fish Gut Inflammation and Virulence. *Microbiol* **2013**, *159*, 1471–1486.
57
- 58 16. Griffin, M.J.; Reichley, S.R.; Greenway, T.E.; Quiniou, S.M.; Ware, C.; Gao, D.X.;
59 Gaunt, P.S.; Yanong, R.P.E.; Pouder, D.B.; Hawke, J.P.; et al. Comparison of
60 *Edwardsiella ictaluri* Isolates from Different Hosts and Geographic Origins. *J Fish*
61 *Dis* **2016**, *39*, 947–969.
62
- 63 17. Patrie-Hanson, L.; Jerald Ainsworth, A. Humoral Immune Responses of Channel
64 Catfish (*Ictalurus punctatus*) Fry and Fingerlings Exposed To *Edwardsiella ictaluri*.
65 *Fish Shellfish Immunol* **1999**, *9*, 579–589.
66
- 67 18. Titball, R.W. Vaccines against Intracellular Bacterial Pathogens. *Drug Discov Today*
68 **2008**, *13*, 596–600.
69
- 70 19. Klesius, P.H.; Shoemaker, C.A. Development and Use of Modified Live
71 *Edwardsiella ictaluri* Vaccine against Enteric Septicemia of Catfish. *Adv Vet Med*
72 **1999**, *41*, 523–537.
73
- 74 20. Wise, D.J.; Greenway, T.E.; Byars, T.S.; Griffin, M.J.; Khoo, L.H. Oral Vaccination
75 of Channel Catfish against Enteric Septicemia of Catfish Using a Live Attenuated
76 *Edwardsiella ictaluri* Isolate. *J Aquat Anim Health* **2015**, *27*, 135–143.
77
- 78 21. Wise, D.J.; Greenway, T.E.; Byars, Todd S., T.S.; et al Validation of *Edwardsiella*
79 *ictaluri* Oral Vaccination Platform in Experimental Pond Trials. *J World Aquacult*
80 *Soc.* **2020**, *51*: 346-363.
81
- 82 22. Greenway, T.E.; Byars, T.S.; Elliot, R.B.; Jin, X.; Griffin, M.J.; Wise, D.J. Validation
83 of Fermentation and Processing Procedures for the Commercial-Scale Production of a
84 Live, Attenuated *Edwardsiella ictaluri* Vaccine for Use in Channel Catfish
85 Aquaculture. *J Aquat Anim Health* **2017**, *29*, 83–88.
86
- 87 23. Vinitnantharat, S.; Plumb, J.A. Protection of Channel Catfish *Ictalurus punctatus*
88 Following Natural Exposure to *Edwardsiella ictaluri* and Effects of Feeding Antigen
89 on Antibody Titer. *Dis Aquat Org* **1993**, *15*, 31–34.
90
- 91 24. LaFrentz, B.R.; Shoemaker, C.A.; Booth, N.J.; Peterson, B.C.; Ourth, D.D. Spleen
92 Index and Mannose-Binding Lectin Levels in Four Channel Catfish Families
93 Exhibiting Different Susceptibilities to *Flavobacterium columnare* and *Edwardsiella*
94 *ictaluri*. *J Aquat Anim Health* **2012**, *24*, 141–147.
95

- 96 25. Grizzle, J.M.; Kiryu, Y. Histopathology of Gill, Liver, and Pancreas, and Serum
97 Enzyme Levels of Channel Catfish Infected with *Aeromonas hydrophila* Complex. *J*
98 *Aquat Anim Health* **1993**, *5*, 36–50.
99
- 100 26. Plumb, J.A. Health Maintenance and Principal Microbial Diseases of Cultured Fishes
101 | Wiley Available online: [https://www.wiley.com/en-](https://www.wiley.com/en-us/Health+Maintenance+and+Principal+Microbial+Diseases+of+Cultured+Fishes-p-9780813822983)
102 [us/Health+Maintenance+and+Principal+Microbial+Diseases+of+Cultured+Fishes-p-](https://www.wiley.com/en-us/Health+Maintenance+and+Principal+Microbial+Diseases+of+Cultured+Fishes-p-9780813822983)
103 [9780813822983](https://www.wiley.com/en-us/Health+Maintenance+and+Principal+Microbial+Diseases+of+Cultured+Fishes-p-9780813822983) (accessed on 24 September 2021).
104
- 105 27. Hawke, J.P.; Thune, R.L. Systemic Isolation and Antimicrobial Susceptibility of
106 *Cytophaga columnaris* from Commercially Reared Channel Catfish. *J Aquat Anim*
107 *Health* **1992**, *4*, 109–113.
108
- 109 28. El-Son, M.A.M.; Nofal, M.I.; Abdel-Latif, H.M.R. Co-Infection of *Aeromonas*
110 *hydrophila* and *Vibrio parahaemolyticus* Isolated from Diseased Farmed Striped
111 Mullet (*Mugil cephalus*) in Manzala, Egypt – A Case Report. *Aquaculture* **2021**, *530*,
112 735738.
113
- 114 29. Sakazaki, R.; Shimada, T. O-serogrouping scheme for mesophilic *Aeromonas* strains.
115 *JJMSB* **1984**, *37*, 247–255.
116
- 117 30. Algammal, A.M.; Mohamed, M.F.; Tawfiek, B.A.; Hozzein, W.N.; El Kazzaz, W.M.;
118 Mabrok, M. Molecular Typing, Antibiogram and PCR-RFLP Based Detection of
119 *Aeromonas hydrophila* Complex Isolated from *Oreochromis niloticus*. *Pathogens*
120 **2020**, *9*, E238.
121
- 122 31. Cai, W.; Willmon, E.; Burgos, F.A.; Ray, C.L.; Hanson, T.; Arias, C.R. Biofilm and
123 Sediment Are Major Reservoirs of Virulent *Aeromonas hydrophila* (VAh) in Catfish
124 Production Ponds. *J Aquat Anim Health* **2019**, *31*, 112–120.
125
- 126 32. Zhi-Hong, M.A.; Hui-Ying, C.; Wen, D. Study on the Pathogen of Epidemic
127 Septicemia Occurred in Cyprinoid Fishes in Beijing, China. *Biodiv Sci* **1998**, *06*, 31.
128
- 129 33. Hemstreet, B. An Update on *Aeromonas hydrophila* from a Fish Health Specialist for
130 Summer. *Catfish J* **2010**, *24*, 4.
131
- 132 34. Hossain, M. J.; Sun, D.; McGarey, D. J.; Wrenn, S.; Alexander, L. M.; Martino,
133 M.E. An Asian Origin of Virulent *Aeromonas hydrophila* Responsible for
134 Disease Epidemics in United States-farmed Catfish. *mBio* **2014**, *5*:e848-14.
135
- 136 35. Schachte, J. Immunization of Channel Catfish, *Ictalurus punctatus*, against Two
137 Bacterial Diseases. *Mar Fish Rev* **1978**, *40*:18-24.
138
- 139 36. Nayak, D.K.; Asha, A.; Shankar, K.M.; Mohan, C.V. Evaluation of Biofilm of
140 *Aeromonas hydrophila* for Oral Vaccination of *Clarias batrachus*--a Carnivore
141 Model. *Fish Shellfish Immunol* **2004**, *16*, 613–619.

- 142
143 37. Harikrishnan, R.; Balasundaram, C.; Heo, M.-S. Effect of Chemotherapy, Vaccines
144 and Immunostimulants on Innate Immunity of Goldfish Infected with *Aeromonas*
145 *hydrophila*. *Dis Aquat Organ* **2009**, *88*, 45–54.
146
- 147 38. Bastardo, A.; Ravelo, C.; Castro, N.; Calheiros, J.; Romalde, J.L. Effectiveness of
148 Bivalent Vaccines against *Aeromonas hydrophila* and *Lactococcus garvieae*
149 Infections in Rainbow Trout *Oncorhynchus mykiss* (Walbaum). *Fish Shellfish*
150 *Immunol* **2012**, *32*, 756–761.
151
- 152 39. Yun, S.; Jun, J.W.; Giri, S.S.; Kim, H.J.; Chi, C.; Kim, S.G.; Kim, S.W.; Park, S.C.
153 Efficacy of PLGA Microparticle-Encapsulated Formalin-Killed *Aeromonas*
154 *hydrophila* Cells as a Single-Shot Vaccine against *A. hydrophila* Infection. *Vaccine*
155 **2017**, *35*, 3959–3965.
156
- 157 40. Minor, P.D. Live Attenuated Vaccines: Historical Successes and Current Challenges.
158 *Virol* **2015**, *479–480*, 379–392.
159
- 160 41. Jiang, X.; Zhang, C.; Zhao, Y.; Kong, X.; Pei, C.; Li, L.; Nie, G.; Li, X. Immune
161 Effects of the Vaccine of Live Attenuated *Aeromonas hydrophila* Screened by
162 Rifampicin on Common Carp (*Cyprinus carpio* L). *Vaccine* **2016**, *34*, 3087–3092.
163
- 164 42. Karunasagar, I.; Rosalind, G.; Karunasagar, I. Immunological Response of the Indian
165 Major Carps to *Aeromonas hydrophila* Vaccine. *J Fish Dis* **1991**, *14*, 413–417.
166
- 167 43. Dash, P.; Sahoo, P.K.; Gupta, P.K.; Garg, L.C.; Dixit, A. Immune Responses and
168 Protective Efficacy of Recombinant Outer Membrane Protein R (ROmpR)-Based
169 Vaccine of *Aeromonas hydrophila* with a Modified Adjuvant Formulation in Rohu
170 (*Labeo rohita*). *Fish Shellfish Immunol* **2014**, *39*, 512–523.
171
- 172 44. Poobalane, S.; Thompson, K.D.; Ardó, L.; Verjan, N.; Han, H.-J.; Jeney, G.; Hirono,
173 I.; Aoki, T.; Adams, A. Production and Efficacy of an *Aeromonas hydrophila*
174 Recombinant S-Layer Protein Vaccine for Fish. *Vaccine* **2010**, *28*, 3540–3547.
175
- 176 45. Zhang, D.; Xu, D.-H.; Shoemaker, C. Experimental Induction of Motile *Aeromonas*
177 Septicemia in Channel Catfish (*Ictalurus punctatus*) by Waterborne Challenge with
178 Virulent *Aeromonas hydrophila*. *Aquaculture Reports* **2016**, *3*, 18–23.
179
- 180 46. Heiss, C.; Wang, Z.; Thurlow, C.M.; Hossain, M.J.; Sun, D.; Liles, M.R.; Saper,
181 M.A.; Azadi, P. Structure of the Capsule and Lipopolysaccharide O-Antigen from the
182 Channel Catfish Pathogen, *Aeromonas hydrophila*. *Carbohydr Res* **2019**, *486*,
183 107858.
184
- 185 47. Thurlow, C.M.; Hossain, M.J.; Sun, D.; Barger, P.; Foshee, L.; Beck, B.H.; Newton,
186 J.C.; Terhune, J.S.; Saper, M.A.; Liles, M.R. The Gfc Operon Is Involved in the

- 187 Formation of the O Antigen Capsule in *Aeromonas hydrophila* and Contributes to
188 Virulence in Channel Catfish. *Aquaculture* **2019**, 512.
189
- 190 48. Pridgeon, J.W.; Klesius, P.H. Development and Efficacy of Novobiocin and
191 Rifampicin-Resistant *Aeromonas hydrophila* as Novel Vaccines in Channel Catfish
192 and Nile Tilapia. *Vaccine* **2011**, 29, 7896–7904.
193
- 194 49. Mu, X.; Pridgeon, J.W.; Klesius, P.H. Transcriptional Profiles of Multiple Genes in
195 the Anterior Kidney of Channel Catfish Vaccinated with an Attenuated *Aeromonas*
196 *hydrophila*. *Fish Shellfish Immunol* **2011**, 31, 1162–1172.
197
- 198 50. Li, J.; Ma, S.; Li, Z.; Yu, W.; Zhou, P.; Ye, X.; Islam, M.S.; Zhang, Y.-A.; Zhou, Y.;
199 Li, J. Construction and Characterization of an *Aeromonas hydrophila* Multi-Gene
200 Deletion Strain and Evaluation of Its Potential as a Live-Attenuated Vaccine in Grass
201 Carp. *Vaccines* **2021**, 9, 451.
202
- 203 51. Zhang, D.; Xu, D.-H.; Beck, B. Analysis of Agglutinants Elicited by Antiserum of
204 Channel Catfish Immunized with Extracellular Proteins of Virulent *Aeromonas*
205 *hydrophila*. *Fish Shellfish Immunol* **2019**, 86, 223–229.
206
- 207 52. Zhang, D.; Pridgeon, J.W.; Klesius, P.H. Vaccination of Channel Catfish with
208 Extracellular Products of *Aeromonas hydrophila* Provides Protection against
209 Infection by the Pathogen. *Fish Shellfish Immunol* **2014**, 36, 270–275.
210
- 211 53. Pridgeon, J.W.; Klesius, P.H. Apolipoprotein A1 in Channel Catfish: Transcriptional
212 Analysis, Antimicrobial Activity, and Efficacy as Plasmid DNA Immunostimulant
213 against *Aeromonas hydrophila* Infection. *Fish Shellfish Immunol* **2013**, 35, 1129–
214 1137.
215
- 216 54. Pridgeon, J.W.; Klesius, P.H.; Dominowski, P.J.; Yancey, R.J.; Kievit, M.S. Chicken-
217 Type Lysozyme in Channel Catfish: Expression Analysis, Lysozyme Activity, and
218 Efficacy as Immunostimulant against *Aeromonas hydrophila* Infection. *Fish Shellfish*
219 *Immunol* **2013**, 35, 680–688.
220
- 221 55. Pridgeon, J.W.; Klesius, P.H. G-Protein Coupled Receptor 18 (GPR18) in Channel
222 Catfish: Expression Analysis and Efficacy as Immunostimulant against *Aeromonas*
223 *hydrophila* Infection. *Fish Shellfish Immunol* **2013**, 35, 1070–1078.
224
- 225 56. Pridgeon, J.W.; Klesius, P.H.; Dominowski, P.J.; Yancey, R.J.; Kievit, M.S.
226 Recombinant Goose-Type Lysozyme in Channel Catfish: Lysozyme Activity and
227 Efficacy as Plasmid DNA Immunostimulant against *Aeromonas hydrophila* Infection.
228 *Fish Shellfish Immunol* **2013**, 35, 1309–1319.
229
- 230 57. Zhang, D.; Xu, D.-H.; Shoemaker, C. Immunization with Recombinant Aerolysin and
231 Haemolysin Protected Channel Catfish against Virulent *Aeromonas hydrophila*.
232 *Aquac Res* **2015**, 48.

- 233
234 58. Abdelhamed, H.; Banes, M.; Karsi, A.; Lawrence, M.L. Recombinant ATPase of
235 Virulent *Aeromonas hydrophila* Protects Channel Catfish Against Motile *Aeromonas*
236 Septicemia. *Front Immunol* **2019**, *10*, 1641.
237
238 59. Abdelhamed, H.; Nho, S.W.; Turaga, G.; Banes, M.M.; Karsi, A.; Lawrence, M.L.
239 Protective Efficacy of Four Recombinant Fimbrial Proteins of Virulent *Aeromonas*
240 *hydrophila* Strain ML09-119 in Channel Catfish. *Vet Microbiol* **2016**, *197*, 8–14.
241
242 60. Wang, N.; Yang, Z.; Zang, M.; Liu, Y.; Lu, C. Identification of Omp38 by
243 Immunoproteomic Analysis and Evaluation as a Potential Vaccine Antigen against
244 *Aeromonas hydrophila* in Chinese Breems. *Fish Shellfish Immunol* **2013**, *34*, 74–81.
245
246 61. Gong, Y.-X.; Zhu, B.; Liu, G.-L.; Liu, L.; Ling, F.; Wang, G.-X.; Xu, X.-G. Single-
247 Walled Carbon Nanotubes as Delivery Vehicles Enhance the Immunoprotective
248 Effects of a Recombinant Vaccine against *Aeromonas hydrophila*. *Fish Shellfish*
249 *Immunol* **2015**, *42*, 213–220.
250
251 62. Davis, H.S. A New Bacterial Disease of Fresh-Water Fishes. *Bulletin of the United*
252 *States Bureau of Fisheries* **1922** *38*, 261-280.
253
254 63. Ordal, E.J.; Rucker, R.R. Pathogenic Myxobacteria. *Exp Biol Med* **1944**, *56*, 15–18.
255
256 64. Garnjobst, L. *Cytophaga columnaris* (Davis) in Pure Culture: A Myxobacterium
257 Pathogenic to Fish 1. *J Bacteriol* **1945**, *49*, 113–128.
258
259 65. Bernardet, J.-F.; Grimont, P.A.D. Deoxyribonucleic Acid Relatedness and
260 Phenotypic Characterization of *Flexibacter columnaris* sp. Nov., Nom. Rev.,
261 *Flexibacter psychrophilus* sp. Nov., Nom. Rev., and *Flexibacter maritimus*
262 Wakabayashi, Hikida, and Masumura 1986. *Int J Syst Bacteriol* **1989**, *39*, 346–354.
263
264 66. Bernardet, J.-F.; Segers, P.; Vancanneyt, M.; Berthe, F.; Kersters, K.; Vandamme, P.
265 Cutting a Gordian Knot: Emended Classification and Description of the Genus
266 *Flavobacterium*, Emended Description of the Family Flavobacteriaceae, and Proposal
267 of *Flavobacterium hydatis* Nom. Nov. (Basonym, *Cytophaga Aquatilis* Strohl and
268 Tait 1978). *Int J Syst Bacteriol* **1996**, *46*, 128–148.
269
270 67. LaFrentz, B.R.; García, J.C.; Waldbieser, G.C.; Evenhuis, J.P.; Loch, T.P.; Liles,
271 M.R.; Wong, F.S.; Chang, S.F. Identification of Four Distinct Phylogenetic Groups in
272 *Flavobacterium columnare* With Fish Host Associations. *Front Microbiol* **2018**, *9*,
273 452.
274
275 68. Peterman, M.A.; Posadas, B.C. Direct Economic Impact of Fish Diseases on the East
276 Mississippi Catfish Industry. *North Am J Aquac* **2019**, *81*, 222–229.
277

- 278 69. Moore, A.A.; Eimers, M.E.; Cardella, M.A. Attempts to Control *Flexibacter*
279 *columnaris* Epizootics in Pond-Reared Channel Catfish by Vaccination. *J Aquat*
280 *Anim Health* **1990**, *2*, 109–111.
281
- 282 70. Shoemaker, C.A.; Klesius, P.H.; Drennan, J.D.; Evans, J.J. Efficacy of a Modified
283 Live *Flavobacterium columnare* Vaccine in Fish. *Fish Shellfish Immunol* **2011**, *30*,
284 304–308.
285
- 286 71. Bebak, J.; Wagner, B. Use of Vaccination against Enteric Septicemia of Catfish and
287 Columnaris Disease by the U.S. Catfish Industry. *J Aquat Anim Health* **2012**, *24*, 30–
288 36.
289
- 290 72. Bhattacharya, M.; Malick, R.C.; Mondal, N.; Patra, P.; Pal, B.B.; Patra, B.C.; Kumar
291 Das, B. Computational Characterization of Epitopic Region within the Outer
292 Membrane Protein Candidate in *Flavobacterium columnare* for Vaccine
293 Development. *J Biomol Struct Dyn* **2020**, *38*, 450–459.
294
- 295 73. Lange, M.D.; Abernathy, J.; Farmer, B.D. Evaluation of a Recombinant
296 *Flavobacterium columnare* DnaK Protein Vaccine as a Means of Protection Against
297 Columnaris Disease in Channel Catfish (*Ictalurus punctatus*). *Front Immunol* **2019**,
298 *10*, 1175.
299
- 300 74. Malecki, J.K.; Roy, L.A.; Arias, C.R.; Nhat Truong, T.; Hanson, T.R.; Lange, M.D.;
301 Shoemaker, C.A.; Beck, B.H. Bioeconomic Analysis of *Flavobacterium columnare*
302 Vaccine Pond Trials with Channel Catfish. *North Am J Aquac* **2021**, *83*, 207–217.
303
- 304 75. Kotob, M.H.; Menanteau-Ledouble, S.; Kumar, G.; Abdelzaher, M.; El-Matbouli, M.
305 The Impact of Co-Infections on Fish: A Review. *Vet Res* **2016**, *47*, 98.
306
- 307 76. Labrie, L.; Komar, C.; Terhune, J.; Camus, A.; Wise, D. Effect of Sublethal Exposure
308 to the Trematode *Bolbophorus spp.* on the Severity of Enteric Septicemia of Catfish
309 In Channel Catfish Fingerlings. *J Aquat Anim Health* **2004**, *16*, 231–237.
310
- 311 77. Wise, D.J.; Griffin, M.J.; Terhune, J.S.; Pote, L.M.; Khoo, L.H. Induction and
312 Evaluation of Proliferative Gill Disease in Channel Catfish Fingerlings. *J Aquat Anim*
313 *Health* **2008**, *20*, 236–244.
314
- 315 78. Ksepka, S.P.; Bullard, S.A. Morphology, Phylogenetics and Pathology of “Red Sore
316 Disease” (Coinfection by *Epistylis Cf. Wuhanensis* and *Aeromonas hydrophila*) on
317 Sportfishes from Reservoirs in the South-Eastern United States. *J Fish Dis* **2021**, *44*,
318 541–551.
319
- 320 79. Xu, D.-H.; Shoemaker, C.A.; Klesius, P.H. *Ichthyophthirius multifiliis* as a Potential
321 Vector of *Edwardsiella ictaluri* in Channel Catfish. *FEMS Microbiol Lett* **2012**, *329*,
322 160–167.
323

- 324 80. Yusoff, S.F.M.; Christianus, A.; Matori, F.U. a. D.; Talba, M.A.; Hamid, N.H.;
325 Hamdan, R.H.; Bakar, S.N.A. The Impact of Natural Co-Infection of *Dactylogyrus*
326 *spp.* and *Aeromonas hydrophila* on Behavioural, Clinical, and Histopathological
327 Changes of Striped Catfish, *Pangasianodon hypophthalmus* (Sauvage, 1878): A Case
328 Study. *J Sustain Sci Manag.* **2020**.
329
- 330 81. Sulumane Ramachandra, K.S.; Dube, P.N.; Pandikkadan Sundaran, S.;
331 Kalappurakkal Gopalan, M.; Mangottil Ayyappan, P.; Nandiath Karayi, S.
332 Coinfection with Two Strains of *Photobacterium damsela* Subsp. *damsela* and
333 *Vibrio harveyi* in Cage Farmed Cobia, *Rachycentron canadum* (Linnaeus, 1766).
334 *Aquac Res* **2021**, *52*, 1525–1537.
335
- 336 82. Bruce, T.J.; Ma, J.; Knupp, C.; Loch, T.P.; Faisal, M.; Cain, K.D. Cross-Protection of
337 a Live-Attenuated *Flavobacterium psychrophilum* Immersion Vaccine against Novel
338 *Flavobacterium spp.* and *Chryseobacterium spp.* Strains. *J Fish Dis* **2020**, *43*, 915–
339 928.
340
- 341 83. Erfanmanesh, A.; Beikzadeh, B.; Aziz Mohseni, F.; Nikaein, D.; Mohajerfar, T.
342 Ulcerative Dermatitis in Barramundi Due to Coinfection with *Streptococcus iniae*
343 and *Shewanella algae*. *Dis Aquat Organ* **2019**, *134*, 89–97.
344
- 345 84. Dinçtürk, E.; Tanrikul, T.T. *Yersinia ruckeri* and *Pseudomonas fluorescens* Co-
346 Infection in Rainbow Trout (*Oncorhynchus mykiss* Walbaum, 1792). *Aquac Res* **2021**,
347 *52*, 4858–4866.
348
- 349 85. Han, Z.; Sun, J.; Jiang, B.; Hu, X.; Lv, A.; Chen, L.; Guo, Y. Concurrent Infections
350 of *Aeromonas veronii* and *Vibrio cholerae* in Koi Carp (*Cyprinus carpio* Var. Koi).
351 *Aquaculture* **2021**, *535*, 736395.
352
- 353 86. Chandrarathna, H.P.S.U.; Nikapitiya, C.; Dananjaya, S.H.S.; Wijerathne, C.U.B.;
354 Wimalasena, S.H.M.P.; Kwun, H.J.; Heo, G.-J.; Lee, J.; De Zoysa, M. Outcome of
355 Co-Infection with Opportunistic and Multidrug Resistant *Aeromonas hydrophila* and
356 *A. veronii* in Zebrafish: Identification, Characterization, Pathogenicity and Immune
357 Responses. *Fish Shellfish Immunol* **2018**, *80*, 573–581.
358
- 359 87. Dong, H.T.; Nguyen, V.V.; Phiwsaiya, K.; Gangnonngiw, W.; Withyachumnarnkul,
360 B.; Rodkhum, C.; Senapin, S. Concurrent Infections of *Flavobacterium columnare*
361 and *Edwardsiella ictaluri* in Striped Catfish, *Pangasianodon hypophthalmus* in
362 Thailand. *Aquaculture* **2015**, *448*, 142–150.
363
- 364 88. Crumlish, M.; Thanh, P.C.; Koesling, J.; Tung, V.T.; Gravningen, K. Experimental
365 Challenge Studies in Vietnamese Catfish, *Pangasianodon hypophthalmus* (Sauvage),
366 Exposed to *Edwardsiella ictaluri* and *Aeromonas hydrophila*. *J Fish Dis* **2010**, *33*,
367 717–722.
368

- 369 89. Nofal, M.I.; Abdel-Latif, H.M.R. Ectoparasites and Bacterial Co-Infections Causing
370 Summer Mortalities among Cultured Fishes at Al-Manzala with Special Reference to
371 Water Quality Parameters. *Life Science Journal* **2017**.
372
- 373 90. Peatman, E.; Mohammed, H.; Kirby, A.; Shoemaker, C.A.; Yildirim-Aksoy, M.;
374 Beck, B.H. Mechanisms of Pathogen Virulence and Host Susceptibility in Virulent
375 *Aeromonas hydrophila* Infections of Channel Catfish (*Ictalurus punctatus*).
376 *Aquaculture* **2018**, *482*, 1–8.
377
- 378 91. Li, C.; Wang, R.; Su, B.; Luo, Y.; Terhune, J.; Beck, B.; Peatman, E. Evasion of
379 Mucosal Defenses during *Aeromonas hydrophila* Infection of Channel Catfish
380 (*Ictalurus punctatus*) Skin. *Dev Comp Immunol* **2013**, *39*, 447–455.
381
- 382 92. Ren, Y.; Zhao, H.; Su, B.; Peatman, E.; Li, C. Expression Profiling Analysis of
383 Immune-Related Genes in Channel Catfish (*Ictalurus punctatus*) Skin Mucus
384 Following *Flavobacterium columnare* Challenge. *Fish Shellfish Immunol* **2015**, *46*,
385 537–542.
- 386 93. Griffin, M.J.; Reichley, S.R.; Baumgartner, W.A.; Aarattuthodiyil, S.; Ware, C.;
387 Steadman, J.M.; Lewis, M.; Gaunt, P.S.; Khoo, L.H.; Wise, D.J. Emergence of
388 *Edwardsiella piscicida* in Farmed Channel ♀, *Ictalurus punctatus* × Blue ♂ ,
389 *Ictalurus furcatus* , Hybrid Catfish Cultured in Mississippi. *J World Aquacult Soc*
390 **2019**, *50*, 420–432.
391
- 392 94. Wolters, W.R.; Wise, D.J.; Klesius, P.H. Survival and Antibody Response of Channel
393 Catfish, Blue Catfish, and Channel Catfish Female × Blue Catfish Male Hybrids after
394 Exposure to *Edwardsiella ictaluri*. *J Aquat Anim Health* **1996**, *8*.
395
- 396 95. Arias, C.R.; Cai, W.; Peatman, E.; Bullard, S.A. Catfish Hybrid *Ictalurus punctatus* ×
397 *I. furcatus* Exhibits Higher Resistance to Columnaris Disease than the Parental
398 Species. *Dis Aquat Organ* **2012**, *100*, 77–81.
399
- 400 96. Danley, M.L.; Goodwin, A.E.; Killian, H.S. Epizootics in Farm-Raised Channel
401 Catfish, *Ictalurus punctatus* (Rafinesque), Caused by the Enteric Redmouth
402 Bacterium *Yersinia ruckeri*. *J Fish Dis* **1999**, *22*, 451–456.
403
404
405
406
407
408
409
410
411
412
413
414

415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460

Chapter 2:

Infection Dynamics of Experimental *Edwardsiella ictaluri* and *Flavobacterium covae*
Coinfection in Channel Catfish (*Ictalurus punctatus*)

This manuscript has been published:

Wise, A.L.; LaFrentz, B.R.; Kelly, A.M.; Liles, M.R.; Griffin, M.; Beck, B.H.; Bruce,
T.J. Infection Dynamics of Experimental *Edwardsiella ictaluri* and *Flavobacterium*
covae Coinfection in Channel Catfish (*Ictalurus punctatus*). *Pathogens* **2023**, *XX*,
XX, doi:10.3390/XXX.

461 2.1 Abstract

462 *Edwardsiella ictaluri* and *Flavobacterium covae* are pervasive bacterial pathogens
463 associated with significant losses in catfish aquaculture. Bacterial coinfections have the
464 potential to increase outbreak severity and can worsen on-farm mortality. A preliminary
465 assessment of *in vivo* bacterial coinfection with *E. ictaluri* (S97-773) and *F. covae* (ALG-
466 00-530) was conducted using juvenile channel catfish (*Ictalurus punctatus*). Catfish were
467 divided into five treatment groups: 1) mock control; 2) *E. ictaluri* full dose (immersion;
468 5.4×10^5 CFU mL⁻¹); 3) *F. covae* full dose (immersion; 3.6×10^6 CFU mL⁻¹); 4) *E.*
469 *ictaluri* half dose (immersion; 2.7×10^5 CFU mL⁻¹) followed by half dose *F. covae*
470 (immersion; 1.8×10^6 CFU mL⁻¹); and 5) *F. covae* half dose followed by half dose *E.*
471 *ictaluri*. In coinfection challenges, the second inoculum was delivered 48 hours after the
472 initial exposure. At 21 days post-challenge (DPC), the single dose *E. ictaluri* infection
473 yielded cumulative percent mortality (CPM) of 90.0 ± 4.1 %, compared with 13.3 ± 5.9
474 % in the *F. covae* group. Mortality patterns in coinfection challenges mimicked the single
475 dose *E. ictaluri* challenge, with CPM of $93.3 \pm 5.4\%$ for fish initially challenged with *E.*
476 *ictaluri* followed by *F. covae*, and 93.3 ± 2.7 % for fish exposed to *F. covae* and
477 subsequently challenged with *E. ictaluri*. Despite similarities in final CPM within the
478 coinfection groups, the onset of peak mortality was delayed in fish exposed to *F. covae*
479 first but was congruent with mortality trends in the *E. ictaluri* challenge. Catfish exposed
480 to *E. ictaluri* in both single and coinfecting treatments displayed increased serum
481 lysozyme activity at 4-DPC ($P < 0.001$). Three pro-inflammatory cytokines (*il8*, *tnfa*,
482 *illβ*) were evaluated for gene expression, revealing increased expression at 7-DPC in all
483 *E. ictaluri* exposed treatments ($P < 0.05$). These data enhance our understanding of the
484 dynamics of *E. ictaluri* and *F. covae* coinfections in US farm-raised catfish.

485 2.2 Introduction

486 Aquaculture within the southeastern United States (Mississippi, Alabama, and
487 Arkansas) is primarily dedicated to rearing channel catfish (*Ictalurus punctatus*;
488 Rafinesque, 1818) and hybrid catfish (*Ictalurus punctatus*♀×*I. furcatus* (Valenciennes,
489 1840)♂) for food production. Aquaculture allows farmers to exert high levels of control
490 and environmental manipulation across various production stages, which permits
491 sustainable, high-quality, safe catfish for consumers [1]. The southeastern economy relies
492 heavily on catfish production, with revenues reaching \$398 million in sales in 2021 [2].
493 With competitive profit margins for large-scale production, producers have adopted more
494 intensive aquaculture systems, such as in-pond raceways and partitioned aquaculture
495 systems, to enhance production efficiency [3]. Though intensive production leads to
496 increased profit yields and more efficient land use, increased stocking densities also
497 increase the risk of disease. These risks are also exacerbated by environmental factors,
498 such as temperature and water quality, which can increase the potential for outbreaks [4].
499 The catfish industry has demonstrated decades of enhancements in production methods,
500 and fish health is a consistent target for improvement. Increased stocking densities in
501 more intensive systems leave catfish more prone to disease, and with limited approved
502 antibiotics or commercially available vaccines, farmers have few options for prevention
503 and treatment [5].

504 Most economic losses in the catfish industry are attributed to bacterial disease, with
505 disease-induced anorexia and direct losses from mortality events leading to decreased
506 production [6]. Three bacterial pathogens, *Edwardsiella ictaluri*, *Flavobacterium covae*
507 (formerly *F. columnare* genetic group 2)[7], and hypervirulent *Aeromonas hydrophila*,

508 are primarily responsible for substantial economic losses throughout the sector [8][9].
509 *Edwardsiella ictaluri* and *F. covae* are the causative agents of enteric septicemia of
510 catfish (ESC) and columnaris disease, respectively, which cause significant losses on
511 farms. Diagnostic reports from the Aquatic Research and Diagnostic Laboratory (ARDL)
512 at Stoneville, MS, over the past decade indicate a high incidence of disease associated
513 with *E. ictaluri* or *F. covae* [10]. These pathogens have primarily been evaluated during
514 single infections. To better manage these disease agents, the dynamics of coinfections
515 need to be assessed.

516 Generally, *E. ictaluri* has been considered a more ruinous bacterial pathogen of US
517 farm-raised catfish [11][12]. However, columnaris disease has been a more frequent
518 diagnosis over the past decade, accounting for 41.7% of cases submitted to ARDL
519 compared with 32.5% for ESC from 2009 to 2019 [10]. Outbreaks of ESC typically occur
520 when first-year fingerlings encounter the bacteria for the first time, often in late
521 summer/early fall [13]. Infected fish exhibit lethargy, exophthalmia, cranial ulcers,
522 ascites, and typically display abnormal swimming behaviors, including spiral swimming
523 patterns and stargazing [14]. Lost productivity due to morbidity and mortality culminates
524 in an estimated \$60 million in annual economic losses to the industry [15].

525 Comparably, *F. covae* is a Gram-negative bacterium responsible for columnaris
526 disease [7]. Columnaris disease typically presents as an external infection of the skin,
527 fins, and gills and often in the presence of other bacterial or parasitic agents. Reports
528 from the Louisiana Aquatic Diagnostic Laboratory in the early 1990s indicated that
529 nearly 90% of Columnaris diagnoses were mixed infections [16]. Columnaris disease,

530 like ESC, is one of the leading causes of mortality in channel catfish [17], with losses due
531 to the pathogen estimated to exceed \$30 million annually [8][18].

532 Coinfections, which occur when a host is infected with multiple pathogens, have
533 been reported for farm-raised catfish, although information regarding prevalence,
534 mortality rates, and mechanisms of infection is scarce [19]. Coinfections between *E.*
535 *ictaluri* and *F. covae* have been documented in catfish diagnostic cases from Alabama
536 and Mississippi [20]. While effective treatment and prevention strategies for each
537 pathogen have been developed [21][22][23][24][25][26], the ability of these approaches
538 to combat coinfections is unknown, and efficacy of approved antibiotics has yet to be
539 defined under conditions where a combination of pathogens infect a single fish.

540 As a first step in defining these coinfection interactions in channel catfish, these
541 pathogens must be assessed in tandem to determine exactly how mortality is impacted
542 along with several innate immune parameters. At present, it is unknown if dual infections
543 of these agents interact synergistically or antagonistically in the fish host [19] and the
544 impact of coinfections of these two agents may be underappreciated. Herein, the
545 dynamics of *E. ictaluri* and *F. covae* coinfections were assessed in juvenile channel
546 catfish under controlled conditions. These studies lay the foundation for future works
547 assessing the pathophysiological and immunologic responses during mixed infections and
548 the development of management strategies to minimize the impact these agents have on
549 catfish health and production.

550

551

552 2.3 Materials and Methods

553 2.3.1. *Bacteria and Culture Conditions*

554 *E. ictaluri* S97-773 [27] (GenBank CP084521) was revived from cryogenic
555 storage (-80 °C) by isolation streaking onto brain heart infusion agar (BHIA) and
556 incubated for 48 h at 28 °C. Following confirmation of morphology, an individual colony
557 was expanded in 20 mL of brain heart infusion broth (BHIB; BD Biosciences; Franklin
558 Lakes, NJ, USA) for 18 h at 28 °C with shaking (175 rpm). After incubation, 100 µL of
559 broth was used to seed 250 mL of BHIB (18 h at 28 °C, 175 rpm). The final challenge
560 culture was adjusted to an optical density at 600 nm (OD₆₀₀) of 1.058 using sterile BHIB
561 and a Biophotometer Plus spectrophotometer (Eppendorf; Enfield, CT, USA). Similarly,
562 *F. covae* ALG-00-530 [7] (GenBank MW353001) was revived from cryostock by
563 isolation streaking on modified Shieh agar (MSA) [28] and 24 h incubation at 28 °C. A
564 single yellow-pigmented adherent rhizoid colony was subsequently transferred to a 50
565 mL conical tube containing 10 mL of sterile, modified Shieh broth (MSB) and expanded
566 for 12 h at 28 °C with shaking (175 rpm). An aliquot (5 mL) was used to seed 200 mL of
567 MSB and expanded for 12 h under the same conditions. As above, the challenge culture
568 was adjusted using sterile MSB to an OD₅₅₀ = 0.707. Viable cell concentrations of
569 adjusted cultures were determined using standard plate count techniques and appropriate
570 media for each pathogen (*E. ictaluri*: BHIA; *F. covae*: MSB).

571

572 2.3.2 *Experimental Design (Trials A and B)*

573 Healthy, juvenile channel catfish (Marion strain; ~15 g) from the E.W. Shell
574 Fisheries Center at Auburn University (Auburn, AL) were reared in a recirculating

575 aquaculture system (RAS) with dechlorinated municipal water prior to study initiation.
576 To characterize coinfections involving *E. ictaluri* and *F. covae*, catfish were arbitrarily
577 assigned to five treatment groups (6 tanks per treatment; 20 fish per tank) for *in vivo*
578 infectivity trials. All fish were transferred into respective tanks containing 38 L (within a
579 64 L tank) at 2 d prior to the challenge. The aquaria were supplied with flow-through
580 dechlorinated municipal water at a rate of 0.5 L min⁻¹ at 28 °C with supplemental
581 aeration. Fish were both monitored and fed twice daily during acclimation. Fish were
582 randomly distributed within tanks and treatment groups were randomly assigned to tanks,
583 and Groups 1 and 2 were exposed by immersion to the full dose of *E. ictaluri* and *F.*
584 *covae*, respectively. Group 3 received a half dose of *E. ictaluri* followed by a half dose of
585 *F. covae* 48 h later. Conversely, Group 4 received a half dose of *F. covae* with a
586 subsequent half dose of *E. ictaluri* after 48 h. Group 5 consisted of mock-challenged fish
587 exposed to sterile phosphate-buffered saline (PBS; pH 7.2). The Group 5 control group
588 received PBS twice (0 h and 48 h), just as the coinfection Groups 3 and 4 to consider any
589 potential stress effect. Throughout the manuscript, treatments that received *F. covae*
590 followed by *E. ictaluri* are defined as co-*F. covae*, while fish exposed to *E. ictaluri*,
591 followed by *F. covae*, are deemed co-*E. ictaluri*. For each treatment, 3 tanks served to
592 estimate challenge mortality, while 3 tanks were used for sampling.

593 During the immersion challenge, the water level was lowered to 10 L for all tanks
594 and was restored to the normal level post-challenge. Group 1 tanks received a 6 mL
595 inoculum (OD₆₀₀= 1.058) of *E. ictaluri*, bathed for 0.5 h in 10 L of rearing water (28 °C),
596 delivering a dose of 5.4×10^5 CFU mL⁻¹. Group 2 tanks were dosed with a 110 mL
597 inoculum (OD₅₅₀= 0.707) of *F. covae* for 0.5 h in 10 L, yielding a delivered dose of 3.63

598 $\times 10^6$ CFU mL⁻¹. Group 3 tanks received 3 mL of the same *E. ictaluri* culture, delivering
599 2.7×10^5 CFU mL⁻¹, followed 48 h later with a 55 mL inoculum of *F. covae* culture (1.8
600 $\times 10^6$ CFU mL⁻¹). Similarly, Group 4 tanks received 55 mL of *F. covae* inoculum
601 delivering 1.8×10^6 CFU mL⁻¹ and subsequent 3 mL of *E. ictaluri* culture 48 h later (2.7
602 $\times 10^5$ CFU mL⁻¹). All challenge doses were administered under the same conditions.
603 Post-initiation, tanks were monitored twice daily, and deceased fish were removed from
604 tanks. Mortality was used as the clinical endpoint for the trials. Feed was offered to fish
605 twice daily, and uneaten pellets were removed at each checkpoint. Up to 20% of daily
606 mortalities were necropsied and cultured to confirm the presence of bacteria. Coinfected
607 groups were plated on both BHIA and MSA to culture both bacteria. The end of the
608 challenge was determined once mortality had ceased for several days.

609 A second immersion trial was conducted to include additional doses equivalent to
610 those administered for coinfection treatments and to discern the contribution of half-
611 doses to mortality for each pathogen. Catfish (~22 g) were distributed to 27 tanks (3 tanks
612 per treatment; 20 fish per tank). Treatments consisted of: Full dose *E. ictaluri*, half dose
613 *E. ictaluri*, full dose *F. covae*, half dose *F. covae*, full dose *E. ictaluri* followed by full
614 dose *F. covae*, half dose *E. ictaluri* followed by half dose *F. covae*, full dose *F. covae*
615 followed by full dose *E. ictaluri*, half dose *F. covae* followed by half dose *E. ictaluri* and
616 sham challenge (sterile PBS). The *E. ictaluri* treatments received 4 mL (full) or 2 mL
617 (half) of inoculum (OD₆₀₀ = 1.065), yielding exposure doses of 3.8×10^5 CFU mL⁻¹ for
618 full doses and 1.9×10^5 CFU mL⁻¹, respectively. Similarly, the *F. covae* treatments
619 received 100 (full) or 50 mL (half) inoculums of culture (OD₅₅₀ = 0.747) which resulted in
620 immersion baths of 7.56×10^6 CFU mL⁻¹ for full doses and 3.78×10^6 CFU mL⁻¹ for the

621 half dose. For the challenge, catfish were bathed for 0.5 h in 10 L water, and secondary
622 doses were delivered 48 h after the initial exposure for coinfection treatments. No
623 sampling tanks were involved in Trial B.

624

625 *2.3.3. Collection and Sampling*

626 Fish from Trial A were sampled (3 fish per tank and triplicate tanks per treatment
627 group) at 2, 4, 7, and 21 days post-challenge. Fish were euthanized with a lethal overdose
628 of buffered tricaine methanesulfonate (MS-222; Syndel, Ferndale, WA) at 250 mg L⁻¹.
629 Anterior kidney, spleen, and blood were collected aseptically and used for extraction of
630 RNA, DNA, and serological analysis, respectively. Kidney and spleen tissues were
631 preserved in DNA/RNA Shield™ (Zymo Research Corp., Irvine, CA, USA) and stored at
632 -20 °C until nucleic acid extraction. To assess serum lysozyme activity, fish were bled
633 from the caudal vein using 22 ga syringes, and samples were allowed to clot overnight at
634 4 °C. Following separation, blood samples were concentrated at 15,000 × g (Eppendorf
635 5420; Enfield, CT, USA) for 5 min, serum collected by micropipette and stored at -80 °C
636 until processing.

637

638 *2.3.4 Bacterial DNA and tissue RNA Extraction*

639 Reisolated bacterial colonies collected from the daily mortalities were subcultured
640 from posterior kidneys and spleen and processed to extract DNA for endpoint PCR to
641 confirm pathogen identity. Genomic DNA was isolated using the Omega E.Z.N.A.™
642 Bacterial DNA Kit (Omega Bio-tek, Inc., Norcross, GA, USA), eluted with 100 µL of
643 provided elution buffer, quantified spectrophotometrically (Nanodrop One^c; Thermo

644 Fisher Scientific, Waltham, MA, USA) and stored at -20 °C until PCR analysis. Kidney
645 tissue samples, harvested at all time points, were manually homogenized in DNA/RNA
646 Shield™ (Zymo Research Corp., Irvine, CA, USA) using a mortar and pestle. RNA was
647 extracted following the Zymo Research Quick-RNA™ MiniPrep Plus kit, eluted with 100
648 µL of nuclease-free water, quantified spectrophotometrically, and stored at -80 °C.

649

650 2.3.5. Gene expression analysis

651 Extracted RNA was diluted to 50 ng µL⁻¹ using nuclease-free water and converted
652 to cDNA using the High-Capacity cDNA Reverse Transcription Kit™ (Applied
653 Biosystems, Waltham, MA, USA) following the manufacturer's instructions. Each 20-
654 µL reaction contained 2 µL of 10x RT buffer, 0.8 µL of 25x dNTP Mix, 2 µL of 10x RT
655 random primers, 1 µL of MultiScribe™ reverse transcriptase, 500 ng of template RNA
656 and nuclease-free water to volume. cDNA was synthesized in a MiniAmp Plus thermal
657 cycler (Applied Biosystems, Carlsbad, CA, USA) programmed for one cycle of 25 °C for
658 10 min, 37 °C for 120 min, and 85 °C for 5 min and subsequently diluted to 2.5 ng µL⁻¹
659 using nuclease-free water. Four genes were evaluated for expression analysis, namely
660 *il1β*, *tnfa* [29], *il8* [30], and *tgfb-1* [31]. The housekeeping genes *ef1a* [30] and *actb* [32]
661 were used for normalization. The PCR was carried out in 10-µL volumes consisting of 5
662 µL PowerUp SYBR Green Master Mix™ (Applied Biosystems, Carlsbad, CA, USA),
663 forward and reverse primers at 500 nM (Supplemental Table 1), 2 µL of sample cDNA
664 nuclease-free water to volume. Each sample was run in duplicate along with no-template
665 controls consisting of nuclease-free water in place of template cDNA. PCRs were run on
666 a QuantStudio™ 5 Real-Time PCR system (Applied Biosystems Carlsbad, CA, USA)

667 programmed for initial steps of 50 °C for 2 min and 95 °C for 2 min, followed by 40
668 cycles of 95 °C for 15 sec, 58 °C for 15 sec, and 72 °C for 30 sec, with data collection
669 occurring after the 72 °C elongation. For each gene target, reaction efficiencies were
670 assessed using serial dilutions of cDNA covering five orders of magnitude, run in
671 duplicate, and starting at 10 ng. For each gene, reaction efficiencies ranging from 90-
672 110% were considered acceptable [33]. For calculations, the $2^{-\Delta\Delta C_t}$ method was
673 implemented [34], taking into consideration the combination of both housekeeping genes
674 along with the control group for each time point. Thus, each fold change of the gene of
675 interest was expressed relative to that of the control group average at that time point.

676

677 2.3.6. Lysozyme Activity Assay

678 Lysozyme activity was ascertained by comparisons to prepared standards
679 following previously published protocols [35]. Standards consisted of dilutions of a stock
680 $480 \mu\text{g mL}^{-1}$ chicken lysozyme egg white (Rockland Immunochemicals, Pottstown, PA,
681 USA) dissolved in sodium phosphate buffer (SPB; 0.04 M Na_2HPO_4 ; pH 6.0) and diluted
682 to create a standard curve with a range of 0-16 $\mu\text{g mL}^{-1}$. Freeze-dried *Micrococcus*
683 *lysodeikticus* (Worthington Biochemical, Lakewood, NJ, USA) was resuspended at 0.25
684 mg mL^{-1} with SPB, and 250 μL of the bacterial suspension was added to each well, along
685 with 10 μL of sera. Each sample was run in duplicate. Absorbances at OD_{450} were
686 collected after a 20 min incubation at 37 °C with Synergy HTX Multimode Reader
687 (BioTek, Winooski, VT, USA) and compared with concurrently run standards.

688

689 2.3.7. PCR Confirmation of Recovered Isolates

690 The identity of presumptive *E. ictaluri* isolates recovered from dead/moribund
691 fish was confirmed by *E. ictaluri*-specific PCR. All PCR were conducted on a MiniAmp
692 thermal cycler (Applied Biosystems, Carlsbad, CA, USA). Colony PCR was performed
693 on representative colonies to confirm presumptive identification as *E. ictaluri*. Specific
694 ESC primers (ESCF and ESCR) [36] were used. Each 25- μ L reaction consisted of a 12.5
695 μ L 2x hot-start PCR-to-gel-master mix (Amresco LLC, Solon, OH, USA), 0.2 mM of
696 each primer, and nuclease-free water to volume. Positive (DNA extracted from *E. ictaluri*
697 (S97-773) and negative controls (nuclease-free water) were run in tandem with samples.
698 Cycle conditions were 95 °C for 5 min, followed by 30 cycles at 95 °C for 15 sec, an
699 annealing temperature of 58 °C for 15 sec, and 72 °C for 15 sec. The final extension was
700 run at 72 °C for 5 min. Aliquots of PCR products (5 μ L) were separated by
701 electrophoresis through 2.0 % agarose gels in Tris-acetate-EDTA (TAE) buffer, stained
702 with GelRed (Biotium Inc., Fremont, CA, USA) and visualized by ultraviolet
703 transillumination in a Gel Doc Go imaging system (Bio-Rad, Inc., Hercules, CA, USA).
704 Samples were run alongside concurrently run molecular weight standards to confirm the
705 presence of appropriately sized bands.

706 Presumptive *F. covae* recovered from dead fish were confirmed by multiplex
707 PCR as described by [7][37]. Each 25 μ L reaction contained a 12.5 μ L 2x hot-start PCR-
708 to-gel-master mix (Amresco LLC, Solon, OH, USA), 2 μ L of the primer cocktail (0.5 μ M
709 GG-forward, 0.1 μ M GG1-reverse, 0.45 μ M GG2-reverse, 0.45 μ M GG3-reverse, 0.3
710 μ M GG4-reverse), 9.5 μ L of nuclease-free water, and 1.0 μ L of template
711 DNA. The cycle parameters used were: 95 °C for 5 mins, 40 cycles of 94 °C for 30
712 seconds, 56 °C for 20 secs, and 72 °C for 1 min, followed by 10 min at 72 °C. The *F.*

713 *covae* AL-02-36^T type strain was run as a positive control. As described above, PCR
714 products (5 µL) were resolved on a 2.0 % agarose gel via electrophoresis.

715

716 2.3.8. Statistical Analyses

717 Comparisons between treatment groups over time for cumulative percent mortality,
718 lysozyme activity (2, 4, and 7 DPC), and gene expression analyses (2, 4, and 7 DPC)
719 were performed using a two-way repeated measures ANOVA ($\alpha= 0.05$) for treatment,
720 time, and treatment x time, with tanks included as a random factor. Serum lysozyme
721 activity was analyzed separately at 21 DPC using a one-way ANOVA due to a lack of
722 surviving fish within sampling tanks. Tukey's post hoc test was conducted when
723 treatment effects were significant ($P<0.05$). Statistical analysis was performed using R
724 statistical software (R core Team, 2021). All errors reported throughout the paper
725 represent the standard error of the mean among treatment tanks, as tanks were defined as
726 the experimental unit.

727 2.4. Results

728

729 2.4.1. Infectivity Trial A

730 Daily mortality was recorded across triplicate tanks over 21 days (Figure 1). The
731 cumulative percent mortality (CPM) of the *E. ictaluri* only group (90.0 ± 4.1 %) or the
732 two coinfection treatments (co-*E. ictaluri*; 93.3 ± 5.4 %; co-*F. covae*; 93.3 ± 2.7 %) was
733 significantly different than CPM of the *F. covae* only group (13.3 ± 5.9 %; $P < 0.001$),
734 indicating mortality observed in this trial was primarily due to *E. ictaluri* infection. The
735 onset of mortality in the co-*F. covae* was delayed compared with treatments receiving *E.*

736 *ictaluri* alone or first. Fish exposed to *E. ictaluri* alone or followed with *F. covae*
737 infection first showed signs of illness such as lethargy, reduced feeding response, and
738 exophthalmia and mortality between 4-6 days post-challenge, while fish exposed to *F.*
739 *covae* followed by *E. ictaluri* challenge 48 h after *F. covae* exposure did not show signs
740 of disease until 9 days post-challenge, although CPM of any treatment exposed to *E.*
741 *ictaluri* were not significantly different ($P > 0.05$) (Figure 1).

742 Fish exposed solely to *E. ictaluri* exhibited exophthalmia, petechial hemorrhaging
743 of pectoral and anal fins, internal hemorrhaging, and eye hemorrhaging (Figure 2). Fish
744 exposed with *F. covae* presented saddleback lesions along the dorsal fin, characteristic of
745 columnaris disease, and exhibited internal hemorrhaging of the intestines and anterior
746 kidneys (Figure 3). Coinfected fish from both treatment combinations demonstrated a
747 mix of single infection clinical signs exhibiting saddleback lesions and intestinal or
748 ocular hemorrhaging (Figures 2A and 3B). Fish exposed to both bacterial pathogens
749 contained both *E. ictaluri* and *F. covae* bacterial colonies, while bacterial colonies
750 recovered from treatment groups exposed to only single pathogens presented only
751 colonies from the pathogen to which they were exposed.

752

753 2.4.2. Infectivity Trial B

754 Trial B included half-doses across treatment groups and was conducted identically
755 to Trial A (Figure 4). Treatment groups showed significant differences in CPM ($P <$
756 0.001). Fish exposed to *F. covae* alone averaged a CPM of $28.3 \pm 11.9\%$. Mortality in
757 fish administered a half-dose of *F. covae* ($6.7 \pm 2.7\%$) was not significantly different (P
758 > 0.05) compared with the full *F. covae* dose due to a high level of variability between

759 replicates. Mortality comparisons between full- and half-doses for each treatment group
760 were also insignificant. The CPM (98.3 ± 1.4 %) for the full dose *E. ictaluri*/*F. covae*
761 treatment group was significantly different from the CPM of the full *F. covae* dose (28.3
762 ± 11.9 %; $P < 0.01$), and the half dose of *F. covae* (6.7 ± 2.7 %; $P < 0.001$). Clinical
763 signs during Trial B were consistent with Trial A; however, fish exposed to *F. covae* and
764 then *E. ictaluri* presented solely with saddleback lesions with mild external hemorrhaging
765 along with distended abdomens.

766

767 2.4.3. Serum Lysozyme Activity

768 Serum lysozyme activity from Trial A was evaluated at 2, 4, and 7 days post-
769 challenge (Figure 5). Comparisons were made amongst treatment groups at and between
770 time points. Interactions between time and treatment were significant ($P < 0.001$). At 2
771 DPC, lysozyme activity was significantly elevated for groups exposed to *E. ictaluri* (co-
772 *E. ictaluri* and *E. ictaluri*) compared with controls ($P < 0.001$). Further, the *E. ictaluri*
773 and co- *E. ictaluri* treatment groups demonstrated significantly ($P < 0.001$) greater
774 lysozyme activity than the co-*F. covae* and *F. covae* treatment groups. Similar results
775 were observed at 4 DPC, although with an increase in lysozyme activity compared with 2
776 DPC ($P < 0.001$). Again, co-*E. ictaluri* and *E. ictaluri* treatment groups exhibited
777 significantly greater ($P < 0.001$) lysozyme activity compared with the *F. covae* treatment
778 and controls ($P < 0.001$). Lysozyme activity significantly increased between 2 and 4 DPC
779 for the co-*F. covae* treatment but was not statistically different than the co-*E. ictaluri* or
780 *E. ictaluri* treatment groups ($P > 0.05$). For all groups, lysozyme activity at 7 DPC was
781 similar to 4 DPC, yet greater than 2 DPC ($P > 0.05$). Again, activity in the *E. ictaluri*, co-

782 *E. ictaluri*, and co-*F. covae* treatment groups were greater than the *F. covae* and control
783 ($P < 0.001$) groups. Peak lysozyme activity occurred at 4 and 7 DPC. When analyzed with
784 all other times, a significant decrease in lysozyme activity at 21 DPC was observed
785 compared with both 4 and 7 DPC ($P < 0.001$). Due to a lack of surviving fish within
786 samplings tanks, 21 DPC lysozyme activity was analyzed separately, and no significance
787 was determined between treatment groups ($P > 0.05$) (Figure 6).

788

789 2.4.4. Gene expression analysis

790 At 2 DPC, single *E. ictaluri* had elevated *il8* expression compared with single *F.*
791 *covae* ($P < 0.05$) (Figure 7). At 4 DPC, *E. ictaluri* and co-*E. ictaluri* treatment groups
792 exhibited greater *il8* gene expression than all other groups ($P < 0.05$). At 7 DPC, *il8*
793 expression peaked, with *E. ictaluri*, co-*E. ictaluri*, and co-*F. covae* treatment groups
794 yielding greater *il8* expression than the *F. covae* treatment and controls ($P < 0.01$). At 2
795 DPC, the *il1 β* expression for *E. ictaluri* and co-*E. ictaluri* treatment groups were
796 increased compared with *F. covae* and co-*F. covae* groups as well as controls ($P < 0.01$)
797 (Figure 8). Similar levels of expression were observed at 4 DPC, although no significant
798 differences existed between treatments or controls. Similar to *il8*, there was increased *il1 β*
799 expression at 7 DPC compared with 2 and 4 DPC ($P < 0.001$), with the *E. ictaluri*
800 treatment exhibiting greater *il1 β* expression than the *F. covae* treatment and control
801 groups ($P < 0.05$). The co-*F. covae*, and co-*E. ictaluri* treatment groups also exhibited
802 significantly greater *il1 β* expression than the control group ($P < 0.01$). There were no
803 statistical differences in the expression of *tnfa* at 2 and 4 DPC (Figure 9). At 7 DPC, *tnfa*
804 was increased in the co- *E. ictaluri*, co- *F. covae*, and *E. ictaluri* treatment groups

805 compared with unexposed controls ($P < 0.001$). There were no significant differences in
806 the expression of *tgfb-1* throughout the experiment (Figure 10). Interactions between time
807 and treatment for each gene (*il1 β* , *tgfb-1*, *tnfa*, *il8*) were evaluated and were not
808 significant ($P > 0.05$).

809 2.5 Discussion

810 Given the prevalence of *E. ictaluri* and *F. covae* throughout US catfish aquaculture,
811 the synergistic dynamics of these two pathogens must be evaluated to appreciate the
812 impact of coinfections on fish health [38]. Concurrent infections are prevalent throughout
813 aquaculture industries and occur with a variety of different pathogens [39]. Tilapia
814 (*Oreochromis niloticus*; Linnaeus, 1758), zebrafish (*Danio rerio*; F. Hamilton, 1822),
815 rainbow trout (*Oncorhynchus mykiss*; Walbaum, 1792), Atlantic salmon (*Salmo salar*;
816 Linnaeus, 1758), koi (*Cyprinus rubrofasciatus*; Lacépède, 1803), shrimp (suborder Caridea;
817 Dana, 1852), and oysters (family Ostreidae; Rafinesque, 1815) all experience
818 coinfections that can augment mortality [40][41][42][43]. Within catfish species,
819 coinfections of *A. hydrophila* and *E. ictaluri* can increase mortality [44]. Though
820 coinfections commonly occur, information on pathogenicity and host response is virtually
821 unknown as most research has focused on single pathogen infections [45][46].
822 Additionally, this information is not frequently investigated or reported within the U.S.
823 catfish industry. In both infectivity trials and previous coinfective work, *E. ictaluri* acts as
824 the primary driver for mortality. In contrast, *F. covae*, though it causes mortality, acted
825 more as a secondary pathogen within this challenge model. The co-*E. ictaluri* group did
826 not demonstrate a difference in mortality compared with *E. ictaluri* alone, while the co-*F.*
827 *covae* group displayed significantly higher mortality than the single dose of *F. covae* in

828 trial A, presumably due to the introduction of *E. ictaluri*. In trial B, the co-*E. ictaluri*
829 group again exhibited higher mortality than observed for all single-infected treatment
830 groups. Previous trials evaluating coinfections associated with *E. ictaluri* reported high
831 mortality levels in *E. ictaluri* only groups [47]. Crumlish et al. (2010) observed high
832 mortality (80%) caused by *E. ictaluri*, whereas *A. hydrophila* induced very low mortality
833 (10%). Comparatively, coinfection with the two yielded 100% mortality, with much of
834 that likely driven by *E. ictaluri* [44]. A culmination of previous coinfection trials using *E.*
835 *ictaluri* and the data presented herein offers strong evidence that *E. ictaluri* is the primary
836 pathogen under these experimental conditions. Still, it would be of interest to repeat this
837 trial work with additional *F. covae* strains and additional pathogen implementation time
838 points to better discern the contributions of each pathogen to the observed mortality.

839 In addition to assessments of cumulative mortality, there were differences in the
840 onset of mortality, depending on which pathogen the fish were exposed to first. In the
841 first trial, differences in the day of the first fatality appeared driven by *E. ictaluri*, with
842 delayed fatality in fish challenged with *E. ictaluri* later. However, in the second trial, the
843 treatment group challenged with a full dose of co-*E. ictaluri* demonstrated 98.33% CPM,
844 while the comparable full dose of the co-*F. covae* group averaged 58.33% CPM.
845 Although not different, this was an interesting decrease observed due to varying the
846 timing of pathogen inoculation. This difference in onset and severity of disease between
847 the alternation of *E. ictaluri* and *F. covae* has not previously been documented. These
848 results suggest the possibility of potential antagonistic interactions between the pathogens
849 depending on which pathogen fish were exposed to first. Such antagonistic interactions
850 may cause pathogens within the host to compete for resources, thus lessening the effects

851 of one pathogen and causing a decrease in mortality [48]. Obtaining a complete
852 understanding of coinfective pathogen interactions may better define the primary and
853 secondary roles of each pathogen concerning virulence and help in developing more
854 effective treatments and mitigation strategies, especially for species raised in natural,
855 open pond environments [20][41]. Further histopathological assessments are needed to
856 confirm and better characterize the clinical differences in co- versus single infections, as
857 they are crucial in assessing disease [49].

858 Lysozyme within diseased channel catfish serves as one of the first immunological
859 host defenses [50]. Within fish, lysozyme is present in the mucosal barrier and sera of
860 fish [51]. The increases in lysozyme activity observed with coinfecting channel catfish
861 relative to single-infected fish provide further evidence that coinfections can drastically
862 upregulate the host's innate immune response, thus giving insight into which innate
863 immune parameters are enhanced due to infection [52]. Lysozyme activity within all
864 groups followed the same pattern as mortality between treatment groups. While
865 monitoring lysozyme activity between groups over 21 days, each treatment follows the
866 same trend with lysozyme activity low at 2 DPC, increasing to maximum observed
867 activity levels at 4 and 7 DPC, then declining at 21 DPC. The increase in lysozyme
868 activity documented in *E. ictaluri*, co- *E. ictaluri*, and co- *F. covae* corresponds with the
869 mortality observed within each group, suggesting that *E. ictaluri* specifically contributed
870 to the observed mortality and increased lysozyme activity. When evaluating enzyme
871 activity between periods (2, 4, 7, 21 DPC), 2 DPC and 21 DPC had no significant
872 difference, coinciding with the infection's beginning and end. At 21 DPC, lysozyme
873 activity dramatically decreased, indicating downregulation of the innate immune

874 components and further suggesting that surviving fish have cleared the infection. Other
875 studies have documented lysozyme activity with *E. ictaluri* and *F. covae* during single
876 infections. Ren et al. (2015) observed catfish exposed to *E. ictaluri* caused a substantial
877 increase in lysozyme expression within major internal organs (liver, spleen, and kidney)
878 and within the mucosal surface of the fish [53]. Similar results were demonstrated within
879 these disease trials in this study. Interestingly, lysozyme activity seems to follow the
880 expression patterns of an *E. ictaluri* infection during coinfections. In trial B, co-*F.covae*
881 treatment had lower mortality than the co-*E. ictaluri* treatment group, but lysozyme levels
882 appeared to increase in response to *E. ictaluri*. Monitoring lysozyme presence throughout
883 illness provides an understanding of host immunological processes in response to specific
884 pathogens like *E. ictaluri*. Due to lysozyme possessing antibacterial properties in the
885 mucosa, liver, and intestinal tract [54], lysozyme activity may, to some degree, mitigate
886 disease [55]. But in this study, lysozyme activity was correlated with fish with a severe *E.*
887 *ictaluri* infection and high ultimate mortality. Thus, further experimentation would help
888 understand the role of lysozyme (both serum and mucus) in targeting specific catfish
889 pathogens via the host immune response.

890 All pro-inflammatory cytokine genes (*il8*, *tnfa*, and *il1 β*) followed the same trend,
891 where they were prominently increased leading up to 7 DPC. Concerning expression
892 changes over time, at 2 and 4 DPC, each immune gene demonstrated no significant
893 differences in expression, while at 7 DPC, each gene had a significant upregulation,
894 indicating that channel catfish have an upregulation of innate pro-inflammatory genes to
895 combat bacterial pathogens during infection. Treatment groups *E. ictaluri*, co-*E. ictaluri*,
896 and co-*F. covae* had significantly more gene expression at day 7 than both *F. covae* and

897 controls. This also indicates that the higher the mortality experienced by treatment, the
898 higher each pro-inflammatory gene is expressed. However, *tgfb-1* expression had no
899 significant differences between the treatment groups or sampling periods, likely due to
900 the function of *tgfb-1* as an immunosuppressive cytokine that inhibits the immune
901 response. During infection, the immune response will upregulate genes that will aid in the
902 fish's survival, so upregulation of *tgfb-1* would be counterproductive. To better discern
903 the impacts of bacterial coinfection, further studies evaluating the link between pathogen
904 and host response (i.e., transcriptomics) may allow researchers to discern the individual
905 contribution of each pathogen on the host cytokine response. Additionally, the
906 simultaneous influence of two bacteria may also produce exhaustion of the host
907 metabolism, which may have a role in cytokine expression dynamics.

908 In summary, a major conclusion of this study was that a combined *E. ictaluri* and *F.*
909 *covae* infection increased fish mortality. Within these experimental conditions, *E. ictaluri*
910 acted as the primary driver of mortality in both trials. While *F. covae* alone resulted in
911 low mortality, when combined with *E. ictaluri*, this pathogen caused a substantial
912 increase in mortality. During the co- or single infection with *E. ictaluri*, an upregulation
913 of lysozyme activity and pro-inflammatory cytokines was observed. Though several
914 characteristics were evaluated during *E. ictaluri* and *F. covae* coinfections, future studies
915 are needed to resolve the respective roles of each bacterial pathogen and how specific
916 virulence factors impact host immune and other responses. A more natural coinfection
917 disease model can aid fish health diagnosticians and channel catfish producers to better
918 control bacterial coinfections with more rapid and accurate disease diagnostics and
919 develop more efficient treatments that consider the presence of multiple pathogens.

920 2.6 References

921

- 922 1. Osmundsen, T.C.; Amundsen, V.S.; Alexander, K.A.; Asche, F.; Bailey, J.; Finstad,
923 B.; Olsen, M.S.; Hernández, K.; Salgado, H. (2020). The operationalisation of
924 sustainability: Sustainable aquaculture production as defined by certification
925 schemes. *Glob. Environ. Change* **2020**, *60*, 102025.
926
- 927 2. United States Department of Agriculture: Stuttgart, AR, USA. National Agricultural
928 Statistics Service Catfish Production 02/11/2022. [(accessed on 1 December
929 2022)];**2021** p. 7. Available
930 online: <https://usda.library.cornell.edu/concern/publications/bg257f046?locale=en>.
931
- 932 3. Kumar, G.; Engle, C.; Hegde, S.; van Senten, J. Economics of US catfish farming
933 practices: Profitability, economies of size, and liquidity. *J. World Aquac. Soc.* **2020**,
934 *51*(4), pp.829-846.
935
- 936 4. Bosworth, B.; Ott, B.; Torrains, L. Effects of stocking density on production traits of
937 channel catfish x blue catfish hybrids. *N. Am. J. Aquac.* **2015**, *77*(4), 437–443.
938
- 939 5. Chuah, L.O.; Effarizah, M.E.; Goni, A.M.; Rusul, G. Antibiotic application and
940 emergence of multiple antibiotic resistance (MAR) in global catfish aquaculture.
941 *Curr. Environ. Health Rep.* **2016**, *3*(2), 118–127.
942
- 943 6. Meyer, F.P. Aquaculture disease and health management. *J. Anim. Sci.* **1991**, *69*(10),
944 4201–4208.
945
- 946 7. LaFrentz, B.R.; Králová, S.; Burbick, C.R.; Alexander, T.L.; Phillips, C.W.; Griffin,
947 M.J.; Waldbieser, G.C.; García, J.C.; de Alexandre Sebastião, F.; Soto, E.; Loch,
948 T.P.; Liles, M.R.; Snekvik, K.R. The fish pathogen *Flavobacterium columnare*
949 represents four distinct species: *Flavobacterium columnare*, *Flavobacterium covae*
950 sp. nov., *Flavobacterium davisii* sp. nov. and *Flavobacterium oreochromis* sp. nov.,
951 and emended description of *Flavobacterium columnare*. *Syst. Appl. Microbiol.* **2022**,
952 *45*(2), 126293.
953
- 954 8. Zhou, T.; Yuan, Z.; Tan, S.; Jin, Y.; Yang, Y.; Shi, H.; Wang, W.; Niu, D.; Gao, L.;
955 Jiang, W.; Gao, D.; Liu, Z. A review of molecular responses of catfish to bacterial
956 diseases and abiotic stresses. *Front. Physiol.* **2018**, *9*, 1113.
957
- 958 9. Rasmussen-Ivey, C.R.; Hossain, M.J.; Odom, S.E.; Terhune, J.S.; Hemstreet, W.G.;
959 Shoemaker, C.A.; Zhang, D.; Xu, D.H.; Griffin, M.J.; Liu, Y.J.; Figueras, M.J.; Liles,
960 M.R. Classification of a hypervirulent *Aeromonas hydrophila* pathotype responsible
961 for epidemic outbreaks in warm-water fishes. *Front. Microbiol.* **2016**, *7*, 1615.
962

- 963 10. Khoo, L.; Gaunt, P.; Griffin, M. 2019 MSU CVM Aquatic Research and Diagnostic
964 Laboratory Report Summary. NWAC News. February 2022. 17(1), pp. 12-13.
965 Accessed 22 January 2023. https://www.tcnwac.msstate.edu/docs/NWAC_2022.pdf
966
- 967 11. Abdelhamed, H.; Lawrence, M. L.; Karsi, A. Development and characterization of a
968 novel live attenuated vaccine against enteric septicemia of catfish. *Front. Microbiol.*
969 **2018**, 9, 1819.
970
- 971 12. Wise, D.J.; Camus, A.C.; Schwedler, T.E.; Terhune, J.S. Health management.
972 In *Developments in Aquaculture and Fisheries Science: Biology and Culture of*
973 *Channel Catfish*, 1st ed.; Tucker, C.S., Hargreaves, J.A., Eds.; Elsevier; Amsterdam,
974 The Netherlands, 2004; Volume 34, pp. 444-503.
975
- 976 13. Wise, D.J.; Camus, A.C.; Schwedler, T.E.; Terhune, J.S. 15 Health Management. In
977 *Developments in Aquaculture and Fisheries Science*; Tucker, C.S., Hargreaves, J.A.,
978 Eds.; Biology and Culture of Channel Catfish; Elsevier, 2004; Vol. 34, pp. 444-503.
979
- 980 14. Newton, J.C.; Wolfe, L.G.; Grizzle, J.M.; Plumb, J.A. Pathology of experimental
981 enteric septicemia in channel catfish, *Ictalurus punctatus* (Rafinesque), following
982 immersion-exposure to *Edwardsiella ictaluri*. *J. Fish Dis.* **1989**, 12(4), 335-347.
983
- 984 15. Shoemaker, C.A.; Klesius, P.H.; Evans, J.J.; Arias, C.R. Use of modified live
985 vaccines in aquaculture. *J. World Aquac. Soc.* **2009**, 40(5), 573-585.
986
- 987 16. Hawke, J.P.; Khoo, L.H. Infectious diseases. In *Developments in Aquaculture and*
988 *Fisheries Science: Biology and Culture of Channel Catfish*, 1st ed.; Tucker, C.S.,
989 Hargreaves, J.A., Eds.; Elsevier; Amsterdam, The Netherlands, 2004; Volume 34, pp.
990 387-443.
991
- 992 17. Shoemaker, C.A.; Olivares-Fuster, O.; Arias, C.R.; Klesius, P.H. *Flavobacterium*
993 *columnare* genomovar influences mortality in channel catfish (*Ictalurus punctatus*).
994 *Vet. Microbiol.* **2008**, 127(3), 353-359.
995
- 996 18. O'Halloran, J. Health maintenance and principal microbial diseases of cultured fishes.
997 *The Can. Vet. J.* **2000**, 41(4), 330. PMID: PMC1476167
998
- 999 19. Kotob, M.H.; Menanteau-Ledouble, S.; Kumar, G.; Abdelzaher, M.; El-Matbouli, M.
1000 The impact of co-infections on fish: A review. *Vet. Res.* **2016**, 47(1), 98.
1001
- 1002 20. Wise, A.L.; LaFrentz, B.R.; Kelly, A.M.; Khoo, L.H.; Xu, T.; Liles, M.R.; Bruce, T.J.
1003 A Review of bacterial co-infections in farmed catfish: Components, diagnostics, and
1004 treatment directions. *Animals* **2021**, 11(11), p.3240.
1005
- 1006 21. Gaunt, P.S.; Chatakondi, N.; Gao, D.; Endris, R. Efficacy of florfenicol for control of
1007 mortality associated with *Edwardsiella ictaluri* in three species of catfish. *J. Aquat.*
1008 *Anim. Health* **2015**, 27(1), 45-49.


- 1009
1010 22. Gaunt, P.S.; Gao, D.; Sun, F.; Endris, R. Efficacy of florfenicol for control of
1011 mortality caused by *Flavobacterium columnare* infection in channel catfish. *J. Aquat.*
1012 *Anim. Health* **2010**, 22(2), 115-122.
1013
- 1014 23. Gaunt, P. S.; McGinnis, A.L.; Santucci, T.D.; Cao, J.; Waeger, P.; Endris, R. G. Field
1015 efficacy of florfenicol for control of mortality in channel catfish, *Ictalurus punctatus*
1016 (Rafinesque), caused by infection with *Edwardsiella ictaluri*. *J. World Aquac. Soc.*
1017 **2006**, 37(1), 1-11.
1018
- 1019 24. Wise, D.J., Greenway, T.E.; Byars, T.S.; Kumar, G.; Griffin, M.J.; Khoo, L.H.;
1020 Chesser, G.; Lowe, J. Validation of *Edwardsiella ictaluri* oral vaccination platform in
1021 experimental pond trials. *J. World Aquac. Soc.* **2020**, 51(2), 346-363.
1022
- 1023 25. Wise, D.J.; Greenway, T.E.; Byars, T.S.; Griffin, M.J.; Khoo, L.H. Oral vaccination
1024 of channel catfish against enteric septicemia of catfish using a live attenuated
1025 *Edwardsiella ictaluri* isolate. *J. Aquat. Anim. Health* **2015**, 27(2), 135–143.
1026
- 1027 26. Shoemaker, C.A.; Klesius, P.H.; Drennan, J.D.; Evans, J.J. Efficacy of a modified
1028 live *Flavobacterium columnare* vaccine in fish. *Fish & Shellfish Immunology* **2011**,
1029 *30*, 304–308.
1030
- 1031 27. Li, M.H.; Wise, D.J.; Manning, B.B.; Robinson, E.H. Effect of dietary total protein
1032 and animal protein on growth and feed efficiency of juvenile channel catfish
1033 *Ictalurus punctatus* and their response to *Edwardsiella ictaluri* challenge. *J. World*
1034 *Aquac. Soc.* **2003**, 34(2), 223-228.
1035
- 1036 28. LaFrentz, B.R.; Klesius, P.H. Development of a culture independent method to
1037 characterize the chemotactic response of *Flavobacterium columnare* to fish mucus. *J.*
1038 *Microbiol. Methods* **2009**, 77(1), 37–40.
1039
- 1040 29. Wang, J.; Xiong, G.; Bai, C.; Liao, T. Anesthetic efficacy of two plant phenolics and
1041 the physiological response of juvenile *Ictalurus punctatus* to simulated transport.
1042 *Aquaculture* **2021**, 538, 736566.
1043
- 1044 30. Jiang, J.; Zhao, W.; Xiong, Q.; Wang, K.; He, Y.; Wang, J.; Chen, D.; Geng, Y.;
1045 Huang, X.; Ouyang, P.; Lai, W. Immune responses of channel catfish following the
1046 stimulation of three recombinant flagellins of *Yersinia ruckeri* *in vitro* and *in*
1047 *vivo*. *Dev. Comp. Immunol.* **2017**, 73, 61-71.
1048
- 1049 31. Moreira, G.S.A.; Shoemaker, C.A.; Zhang, D.; Xu, D.H. Expression of immune
1050 genes in skin of channel catfish immunized with live theronts of *Ichthyophthirius*
1051 *multifiliis*. *Parasite Immunol.* **2017**, 39(1), e12397.
1052

- 1053 32. Hao, K.; Yuan, S.; Yu, F.; Chen, X.H.; Bian, W.J.; Feng, Y.H.; Zhao, Z. Acyclovir
1054 inhibits channel catfish virus replication and protects channel catfish ovary cells from
1055 apoptosis. *Virus Res.* **2021**, *292*, 198249.
1056
- 1057 33. Taylor, S.; Wakem, M.; Dijkman, G.; Alsarraj, M.; Nguyen, M. A practical approach
1058 to RT-qPCR—publishing data that conform to the MIQE guidelines. *Methods* **2010**,
1059 *50*(4), S1-S5.
1060
- 1061 34. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative Ct
1062 method. *Nat. Protoc.* **2008**, *3*, 1101-1108.
1063
- 1064 35. Welker, T.L.; Lim, C.; Yildirim-Aksoy, M.; Klesius, P.H. Effects of dietary
1065 supplementation of a purified nucleotide mixture on immune function and disease
1066 and stress resistance in channel catfish, *Ictalurus punctatus*. *Aquac. Res.* **2011**,
1067 *42*(12), 1878–1889.
1068
- 1069 36. Griffin, M.J.; Mauel, M.J.; Greenway, T.E.; Khoo, L.H.; Wise, D.J. A real-time
1070 polymerase chain reaction assay for quantification of *Edwardsiella ictaluri* in catfish
1071 pond water and genetic homogeneity of diagnostic case isolates from Mississippi. *J.*
1072 *Aquat. Anim. Health* **2011**, *23*(4), 178–188.
1073
- 1074 37. LaFrentz, B.R.; García, J.C.; Shelley, J.P. Multiplex PCR for genotyping
1075 *Flavobacterium columnare*. *J. Fish Dis.* **2019**, *42*(11), 1531–1542.
1076
- 1077 38. Mohammed, H.H.; Peatman, E. Winter kill in intensively stocked channel catfish
1078 (*Ictalurus punctatus*): Co-infection with *Aeromonas veronii*, *Streptococcus*
1079 *parauberis* and *Shewanella putrefaciens*. *J. Fish Dis.* **2018**, *41*(9), 1339–1347.
1080
- 1081 39. Xu, D.H.; Shoemaker, C.A.; Zhang, Q.; Klesius, P.H. Naturally infected channel
1082 catfish (*Ictalurus punctatus*) concurrently transmit *Ichthyophthirius multifiliis* and
1083 *Edwardsiella ictaluri* to naïve channel catfish. *Aquaculture* **2013**, *376–379*, 133–136.
1084
- 1085 40. Han, Z.; Sun, J.; Jiang, B.; Hu, X.; Lv, A.; Chen, L.; Guo, Y. Concurrent infections of
1086 *Aeromonas veronii* and *Vibrio cholerae* in koi carp (*Cyprinus carpio* var. Koi).
1087 *Aquaculture* **2021**, *535*, 736395.
1088
- 1089 41. Nicholson, P.; Mon-on, N.; Jaemwimol, P.; Tattiyapong, P.; Surachetpong, W. Co-
1090 infection of tilapia lake virus and *Aeromonas hydrophila* synergistically increased
1091 mortality and worsened the disease severity in tilapia (*Oreochromis spp.*).
1092 *Aquaculture* **2020**, *520*, 734746.
1093
- 1094 42. Figueroa, C.; Bustos, P.; Torrealba, D.; Dixon, B.; Soto, C.; Conejeros, P.; Gallardo,
1095 J.A. Co-infection takes its toll: Sea lice override the protective effects of vaccination
1096 against a bacterial pathogen in Atlantic salmon. *Sci. Rep.* **2017**, *7*(1), 17817.
1097

- 1098 43. Zhang, X.; Song, X.; Huang, J. Impact of *Vibrio parahaemolyticus* and white spot
1099 syndrome virus (WSSV) co-infection on survival of penaeid shrimp *Litopenaeus*
1100 *vannamei*. *Chin. J. Oceanol. Limnol.* **2016**, *34*(6), 1278–1286.
1101
- 1102 44. Crumlish, M.; Thanh, P.C.; Koesling, J.; Tung, V.T.; Gravningen, K. Experimental
1103 challenge studies in Vietnamese catfish, *Pangasianodon hypophthalmus* (Sauvage),
1104 exposed to *Edwardsiella ictaluri* and *Aeromonas hydrophila*. *J. Fish Dis.* **2010**,
1105 *33*(9), 717–722.
1106
- 1107 45. Machimbirike, V.I.; Crumlish, M.; Dong, H.T.; Santander, J.; Khunrae, P.;
1108 Rattanarojpong, T. *Edwardsiella ictaluri*: A systemic review and future perspectives
1109 on disease management. *Rev. Aquac.* **2022**, *14*(3), 1613–1636.
1110
- 1111 46. Declercq, A.M.; Haesebrouck, F.; Van den Broeck, W.; Bossier, P.; Decostere, A.
1112 Columnaris disease in fish: A review with emphasis on bacterium-host interactions.
1113 *Vet. Res.* **2013**, *44*(1), 27.
1114
- 1115 47. Dong, H.T.; Nguyen, V.V.; Phiwsaiya, K.; Gangnonngiw, W.; Withyachumnarnkul,
1116 B.; Rodkhum, C.; Senapin, S. Concurrent infections of *Flavobacterium columnare*
1117 and *Edwardsiella ictaluri* in striped catfish, *Pangasianodon hypophthalmus* in
1118 Thailand. *Aquaculture* **2015**, *448*, 142–150.
1119
- 1120 48. Manna, S.; McAuley, J.; Jacobson, J.; Nguyen, C. D.; Ullah, M.A.; Williamson, V.;
1121 Mulholland, E. K.; Wijburg, O.; Phipps, S.; Satzke, C. Synergism and antagonism of
1122 bacterial-viral co-infection in the upper respiratory tract. *mSphere*, **2020**, *7*(1),
1123 e0098421.
1124
- 1125 49. Ananda Raja, R.; Jithendran, K.P. Aquaculture Disease Diagnosis and Health
1126 Management. In *Advances in Marine and Brackishwater Aquaculture*, 1st ed.;
1127 Perumal, S., Thirunavukkarasu A.R., Pachiappan, P., Eds.; Springer: New Delhi,
1128 India, 2015; pp. 247-255.
1129
- 1130 50. Bladen, H.; Hageage, G.; Harr, R.; Pollock, F. Lysis of certain organisms by the
1131 synergistic action of complement and lysozyme. *J. Dent. Res.* **1973**, *52*(2), 371–376.
1132
- 1133 51. Magnadottir, B.; Lange, S.; Gudmundsdottir, S.; Bøgwald, J.; Dalmo, R.A. Ontogeny
1134 of humoral immune parameters in fish. *Fish Shellfish Immunol.* **2005**, *19*(5), 429–.
1135
- 1136 52. Marsh, M.B.; Rice, C.D. Development, characterization, and technical applications of
1137 a fish lysozyme-specific monoclonal antibody (mAb M24-2). *Comp. Immunol.*
1138 *Microbiol. Infect. Dis.* **2010**, *33*(6), e15–e23.
1139
- 1140 53. Ren, Y.; Zhao, H.; Su, B.; Peatman, E.; Li, C. Expression profiling analysis of
1141 immune-related genes in channel catfish (*Ictalurus punctatus*) skin mucus following
1142 *Flavobacterium columnare* challenge. *Fish Shellfish Immunol.* **2015**, *46*(2), 537-542.
1143

1144 54. Fu, G.H.; Bai, Z.Y.; Xia, J.H.; Liu, F.; Liu, P.; Yue, G.H. Analysis of two lysozyme
1145 genes and antimicrobial functions of their recombinant proteins in Asian seabass.
1146 *PLoS one* **2013**, 8(11), e79743.
1147
1148 55. Ferraboschi, P.; Ciceri, S.; Grisenti, P. Applications of lysozyme, an innate immune
1149 defense factor, as an alternative antibiotic. *Antibiotics* **2021**, 10(12), 1534.
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172

1173 Figures



1174

1175

1176 Figure 1. Cumulative percent mortality due to single infections of *E. ictaluri* and *F. covae*

1177 and co-infections from both pathogens over the entirety of the trial (21 days). Each

1178 treatment group had three tanks (n=3). Bars represent the standard error of the mean for

1179 each day.

1180

1181

1182

1183

1184

1185


1186

1187

1188

1189


1190



1191
1192
1193
1194
1195
1196
1197


1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209

Figure 2. Images depict catfish with clinical signs due to (A) co-infection with *E. ictaluri* first, then *F. covae* 48 h post-initial inoculation, exhibiting both saddleback lesions, discoloration, and external hemorrhaging (B) infection only with *E. ictaluri*, exhibiting ocular and fin hemorrhaging and exophthalmia.




1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225

Figure 3. Images depict catfish with clinical signs due to (A) co-infection with *F. covae* first, then *E. ictaluri* 48 h post-initial inoculation, or (B) infection only with *F. covae*.




1226
 1227
 1228
 1229
 1230
 1231
 1232
 1233
 1234
 1235
 1236
 1237
 1238
 1239
 1240
 1241
 1242
 1243

Figure 4. Cumulative percent mortality from Trial B due to single infections of *E. ictaluri* or *F. covae* and co-infections from both pathogens over the entirety of the trial (11 days). Each treatment group had three tanks (n=3). Bars represent the standard error of the mean for each day.




1244
 1245
 1246
 1247
 1248
 1249
 1250
 1251
 1252
 1253
 1254
 1255
 1256
 1257
 1258
 1259
 1260
 1261
 1262
 1263
 1264
 1265
 1266
 1267
 1268

Figure 5. Lysozyme activity ($\mu\text{g mL}^{-1}$) in sera from sampled fish at 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate ($n=3$). Capital letters indicate significant differences in activity between treatment time periods, and lowercase letters represent significance within treatment groups. Error bars represent the standard error of the mean for each treatment group.




1269
 1270
 1271
 1272
 1273
 1274
 1275
 1276
 1277
 1278
 1279
 1280
 1281
 1282
 1283
 1284
 1285
 1286
 1287
 1288
 1289
 1290
 1291
 1292

Figure 6. Lysozyme activity ($\mu\text{g mL}^{-1}$) in sera from sampled fish at 21 days post-challenge. Each treatment group was conducted in triplicate ($n=3$). Error bars represent the standard error of the mean for each treatment group.




1293
 1294
 1295
 1296
 1297
 1298
 1299
 1300
 1301
 1302
 1303
 1304
 1305
 1306
 1307
 1308
 1309
 1310
 1311
 1312
 1313
 1314

Figure 7. *il8* expression (fold-change) was evaluated from extracted anterior kidneys 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Error bars represent the standard error of the mean for each treatment.




1315
 1316
 1317
 1318
 1319
 1320
 1321
 1322
 1323
 1324
 1325
 1326
 1327
 1328
 1329
 1330
 1331
 1332
 1333

Figure 8. *il1β* expression (fold-change) was evaluated from extracted anterior kidneys during 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment.



1334
 1335
 1336
 1337
 1338
 1339
 1340
 1341
 1342
 1343
 1344
 1345
 1346
 1347
 1348
 1349
 1350
 1351
 1352
 1353
 1354
 1355
 1356
 1357
 1358

Figure 9. *tifa* expression (fold-change) was evaluated at 2, 4, and 7 days post-challenge. Each treatment group was conducted in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment.



1359
 1360
 1361
 1362
 1363
 1364

Figure 10. *tgfb-1* expression (fold-change) was evaluated from extracted anterior kidneys during 2, 4, and 7 days post-challenge. Each treatment group was assessed in triplicate (n=3). Bars represent the standard error of the mean for each treatment.

1365
 1366
 1367
 1368
 1369
 1370
 1371
 1372
 1373
 1374
 1375
 1376
 1377
 1378
 1379
 1380
 1381
 1382
 1383

1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422

1423

1424

1425

1426

Chapter 3:

Coinfection of Channel Catfish (*Ictalurus punctatus*) with Virulent *Aeromonas hydrophila* and *Flavobacterium covae* Exacerbates Mortality

1427 3.1 Abstract

1428

1429 *Flavobacterium covae* and virulent *Aeromonas hydrophila* are prevalent bacterial
1430 pathogens within the U.S. catfish industry that can cause high mortality in production
1431 ponds. An assessment of *in vivo* bacterial coinfection with virulent *A. hydrophila* (ML09-
1432 119) and *F. covae* (ALG-00-530) was conducted in juvenile channel catfish (*Ictalurus*
1433 *punctatus*). For the pathogen challenge, catfish were divided into seven treatments: 1)
1434 mock control; 2 and 3) full and half doses of virulent *A. hydrophila*; 4 and 5) full and half
1435 doses of *F. covae*; 6 and 7) coinfection full and half doses of virulent *A. hydrophila* and
1436 *F. covae*. In addition to the mortality assessment, head kidney and spleen tissues were
1437 collected to evaluate immune gene expression and quantify bacterial load using qPCR. At
1438 96 h post-challenge (hpc), the full-dose, single virulent *A. hydrophila* infection
1439 (immersed in 2.3×10^7 CFU mL⁻¹) resulted in final cumulative percent mortality (CPM)
1440 of 28.3 ± 9.5 %. The CPM for the full dose *F. covae* group (immersed in 5.2×10^6 CFU
1441 mL⁻¹) was 23.3 ± 12.9 %. When the single pathogens were compared to the coinfections,
1442 the coinfective full-dose combination (98.3 ± 1.36) and half-dose combination ($76.7 \pm$
1443 17.05 %) significantly increased mortality ($P < 0.001$). Sera lysozyme activity among
1444 treatment groups was not different, yet a significant increase ($P < 0.002$) in lysozyme
1445 activity was observed at 12 hpc, and a decrease was observed at 96 hpc ($P < 0.001$). Three
1446 proinflammatory cytokines (*tnfa*, *il8*, *il1b*) demonstrated increased expression at 48 hpc.
1447 The results emphasize the importance of evaluating coinfections and demonstrate
1448 dramatic increases in mortality when two pathogens are combined, even at half-doses.
1449 The synthesis of these mortality and health metrics will aid fish health diagnosticians and

1450 channel catfish producers in developing therapeutants and prevention methods to control
1451 bacterial coinfections better.

1452

1453 3.2 Introduction

1454

1455 Aquaculture in the United States provides sustainable fish stocks and is a rapidly
1456 growing industry [1]. The southern economy tremendously depends on aquaculture
1457 revenue from farming catfish [2], and catfish production alone in 2021 accounted for
1458 \$398 million in sales [3](NASS 2022). Aquaculture practices have improved, allowing
1459 more efficient husbandry techniques yielding higher-quality catfish [4]. Along with
1460 enhanced rearing techniques, the intensity at which the fish are being produced has also
1461 been adapted. Nevertheless, increased production can potentiate risks for disease
1462 outbreaks [5,6].

1463 Bacterial diseases are the leading cause of losses within the catfish industry. Not
1464 only do disease outbreaks decimate potential fish stocks, but the medicated feed used to
1465 treat surviving fish also comes at a high cost to farmers, with the potential for
1466 antimicrobial resistance within prevalent pathogens [7,8]. Due to the cost of the already
1467 limited selection of available antimicrobial treatments, disease prevention within all
1468 aquaculture industries is essential to avoid significant economic losses [9,10]. Though
1469 several factors contribute to losses within the industry, *Flavobacterium covae* (formerly
1470 *F. columnare* genetic group 2) and virulent *Aeromonas hydrophila* (vAh) significantly
1471 contribute to the majority of losses within this sector and are opportunistic pathogens
1472 [11–13].

1473 *F. covae* alone can contribute upwards of \$30 million in annual losses and can
1474 lead to 90% mortality within production ponds during severe infections [14]. *F. covae*
1475 affects channel catfish by causing columnaris disease, which primarily manifests as an
1476 external infection but may also be systemic [15]. The pathogen first interacts with the
1477 host externally by penetrating the gills, leading to the asphyxiation of the host [16].
1478 Clinical signs associated with columnaris include gill, skin necrosis, and frequently a
1479 distinct dorsal lesion known as saddleback [17]. There are few treatments and
1480 preventative strategies to mitigate *F. covae* infections, ranging from antimicrobial feed to
1481 vaccination. *F. covae* vaccines have demonstrated variable efficacy and are not a reliable
1482 treatment, but they are a promising disease prevention avenue [18].

1483 *Aeromonas hydrophila*, a gram-negative bacterium, is responsible for motile
1484 aeromonad septicemia (MAS) and infects many fish hosts. *A. hydrophila* is typically an
1485 opportunistic pathogen and can cause devastating effects when coupled with stressors
1486 brought onto the fish [19]. Fish afflicted with the disease demonstrated multiple clinical
1487 signs, including severe internal and external hemorrhaging throughout the fish. The first
1488 mass mortality outbreak of MAS resulting from a virulent strain of *A. hydrophila*
1489 occurred in 2009 [12]. This outbreak caused high mortalities and immense economic
1490 losses (\$35 million annually). Though *A. hydrophila* is often opportunistic, it is unknown
1491 if vAh, which typically causes intense mortality over a short period, acts as the primary
1492 pathogen or requires initial stressors before infection [20,21].

1493 Reports of coinfections associated with *F. covae* and vAh are problematic due to
1494 the lack of information on how either pathogen manifests within the host during dual
1495 infections and with the potential to cause massive amounts of mortality. Coinfections

1496 exist within multiple aquaculture industries affecting many hosts with any combination of
1497 pathogens [22–24]. Though coinfections are well-known in the catfish industry,
1498 information is scarce due to a lack of knowledge of prevalence due to underreporting and
1499 the mechanism associated with outbreaks [25]. Documented diagnostic cases in the
1500 southeastern region of the U.S. have reported coinfections between the two pathogens
1501 [13]. However, with respect to treatment, antibiotic efficacy during coinfections remains
1502 unclear. Treatments approved for single infections have not been efficiently tested during
1503 coinfections. In addition to few available treatment options, infections involving *F. covae*
1504 may increase the likelihood of coinfections with other opportunistic pathogens by
1505 creating a portal of entry through lesion lesions and damaged gill tissue [11,12, 26].
1506 Coinfective interactions and their impact on mortality and potential to increase already
1507 catastrophic losses are unknown. Assessing mortality and immune responses through an
1508 experimental challenge model provides crucial information on the severity and a
1509 preliminary understanding of immunological effects. Due to the severity of mortality
1510 each pathogen elicits, we hypothesized that coinfection of vAh and *F. covae* would
1511 increase mortality in coinfecting treatment groups. Therefore, this study documents the
1512 coinfective effects of vAh and *F. covae* on mortality and the associated immune response
1513 in channel catfish. The investigation of these parameters will shed light on improved
1514 mitigation strategies and future treatment approaches for these complex bacterial
1515 interactions.

1516

1517 3.3 Materials and Methods

1518

1519 3.3.1 *Bacteria and Culture Conditions*

1520 A pure culture of vAh (ML09-119; [27,28]) was recovered from cryostock on
1521 tryptic soy agar (TSA) at 28 °C for 24 h. A single colony pick was expanded in 20 mL of
1522 tryptic soy broth (TSB) containing 0.4 mM xenosiderophore (iron chelator) deferoxamine
1523 mesylate (DFO; Sigma, St. Louis, MO, USA; [29]), and the culture was incubated at 28
1524 °C for 12 h, 175 rotations per minute (rpm). After incubation, 20 mL of broth was used to
1525 inoculate 1 L of TSB with 0.4 mM of DFO (12 h at 28 °C, 175 rpm). The final
1526 inoculation broth was adjusted to $OD_{600}=2.026$ using a Biophotometer Plus
1527 spectrophotometer (Eppendorf; Enfield, CT). *Flavobacterium covae* (ALG-00-530;
1528 [11,30]); was also revived from cryostock and grown on modified Shieh agar (MSA;
1529 [31] for 24 h at 28 °C. A single colony was subsequently transferred to a 50 mL conical
1530 tube containing 12 mL of sterile, modified Shieh broth (MSB) and expanded for 12 h at
1531 28 °C with shaking (175 rpm). An aliquot (6 mL) was used to seed 200 mL of MSB and
1532 expanded for 12 h under the same conditions. As mentioned above, the challenge culture
1533 was adjusted using sterile MSB to an $OD_{550} = 0.707$. Colony forming units (CFU) mL^{-1}
1534 of the adjusted cultures were determined using standard spread plate count techniques
1535 and appropriate media for each pathogen (virulent *A. hydrophila*: TSA; *F. covae*: MSA).

1536

1537 3.3.2 *Experimental Design*

1538 *F. covae* and vAh coinfections were characterized using seven treatment groups in
1539 triplicate tanks (20 fish tank⁻¹) during an *in vivo* pathogen challenge with ~22 g channel
1540 catfish (Marion strain; Table 1). Groups 1 and 2 were challenged by immersion with full
1541 and half doses of *A. hydrophila*, while groups 3 and 4 were challenged with half doses

1542 and full doses of *F. covae*. Groups 5 and 6 were challenged by immersion with half and
1543 full doses of each pathogen (coinfection groups). Group 7 consisted of mock-challenged
1544 fish, and fish were exposed to sterile phosphate-buffered saline (PBS; pH 7.2) in lieu of
1545 bacterial inoculum (Figure 11). Supplementary sampling tanks (n = 21, 3 tanks per
1546 group) were used to replicate each treatment group to collect timepoint tissues without
1547 disturbing mortality data. These sampling tanks were subjected to the same inoculum and
1548 pathogen challenge conditions.

1549

1550 3.3.3 Immersion Challenge

1551 Prior to the challenge, all fish were transferred and randomly allocated into
1552 respective 60 L tanks containing 37.9 L. Catfish were acclimated for 2 d, in which they
1553 were monitored and fed twice daily a commercial floating catfish diet (Optimal Fish
1554 Food, Omaha, Nebraska). Tanks were supplied with $28^{\circ}\text{C} \pm 1^{\circ}\text{C}$ dechlorinated municipal
1555 water at a rate of 0.4 L min^{-1} , and supplemental aeration was provided via an airstone.
1556 Dissolved oxygen (DO) was maintained level between $8.0 \pm 1.0 \text{ mg L}^{-1}$. All channel
1557 catfish, including controls, were fed to satiety 4 h before the challenge. The adipose fin
1558 was clipped following anesthetization in water containing 100 mg L^{-1} of tricaine
1559 methanesulfonate (MS-222; Syndel, Ferndale, Washington) and 100 mg L^{-1} of sodium
1560 bicarbonate [32]. Then, the water flow to each tank was turned off, the water level was
1561 lowered to 10 L, and the volume of bacteria or PBS for the mock challenge was added.
1562 Fish were exposed for 1 hour, and the water flow was restored to 0.5 L min^{-1} [29]. Single
1563 pathogen groups were inoculated with 100 mL for full doses and 50 mL for half doses of
1564 the respective pathogen. Coinfected groups received 100 mL (full) and 50 mL (half) of

1565 both bacteria. Groups exposed to vAh (half and full doses of single vAh and coinfecting
1566 treatment groups) received 2.3×10^7 CFU mL⁻¹ at full dose and 1.1×10^7 CFU mL⁻¹ at
1567 half doses. Fish exposed to *F. covae* (half and full doses of single *F. covae* and coinfecting
1568 treatment groups) were inoculated with 5.2×10^6 CFU mL⁻¹ (full doses) and 2.6×10^6
1569 CFU mL⁻¹ (half doses) (Table 3).

1570

1571 *3.3.4 Collection and Sampling*

1572 Fish were sampled in triplicate (n=3 tanks, with 3 fish per tank) from each group
1573 at 6 h, 12 h, 24 h, 48 h, and 96 hours post-challenge from supplementary sampling tanks.
1574 Anterior kidney, spleen, and blood were collected aseptically and used to extract RNA,
1575 DNA, and sera, respectively. Kidney and spleen tissues were preserved in DNA/RNA
1576 Shield (Zymo Research Corp., Irvine, California) and stored at -20 °C until nucleic acid
1577 extraction. Sera for lysozyme activity was collected by bleeding fish from the caudal vein
1578 using 22-gauge syringes and placing blood into microtubes. Blood was allowed to clot
1579 overnight at 4 °C, centrifuged at $16,000 \times g$ (Eppendorf 5420; Enfield, CT) for 5 min,
1580 and then sera were harvested and stored at -80 °C until needed. Post-challenge, only
1581 deceased fish were removed from tanks. Kidney and spleen tissue from 20% of daily
1582 mortalities were cultured to confirm the cause of death. Tissues from coinfecting groups
1583 were plated on TSA and MSA to target both bacteria.

1584

1585 *3.3.5 DNA and RNA Extraction*

1586 Spleen tissues were homogenized with pestles within 1.5 mL microtubes.
1587 According to the manufacturer's directions, DNA was extracted using the Omega

1588 E.Z.N.A. Tissue DNA Kit (Omega Bio-tek, Inc., Norcross, Georgia). Kidney tissue
1589 samples were manually homogenized with pestles in DNA/RNA Shield (Zymo Research
1590 Corp., Irvine, California). RNA was extracted using a Zymo Research Quick-RNA™
1591 MiniPrep Plus kit (Zymo Research Corp., Irvine, California) according to the
1592 manufacturer's directions. Reisolated *F. covae* bacterial pellets collected from fresh
1593 mortalities were processed to extract DNA for endpoint PCR to confirm pathogen
1594 identity. Genomic DNA was isolated using the Omega E.Z.N.A.® DNA Kit (Omega
1595 Bio-tek, Inc., Norcross, Georgia, USA) according to the manufacturer's directions.
1596 Virulent *A. hydrophila* isolates were confirmed through colony pick PCR using a vAh-
1597 specific primer set. All DNA and RNA samples were eluted with 100 µL of nuclease-free
1598 water. Extracted RNA and DNA samples were quantified spectrophotometrically with
1599 Nanodrop One^c (Thermo Fisher Scientific, Waltham, Massachusetts, USA) and stored at
1600 -20 °C until needed.

1601

1602 3.3.6 Gene expression analysis

1603 Extracted RNA was diluted to 50 ng µL⁻¹ using nuclease-free water and converted
1604 into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied
1605 Biosystems, Waltham, MA), according to assay directions. Each 20 µL reaction
1606 contained 2 µL of 10x R.T. buffer, 0.8 uL of 25x dNTP Mix, 2 µL of 10x R.T. random
1607 primers, 1µL of Multiscribe™ reverse transcriptase, 500 ng of template RNA and
1608 nuclease-free water to volume. cDNA samples were synthesized in a MiniAmp Plus
1609 thermal cycler (Applied Biosystems, Carlsbad, California) programmed for a single cycle
1610 of 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 min. Once the reaction was

1611 complete, the cDNA-was diluted to 2.5 ng μL^{-1} with nuclease-free water. Four genes were
1612 evaluated for expression analysis, namely *il-1 β* , *tnf α* [33], *il8* [34], and *tgf β -1* [35]. The
1613 housekeeping genes *ef1 α* [36] and *actb* [24] were used for normalization. The PCR was
1614 performed in 10- μL volumes consisting of 5 μL PowerUp™ SYBR™ Green Master Mix
1615 (Applied Biosystems), 0.25 μM of each forward and reverse primer (Supplemental Table
1616 1), 3 μL of sample cDNA nuclease-free water to volume (1 μL). Each sample was run in
1617 duplicate along with no-template controls consisting of nuclease-free water in place of
1618 template cDNA. qPCR was run on a QuantStudio™ 5 Real-Time PCR system (Applied
1619 Biosystems) programmed for initial steps of 50 °C for 2 min and 95 °C for 2 min,
1620 followed by 40 cycles of 95 °C for 15 sec, 58 °C for 15 sec, and 72 °C for 30 sec, with
1621 data collection occurring after the 72 °C elongation. For each gene target, reaction
1622 efficiencies were assessed using serial dilutions of cDNA covering five orders of
1623 magnitude, run in duplicate, and starting at 50 μg . For each gene, reaction efficiencies
1624 ranging from 90-110% were considered acceptable [37]. The $2^{-\Delta\Delta\text{Ct}}$ method was used to
1625 calculate all gene expression values [38], combining housekeeping genes (*ef1 α* and *actb*)
1626 and control groups for each sampling period, allowing each fold change of each gene to
1627 be expressed relative to control averages.

1628

1629 3.3.7 Lysozyme Activity Assay

1630 Lysozyme activity was quantified following previously published protocols [39].
1631 Lysozyme standards consisted of serial dilutions of chicken lysozyme egg white
1632 (Rockland Immunochemicals, Pottstown, Pennsylvania, USA) dissolved in sodium
1633 phosphate buffer (SPB; 0.04 M Na_2HPO_4 ; pH 6.0), and diluted to create a standard curve

1634 with a range of 0-16 $\mu\text{g mL}^{-1}$. Freeze-dried *Micrococcus lysodeikticus* (Worthington
1635 Biochemical, Lakewood, New Jersey, USA) was resuspended into 40 mL SPB at 0.25 mg
1636 μL^{-1} , and 250 μL of the bacterial suspension added to each well, along with 10 μL of
1637 sera. Each sample was run in duplicate. Absorbances at OD₄₅₀ were collected after a 20
1638 min incubation at 37 °C with a Synergy HTX™ Multimode Reader (BioTek, Winooski,
1639 Vermont, USA) and compared to a standard curve assembled from prepared standards
1640 mentioned above run in tandem.

1641

1642 3.3.8 Quantification of Bacterial Load

1643 Quantitative polymerase chain reaction (qPCR) was performed with QuantStudio
1644 5 Real-Time PCR instrument (Applied Biosystems, Carlsbad, California) to quantify the
1645 bacterial load within sampled spleens. Extracted DNA samples were diluted to 10 ng μL^{-1} .
1646 To quantify vAh present in splenic tissue, each qPCR reaction consisted of 9.5 μL of
1647 TaqMan Fast Advanced Master Mix (Applied Biosystems, Carlsbad, California), 1 μL of
1648 forward and reverse primers (20 mM; S1), 1 μL of vAh probe (2 mM) (Supplementary
1649 Table 1; [40]), 1 μL of spud template DNA (500 copies), 0.5 μL of SPUD primers
1650 (Supplementary Table 1), 0.5 μL of SPUD probe (Supplementary Table 1; [41]), 5 μL of
1651 template (50 ng reaction⁻¹) and 6.5 μL of nuclease-free water. Run conditions were
1652 programmed with a denaturation for 15 min at 95 °C, 40 cycles of another 15 sec
1653 denaturation at 95 °C, and an annealing step at 60 °C for 1 min. The data collection
1654 occurred at the end of the annealing step of each cycle [40,42]. *F. covae* was quantified in
1655 spleen tissue by running the same reaction with *F. covae*-specific primers and probe
1656 (Supplementary Table 1; [42]). Primer concentrations and run conditions were identical

1657 for quantifying *vAh* and *F. covae*. SPUD DNA and probes were a positive control to
1658 ensure no inhibition was present. Each reaction plate contained samples run in duplicate
1659 along with negative controls (no template, only TE buffer) and five serially-diluted
1660 standards of the target bacteria [43].

1661

1662 3.3.9 PCR Confirmation

1663 The presence of each bacterial pathogen in single and coinfecting treatment groups
1664 was evaluated from challenge mortalities. All PCR reactions were conducted on a
1665 MiniAmp thermal cycler (Applied Biosystems, Carlsbad, CA). Colony PCR was
1666 performed on representative colonies to confirm presumptive identification as *vAh* by
1667 harvesting a single bacterium colony from a TSA plate and inserting it directly into the
1668 following reaction. Specific *vAh* primers (2968F and 2968R;[44]) were incorporated into
1669 the assay. Each 25 μ L reaction consisted of a 12.5 μ L hot-start master mix (Trilink
1670 BioTechnologies, San Diego, CA), 0.5 μ L 2968F (10 μ M stock), 0.5 μ L (10 μ M stock) of
1671 2968R, and nuclease-free water to volume. Positive (DNA extracted from *vAh* (ML09-
1672 119)) and negative (nuclease-free water) controls were run in tandem with samples.
1673 Cycle conditions were 95°C for 5 min, followed by 30 cycles at 95°C for 15 sec, an
1674 annealing temperature of 58°C for 15 sec, and 72 °C for 15 sec. The final extension was
1675 run at 72°C for 5 min. Aliquots of PCR products (5 μ L) were separated by
1676 electrophoresis through 2.0% agarose gels in Tris-acetate-EDTA (TAE) buffer, stained
1677 with GelRed (Biotium Inc., Fremont, California, USA) and visualized by ultraviolet
1678 transillumination in a Gel Doc Go imaging system (Bio-Rad, Inc., Hercules, California,

1679 USA). Samples were run alongside concurrently run molecular weight standards to
1680 confirm the presence of appropriately sized bands (200 bp).

1681 DNA extracted from presumptive *F. covae* colonies recovered from
1682 dead/moribund fish was confirmed by multiplex PCR [11,45]. Each 25 μ L reaction
1683 contained a 12.5 μ L hot-start master mix (Trilink BioTechnologies, San Diego, CA), 2
1684 μ L of a primer mixture (0.5 μ M GG-forward, 0.1 μ M GG1-reverse, 0.45 μ M GG2-
1685 reverse, 0.45 μ M GG3-reverse, 0.3 μ M GG4-reverse), 9.5 μ L of nuclease-free water, and
1686 1.0 μ L of gDNA (5 ng μ L⁻¹). The cycle parameters used were: 95 °C for 5 mins, 40
1687 cycles of 94 °C for 30 seconds, 56 °C for 20 secs, and 72 °C for 1 min, followed by 10
1688 mins at 72 °C. The *F. covae* AL-02-36^T type strain was run as a positive control. As
1689 described above, PCR products (5 μ L) were also resolved on a 2.0 % agarose gel via
1690 electrophoresis and confirmed with a positive control (300 bp).

1691

1692 3.3.10 Statistical Analyses

1693 Comparisons between treatment groups and time for cumulative percent
1694 mortality, lysozyme activity, and gene expression analyses were performed using
1695 repeated measures two-way ANOVA ($\alpha = 0.05$) evaluating treatment, time, treatment \times
1696 time, and incorporating tanks as a random factor. Data from 48 and 96 hpc was not
1697 included for the full dose coinfection treatment due to a lack of surviving fish (tanks had
1698 reached 100% mortality in sampling tanks). Tukey's post hoc test was incorporated when
1699 differences were significant ($P < 0.05$) to identify which groups were different. Statistical
1700 analysis was conducted using R statistical software (R core Team, 2021). All errors
1701 reported represent the standard error of the mean between treatments.

1702

1703 3.4 Results

1704

1705

1706 3.4.1 Mortality due to *in vivo* pathogen challenge

1707 Mortality was recorded daily throughout the trial, and endpoint cumulative
1708 percent mortality (CPM) was calculated (96 h; Figures 12). Treatment groups exposed to
1709 vAh (half and full vAh and coinfecting groups) began dying at 6 h. Full and half vAh
1710 doses stopped experiencing mortality at approximately 48 h, while full dose coinfecting
1711 groups stopped dying 12 h prior. Mortality for full and half *F. covae* treatment groups
1712 only began between 24-48 h and ceased at 84 h. All single infection groups at both full
1713 and half doses (*F. covae* and vAh) had significantly lower CPM than coinfecting groups
1714 (half and full doses) ($P < 0.05$). The full-dose coinfecting group experienced 98.3 ± 0.3 %
1715 CPM; even at half doses of both pathogens, the coinfecting group still showed high
1716 mortality (76.7 ± 4.2 %). Full doses of single *F. covae* (23.3 ± 2.6 %) and vAh ($28.33 \pm$
1717 1.5 %) did not reach half of the mortality observed in half or full-dose coinfecting groups.
1718 Half doses of single-infected *F. covae* (10.0 ± 1.0 %) and vAh (23.3 ± 1.9 %) groups
1719 were not significantly less than the respective full doses for each group ($P > 0.05$). All
1720 control tanks experienced no mortality throughout the trial.

1721

1722 3.4.2 Presence of Clinical Signs

1723 Fish exposed to vAh exhibited severe ocular hemorrhaging and external
1724 hemorrhaging of the anal and caudal fins (Figure 18). Internally, fish demonstrated
1725 hemorrhaging within the gastrointestinal tract. Clinical signs due to *F. covae* were typical
1726 of this infection, with discoloration, gill necrosis, and dorsal lesions (saddleback). Fish

1727 coinfecting with both pathogens demonstrated an amalgam of clinical signs. Clinical signs
1728 also differed depending upon the disease stage over time. Deceased fish collected soon
1729 after the initial infection (12 h) either had discoloration consistent with *F. covae*
1730 infections or only mild external hemorrhaging (typical of *vAh* infection) and internal
1731 hemorrhaging (Figure 19). In comparison, mortalities at 36 h exhibited extreme external
1732 and internal hemorrhaging and epithelial sloughing consistent with clinical symptoms
1733 from both pathogens (Figure 20).

1734

1735 3.4.3 Sera lysozyme activity

1736 Sera lysozyme activity was compared among all treatment groups (half and full
1737 doses of coinfecting and single infected groups) at 6, 12, 24, 48, and 96 hpc (Figure 13). A
1738 significant interaction ($P < 0.05$) was present between time and treatment. Comparisons
1739 between time demonstrated increased activity at 12 hpc compared to 6, 24, and 48 hpc (P
1740 < 0.05). However, a significant decrease in activity was observed at 96 hpc compared to
1741 all other periods ($P < 0.05$). There were no significant differences between treatment
1742 groups at 6, 12, 24, and 96 hpc ($P > 0.05$), while at 48 hpc, treatment differences were
1743 observed ($P < 0.05$). Catfish challenged with full doses of *vAh*, and *F. covae* exhibited
1744 significantly higher lysozyme activity at 48 hpc than the control group ($P < 0.05$). The
1745 half *vAh* group, when compared to full *F. covae* treatment, had significantly lower
1746 lysozyme activity ($P < 0.05$).

1747

1748 3.4.4 Gene expression analysis

1749 The expression of *il1 β* gene was evaluated at 6, 12, 24, 48, and 96 hpc (Figure 14). An
1750 increase in expression was observed at 48 hpc compared to all other time points ($P <$
1751 0.05); however, there were no significant differences between treatment groups at all
1752 sampling times ($P > 0.05$). Similar expression patterns were observed with the *il8* gene,
1753 except no significant differences were observed between 96 and 48 hpc ($P > 0.05$; Figure
1754 15). The expression of *tgfb* and *tnfa* genes were evaluated, and differences were only
1755 detected between periods for both genes (Figures 16 and 17). An increase in *tgfb*
1756 expression was seen at 48 hpc compared to 12 hpc ($P < 0.05$). No significant interactions
1757 were seen between time and treatment for all genes evaluated ($P < 0.05$). All three
1758 proinflammatory cytokines demonstrated an increase in expression at 48 hpc.

1759

1760 3.4.5 Quantification of bacterial load

1761 The bacterial load of each pathogen was quantified at 6, 12, 24, 48, and 96 hpc
1762 (Figure 21). For vAh, the bacteria were present in all groups exposed to vAh at 6 h. At 12
1763 hpc, only full dose vAh and full dose coinfecting groups displayed the presence of virulent
1764 *A. hydrophila* in the splenic tissue. The coinfecting treatment receiving a full dose of both
1765 pathogens was the only group with detectable vAh copies at 24 hpc. At 48 and 96 hpc, no
1766 bacteria were detected in any treatments. Unfortunately, full-dose, coinfecting catfish at
1767 48 and 96 h could not be measured due to a lack of surviving fish. No significant
1768 differences were seen between time or within treatment groups ($P > 0.05$).

1769 The bacterial load quantified for *F. covae* increased at 6 hpc compared to 12 and 48 hpc
1770 ($P < 0.05$). Only at 6 and 48 hpc, were differences among treatment groups observed. At
1771 6 hours, full coinfection was statistically different from controls and full *F. covae* ($P <$

1772 0.05). Both of which had no detectable presence of *F. covae*. However, at 48 h, full *F.*
1773 *covae* had significantly more bacteria present than all other treatments ($P < 0.05$).

1774

1775 3.5 Discussion

1776

1777 Coinfections occur in multiple aquaculture industries, causing significant
1778 mortality and economic losses [46–48]. Coinfections amongst opportunistic pathogens
1779 have been seen to augment mortality severity during challenges, thus increasing the
1780 potential economic losses in production ponds [49]. Within the catfish industry,
1781 coinfections have become an increasing threat amongst vAh and *F. covae* due to the
1782 increased prevalence of *F. covae* in catfish production and the ability to act as a portal of
1783 entry for the opportunistic vAh [13]. Though the threat of coinfection is highly probable
1784 and lethal in production ponds, little is known concerning infection mechanics, severity,
1785 and mitigation strategies [50]. This lack of information is supplemented due to the
1786 majority of research focusing on the effect of single infections [17], thus presenting a
1787 great need for research into coinfective bacterial pathogens within the catfish industry
1788 [51]. This study evaluated the effects of two opportunistic pathogens (vAh and *F. covae*)
1789 on mortality when channel catfish are infected concurrently. Previous studies have
1790 observed coinfections associated with these two bacterial pathogens investigating each
1791 but in combination with another pathogen within a different host [49,52].

1792 Channel catfish exposed to both pathogens experienced severely augmented
1793 mortality at half the dose compared to full single infection doses. Providing more
1794 evidence of how coinfections can impact production ponds, thus shedding light on how
1795 crucial it is to assess coinfections amongst other devastating pathogens. The interactions

1796 observed here detailed how portals of entry created by pathogens increase the likelihood
1797 of a coinfection, thus increasing mortality. This presents a possible explanation for why a
1798 coinfection with a bacterium creating a portal of entry (*F. covae*) and a bacterium that
1799 relies on internal exposure (vAh) create such a deadly combination.

1800 Lysozyme is a primary immunological barrier, protecting hosts from potential
1801 pathogens [53]. Lysozyme is present throughout the mucosa of channel catfish and is
1802 contained within their sera [54]. Lysozyme activity was investigated in this study to
1803 measure one of the host's innate immune responses due to coinfections. The present
1804 study detected few differences in lysozyme activity among treatment groups. This
1805 contrasted with a study by Wise et al. (2023) which documented that coinfecting groups
1806 exposed to *E. ictaluri* and *F. covae* experienced significantly more lysozyme activity than
1807 single-infected groups. Authors noted that *E. ictaluri* acted as the primary driver for
1808 mortality and lysozyme activity [55]. However, a coinfection between two opportunistic
1809 pathogens (*F. covae* and vAh) presented no differences except at 48 hpc. Single full-dose
1810 infections were the only two treatment groups that experienced slightly elevated activity
1811 compared to controls. For *Aeromonas* spp. infections, it has been previously documented
1812 that *A. veronii* infection increased lysozyme expression in grass carp (*Ctenopharyngodon*
1813 *idellus*; [56]) and that *A. hydrophila* increased lysozyme activity for up to 21d in blunt
1814 nose sea bream (*Megalobrama amblycephala*; [57]). Unfortunately, samples from
1815 coinfecting treatment groups were not obtainable at 48 or 96 h due to total fish mortality at
1816 full doses. At half doses, coinfecting groups did not present a difference in activity to
1817 other treatments. Though there were no differences between treatments, there were slight
1818 differences between time. Valuable information about the onset and lapse of infection

1819 was provided due to the increase observed at 12 hpc compared to 6 h, 24 h, and 48 h,
1820 with a decrease at 96 hpc. The decline at 96 hpc in lysozyme activity, combined with the
1821 lack of mortality, was indicative of the end of the infection. While the initiation of
1822 infection occurred between 6 and 12 hpc, coinciding with the mortality. Little research
1823 has evaluated sera lysozyme activity within channel catfish exposed to vAh. Previous
1824 work investigated *A. hydrophila*'s effects on lysozyme activity but within other hosts [57]
1825 These results provide insight into novel infection dynamics (beginning, peak, and end of
1826 infection) of both single and coinfections between *F. covae* and vAh. Simultaneously,
1827 illustrating *F. covae* and vAh coinfections do not elicit a significant increase in lysozyme
1828 activity compared to single infections.

1829 Bacterial load was measured for each bacterium within the spleen. Results
1830 indicated higher doses persist longer within host spleens than half doses regardless of a
1831 coinfection at 12 hpc for vAh. A trend was observed depicting a high presence vAh early
1832 in the infection (6 hpc), then no presence of 48 or 96 hpc. Similar results were seen in
1833 previous studies. Zhang et al. (2016) conducted a waterborne vAh and measured bacterial
1834 load within internal tissues. This research observed the highest quantities of vAh within
1835 the spleen being between 1 to 4 hpc, and no vAh was detected at 48 hpc [58]. Both
1836 studies depict an increase in vAh presence within the spleen early in infection and no
1837 presence after 48 hpc. This corresponds with mortality trends observed in this study. Fish
1838 began to experience death between 6-12 hpc during the vAh infection, which correlates
1839 with the bacterial presence detected within internal organs.

1840 Proinflammatory cytokines (IL-8, TNF- α , and IL-1 β) and an immunosuppressive
1841 cytokine (TGF- β) were measured to evaluate the innate immune system during

1842 coinfections. Interestingly, all genes demonstrated significantly higher expression at 48
1843 hpc , primarily induced by vAh, but no treatment differences were observed within any
1844 genes. These results present critical information about coinfection immune responses.
1845 These cytokines levels were not affected during coinfection despite severely
1846 exponentiated mortality. However, differences in expression between single and
1847 coinfecting treatment groups could not be made due to sample variation.

1848 In summary, a coinfection between *F. covae* and virulent *A. hydrophila* under
1849 these laboratory conditions significantly increases mortality compared to single infections
1850 of both pathogens. Even half coinfective doses caused more mortality than full doses of
1851 single pathogens. Previous studies have characterized both *A. hydrophila* and *F. covae* as
1852 more opportunistic, causing devastating mortality when fish are stressed. This study
1853 demonstrates that combining two ubiquitous pathogens can significantly affect mortality,
1854 thus potentially augmenting the economic impact. Along with critical mortality data,
1855 immune data was also collected. Most immune data correlated with mortality trends
1856 seeing the highest values around 48 hpc, while few treatment differences were observed.
1857 A culmination of these data allows us to conclude that coinfections between *F. covae* and
1858 virulent *A. hydrophila* increase mortality while causing the immunomodulation of
1859 proinflammatory genes at 48 hpc, and increased lysozyme activity at 12 hpc.

1860 Future studies must investigate the effects of treatment options used during single
1861 infections on coinfections. Another promising avenue to explore could be looking deeper
1862 into coinfective infection dynamics due to portals of entry caused by other pathogens.
1863 This research documents the interaction between two bacterial pathogens exposed to
1864 channel catfish. Here mortality was greatly increased, even at half coinfection doses. This

1865 work illustrates the potential for coinfections to cost production farmers millions, thus
1866 acting as a springboard for the further exploration of coinfection dynamics within the
1867 catfish industry.

1868

1869 3.6 References

1870

- 1871 1. Klingler, D.; Naylor, R. Searching for Solutions in Aquaculture: Charting a
1872 Sustainable Course. *Annual Review of Environment and Resources* **2012**, *37*, 247–
1873 276, doi:10.1146/annurev-environ-021111-161531.
- 1874 2. Osmundsen, T.C.; Amundsen, V.S.; Alexander, K.A.; Asche, F.; Bailey, J.; Finstad,
1875 B.; Olsen, M.S.; Hernández, K.; Salgado, H. The Operationalisation of Sustainability:
1876 Sustainable Aquaculture Production as Defined by Certification Schemes. *Global*
1877 *Environmental Change* **2020**, *60*, 102025, doi:10.1016/j.gloenvcha.2019.102025.
- 1878 3. United States Department of Agriculture: Stuttgart, AR, USA. National Agricultural
1879 Statistics Service Catfish Production 02/11/2022. [(accessed on 1 December
1880 2022)];**2021** p. 7. Available
1881 online: <https://usda.library.cornell.edu/concern/publications/bg257f046?locale=en>.
1882
- 1883 4. Stickney, R.R. Principles of Aquaculture. *Principles of aquaculture*. **1994**.
- 1884 5. Bosworth, B.; Ott, B.; Torrans, L. Effects of Stocking Density on Production Traits of
1885 Channel Catfish×Blue Catfish Hybrids. *North American Journal of Aquaculture*
1886 **2015**, *77*, 437–443, doi:10.1080/15222055.2015.1024363.
- 1887 6. Cole, D.W.; Cole, R.; Gaydos, S.J.; Gray, J.; Hyland, G.; Jacques, M.L.; Powell-
1888 Dunford, N.; Sawhney, C.; Au, W.W. Aquaculture: Environmental, Toxicological,
1889 and Health Issues. *International Journal of Hygiene and Environmental Health* **2009**,
1890 *212*, 369–377, doi:10.1016/j.ijheh.2008.08.003.
- 1891 7. Chuah, L.-O.; Effarizah, M.E.; Goni, A.M.; Rusul, G. Antibiotic Application and
1892 Emergence of Multiple Antibiotic Resistance (MAR) in Global Catfish Aquaculture.
1893 *Curr Envir Health Rpt* **2016**, *3*, 118–127, doi:10.1007/s40572-016-0091-2.
- 1894 8. Wise, D.J.; Greenway, T.E.; Byars, T.S.; Griffin, M.J.; Khoo, L.H. Oral Vaccination
1895 of Channel Catfish against Enteric Septicemia of Catfish Using a Live Attenuated
1896 *Edwardsiella ictaluri* Isolate. *Journal of Aquatic Animal Health* **2015**, *27*, 135–143,
1897 doi:10.1080/08997659.2015.1032440.

- 1898 9. Tekedar, H.C.; Arick, M.A.; Hsu, C.-Y.; Thrash, A.; Blom, J.; Lawrence, M.L.;
1899 Abdelhamed, H. Identification of Antimicrobial Resistance Determinants in
1900 *Aeromonas veronii* Strain MS-17-88 Recovered From Channel Catfish (*Ictalurus*
1901 *punctatus*). *Frontiers in Cellular and Infection Microbiology* **2020**, *10*.
- 1902 10. Ananda Raja, R.; Jithendran, K.P. Aquaculture Disease Diagnosis and Health
1903 Management. In *Advances in Marine and Brackishwater Aquaculture*; Perumal, S.,
1904 A.R., T., Pachiappan, P., Eds.; Springer India: New Delhi, 2015; pp. 247–255 ISBN
1905 978-81-322-2271-2.
- 1906 11. LaFrentz, B.R.; Králová, S.; Burbick, C.R.; Alexander, T.L.; Phillips, C.W.; Griffin,
1907 M.J.; Waldbieser, G.C.; García, J.C.; de Alexandre Sebastião, F.; Soto, E.; et al. The
1908 Fish Pathogen *Flavobacterium Columnare* Represents Four Distinct Species:
1909 *Flavobacterium columnare*, *Flavobacterium covae* sp. Nov., *Flavobacterium davisii*
1910 sp. Nov. and *Flavobacterium oreochromis* sp. Nov., and Emended Description of
1911 *Flavobacterium columnare*. *Systematic and Applied Microbiology* **2022**, *45*, 126293,
1912 doi:10.1016/j.syapm.2021.126293.
- 1913 12. Zhou, T.; Yuan, Z.; Tan, S.; Jin, Y.; Yang, Y.; Shi, H.; Wang, W.; Niu, D.; Gao, L.;
1914 Jiang, W.; et al. A Review of Molecular Responses of Catfish to Bacterial Diseases
1915 and Abiotic Stresses. *Front Physiol* **2018**, *9*, 1113, doi:10.3389/fphys.2018.01113.
- 1916 13. Wise, A.L.; LaFrentz, B.R.; Kelly, A.M.; Khoo, L.H.; Xu, T.; Liles, M.R.; Bruce, T.J.
1917 A Review of Bacterial Co-Infections in Farmed Catfish: Components, Diagnostics,
1918 and Treatment Directions. *Animals (Basel)* **2021**, *11*, 3240,
1919 doi:10.3390/ani11113240.
- 1920 14. Abdelrahman, H.A.; Hemstreet, W.G.; Roy, L.A.; Hanson, T.R.; Beck, B.H.; Kelly,
1921 A.M. Epidemiology and Economic Impact of Disease-Related Losses on Commercial
1922 Catfish Farms: A Seven-Year Case Study from Alabama, USA. *Aquaculture* **2023**,
1923 *566*, 739206, doi:10.1016/j.aquaculture.2022.739206.
- 1924 15. Hawke, J.P.; Thune, R.L. Systemic Isolation and Antimicrobial Susceptibility of
1925 *Cytophaga columnaris* from Commercially Reared Channel Catfish. *Journal of*
1926 *Aquatic Animal Health* **1992**, *4*, 109–113, doi:10.1577/1548-
1927 8667(1992)004<0109:SIAASO>2.3.CO;2.
- 1928 16. Shoemaker, C.A.; Olivares-Fuster, O.; Arias, C.R.; Klesius, P.H. *Flavobacterium*
1929 *columnare* Genomovar Influences Mortality in Channel Catfish (*Ictalurus punctatus*).
1930 *Veterinary Microbiology* **2008**, *127*, 353–359, doi:10.1016/j.vetmic.2007.09.003.
- 1931 17. Declercq, A.M.; Haesebrouck, F.; Van den Broeck, W.; Bossier, P.; Decostere, A.
1932 Columnaris Disease in Fish: A Review with Emphasis on Bacterium-Host
1933 Interactions. *Veterinary Research* **2013**, *44*, 27, doi:10.1186/1297-9716-44-27.
- 1934 18. Bebak, J.; Wagner, B. Use of Vaccination against Enteric Septicemia of Catfish and
1935 Columnaris Disease by the U.S. Catfish Industry. *Journal of Aquatic Animal Health*
1936 **2012**, *24*, 30–36, doi:10.1080/08997659.2012.667048.

- 1937 19. Plumb, J.A.; Hanson, L. *Health Maintenance and Principal Microbial Diseases of*
1938 *Cultured Fishes, 3rd Edition* / Wiley; 2010;
- 1939 20. Baumgartner, W.A.; Ford, L.; Hanson, L. Lesions Caused by Virulent *Aeromonas*
1940 *Hydrophila* in Farmed Catfish (*Ictalurus punctatus* and *I. punctatus* × *I. furcatus*) in
1941 Mississippi. *J VET Diagn Invest* **2017**, *29*, 747–751,
1942 doi:10.1177/1040638717708584.
- 1943 21. Hemstreet, B. An Update on *Aeromonas hydrophila* from a Fish Health Specialist for
1944 Summer. **2010**.
- 1945 22. Erfanmanesh, A.; Beikzadeh, B.; Aziz Mohseni, F.; Nikaein, D.; Mohajerfar, T.
1946 Ulcerative Dermatitis in Barramundi Due to Coinfection with *Streptococcus iniae*
1947 and *Shewanella algae*. *Dis Aquat Organ* **2019**, *134*, 89–97, doi:10.3354/dao03363.
- 1948 23. Figueroa, C.; Bustos, P.; Torrealba, D.; Dixon, B.; Soto, C.; Conejeros, P.; Gallardo,
1949 J.A. Coinfection Takes Its Toll: Sea Lice Override the Protective Effects of
1950 Vaccination against a Bacterial Pathogen in Atlantic Salmon. *Sci Rep* **2017**, *7*, 17817,
1951 doi:10.1038/s41598-017-18180-6.
- 1952 24. Hao, K.; Yuan, S.; Yu, F.; Chen, X.H.; Bian, W.J.; Feng, Y.H.; Zhao, Z. Acyclovir
1953 Inhibits Channel Catfish Virus Replication and Protects Channel Catfish Ovary Cells
1954 from Apoptosis. *Virus Research* **2021**, *292*, 198249,
1955 doi:10.1016/j.virusres.2020.198249.
- 1956 25. Kotob, M.H.; Menanteau-Ledouble, S.; Kumar, G.; Abdelzaher, M.; El-Matbouli, M.
1957 The Impact of Co-Infections on Fish: A Review. *Veterinary Research* **2016**, *47*, 98,
1958 doi:10.1186/s13567-016-0383-4.
- 1959 26. Labrie, L.; Komar, C.; Terhune, J.; Camus, A.; Wise, D. Effect of Sublethal Exposure
1960 to the Trematode *Bolbophorus spp.* on the Severity of Enteric Septicemia of Catfish
1961 In Channel Catfish Fingerlings. *Journal of Aquatic Animal Health* **2004**, *16*, 231–
1962 237, doi:10.1577/H04-011.1.
- 1963 27. Tekedar, H.C.; Waldbieser, G.C.; Karsi, A.; Liles, M.R.; Griffin, M.J.; Vamenta, S.;
1964 Sonstegard, T.; Hossain, M.; Schroeder, S.G.; Khoo, L.; et al. Complete Genome
1965 Sequence of a Channel Catfish Epidemic Isolate, *Aeromonas hydrophila* Strain
1966 ML09-119. *Genome Announcements* **2013**, *1*, e00755-13,
1967 doi:10.1128/genomeA.00755-13.
- 1968 28. Hossain, M.J.; Waldbieser, G.C.; Sun, D.; Capps, N.K.; Hemstreet, W.B.; Carlisle,
1969 K.; Griffin, M.J.; Khoo, L.; Goodwin, A.E.; Sonstegard, T.S.; et al. Implication of
1970 Lateral Genetic Transfer in the Emergence of *Aeromonas hydrophila* Isolates of
1971 Epidemic Outbreaks in Channel Catfish. *PLOS ONE* **2013**, *8*, e80943,
1972 doi:10.1371/journal.pone.0080943.
- 1973 29. Peatman, E.; Mohammed, H.; Kirby, A.; Shoemaker, C.A.; Yildirim-Aksoy, M.;
1974 Beck, B.H. Mechanisms of Pathogen Virulence and Host Susceptibility in Virulent

- 1975 *Aeromonas hydrophila* Infections of Channel Catfish (*Ictalurus punctatus*).
1976 *Aquaculture* **2018**, 482, 1–8, doi:10.1016/j.aquaculture.2017.09.019.
- 1977 30. LaFrentz, B.R.; Shoemaker, C.A.; Booth, N.J.; Peterson, B.C.; Ourth, D.D. Spleen
1978 Index and Mannose-Binding Lectin Levels in Four Channel Catfish Families
1979 Exhibiting Different Susceptibilities to *Flavobacterium columnare* and *Edwardsiella*
1980 *ictaluri*. *Journal of Aquatic Animal Health* **2012**, 24, 141–147,
1981 doi:10.1080/08997659.2012.675936.
- 1982 31. LaFrentz, B.R.; Klesius, P.H. Development of a Culture Independent Method to
1983 Characterize the Chemotactic Response of *Flavobacterium columnare* to Fish Mucus.
1984 *J Microbiol Methods* **2009**, 77, 37–40, doi:10.1016/j.mimet.2008.12.011.
- 1985 32. Zhang, D.; Xu, D.-H.; Shoemaker, C. Experimental Induction of Motile *Aeromonas*
1986 Septicemia in Channel Catfish (*Ictalurus punctatus*) by Waterborne Challenge with
1987 Virulent *Aeromonas hydrophila*. *Aquaculture Reports* **2016**, 3, 18–23,
1988 doi:10.1016/j.aqrep.2015.11.003.
- 1989 33. Wang, J.; Xiong, G.; Bai, C.; Liao, T. Anesthetic Efficacy of Two Plant Phenolics
1990 and the Physiological Response of Juvenile *Ictalurus punctatus* to Simulated
1991 Transport. *Aquaculture* **2021**, 538, 736566, doi:10.1016/j.aquaculture.2021.736566.
- 1992 34. Jiang, X.; Zhang, C.; Zhao, Y.; Kong, X.; Pei, C.; Li, L.; Nie, G.; Li, X. Immune
1993 Effects of the Vaccine of Live Attenuated *Aeromonas hydrophila* Screened by
1994 Rifampicin on Common Carp (*Cyprinus carpio* L). *Vaccine* **2016**, 34, 3087–3092,
1995 doi:10.1016/j.vaccine.2016.04.075.
- 1996 35. Moreira, G.S.A.; Shoemaker, C.A.; Zhang, D.; Xu, D.-H. Expression of Immune
1997 Genes in Skin of Channel Catfish Immunized with Live Theronts of *Ichthyophthirius*
1998 *multifiliis*. *Parasite Immunol* **2017**, 39, e12397, doi:10.1111/pim.12397.
- 1999 36. Jiang, J.; Zhao, W.; Xiong, Q.; Wang, K.; He, Y.; Wang, J.; Chen, D.; Geng, Y.;
2000 Huang, X.; Ouyang, P.; et al. Immune Responses of Channel Catfish Following the
2001 Stimulation of Three Recombinant Flagellins of *Yersinia ruckeri* in Vitro and
2002 in Vivo. *Developmental & Comparative Immunology* **2017**, 73, 61–71,
2003 doi:10.1016/j.dci.2017.02.015.
- 2004 37. Taylor, S.; Wakem, M.; Dijkman, G.; Alsarraj, M.; Nguyen, M. A Practical Approach
2005 to RT-QPCR-Publishing Data That Conform to the MIQE Guidelines. *Methods* **2010**,
2006 50, S1-5, doi:10.1016/j.ymeth.2010.01.005.
- 2007 38. Schmittgen, T.D.; Livak, K.J. Analyzing Real-Time PCR Data by the Comparative
2008 CT Method. *Nat Protoc* **2008**, 3, 1101–1108, doi:10.1038/nprot.2008.73.
- 2009 39. Welker, T.L.; Lim, C.; Yildirim-Aksoy, M.; Klesius, P.H. Effects of Dietary
2010 Supplementation of a Purified Nucleotide Mixture on Immune Function and Disease
2011 and Stress Resistance in Channel Catfish, *Ictalurus punctatus*. *Aquaculture Research*
2012 **2011**, 42, 1878–1889, doi:10.1111/j.1365-2109.2010.02794.x.

- 2013 40. Griffin, M.J.; Mauel, M.J.; Greenway, T.E.; Khoo, L.H.; Wise, D.J. A Real-Time
2014 Polymerase Chain Reaction Assay for Quantification of *Edwardsiella ictaluri* in
2015 Catfish Pond Water and Genetic Homogeneity of Diagnostic Case Isolates from
2016 Mississippi. *Journal of Aquatic Animal Health* **2011**, *23*, 178–188,
2017 doi:10.1080/08997659.2011.637006.
- 2018 41. Nolan, T.; Hands, R.E.; Ogunkolade, W.; Bustin, S.A. SPUD: A Quantitative PCR
2019 Assay for the Detection of Inhibitors in Nucleic Acid Preparations. *Analytical*
2020 *Biochemistry* **2006**, *351*, 308–310, doi:10.1016/j.ab.2006.01.051.
- 2021 42. Gibbs, G.D.; Griffin, M.J.; Mauel, M.J.; Lawrence, M.L. Validation of a Quantitative
2022 PCR Assay for the Detection of 2 *Flavobacterium columnare* Genomovars. *J VET*
2023 *Diagn Invest* **2020**, *32*, 356–362, doi:10.1177/1040638720915760.
- 2024 43. Richardson, B.M.; Griffin, M.J.; Colvin, M.E.; Wise, D.J.; Ware, C.; Mischke, C.C.;
2025 Greenway, T.E.; Byars, T.S.; Hanson, L.A.; Lawrence, M.L. Using Quantitative
2026 Polymerase Chain Reaction (QPCR) and Occupancy Models to Estimate Atypical
2027 *Aeromonas hydrophila* (AAh) Prevalence in Catfish. *Aquaculture* **2021**, *530*, 735687,
2028 doi:10.1016/j.aquaculture.2020.735687.
- 2029 44. Griffin, M.J.; Goodwin, A.E.; Merry, G.E.; Liles, M.R.; Williams, M.A.; Ware, C.;
2030 Waldbieser, G.C. Rapid Quantitative Detection of *Aeromonas hydrophila* Strains
2031 Associated with Disease Outbreaks in Catfish Aquaculture. *J VET Diagn Invest* **2013**,
2032 *25*, 473–481, doi:10.1177/1040638713494210.
- 2033 45. LaFrentz, B.R.; García, J.C.; Shelley, J.P. Multiplex PCR for Genotyping
2034 *Flavobacterium columnare*. *J Fish Dis* **2019**, *42*, 1531–1542, doi:10.1111/jfd.13068.
- 2035 46. Nicholson, P.; Mon-on, N.; Jaemwimol, P.; Tattiyapong, P.; Surachetpong, W.
2036 Coinfection of Tilapia Lake Virus and *Aeromonas Hydrophila* Synergistically
2037 Increased Mortality and Worsened the Disease Severity in Tilapia (*Oreochromis*
2038 spp.). *Aquaculture* **2020**, *520*, 734746, doi:10.1016/j.aquaculture.2019.734746.
- 2039 47. Jansen, M.D.; Dong, H.T.; Mohan, C.V. Tilapia Lake Virus: A Threat to the Global
2040 Tilapia Industry? *Reviews in Aquaculture* **2019**, *11*, 725–739, doi:10.1111/raq.12254.
- 2041 48. Ma, J.; Bruce, T.J.; Oliver, L.P.; Cain, K.D. Co-Infection of Rainbow Trout
2042 (*Oncorhynchus mykiss*) with Infectious Hematopoietic Necrosis Virus and
2043 *Flavobacterium psychrophilum*. *Journal of Fish Diseases* **2019**, *42*, 1065–1076,
2044 doi:10.1111/jfd.13012.
- 2045 49. Crumlish, M.; Thanh, P.C.; Koesling, J.; Tung, V.T.; Gravningen, K. Experimental
2046 Challenge Studies in Vietnamese Catfish, *Pangasianodon hypophthalmus* (Sauvage),
2047 Exposed to *Edwardsiella ictaluri* and *Aeromonas hydrophila*. *J Fish Dis* **2010**, *33*,
2048 717–722, doi:10.1111/j.1365-2761.2010.01173.x.
- 2049 50. Machimbirike, V.I.; Crumlish, M.; Dong, H.T.; Santander, J.; Khunrae, P.;
2050 Rattanarajpong, T. *Edwardsiella ictaluri*: A Systemic Review and Future

- 2051 Perspectives on Disease Management. *Reviews in Aquaculture* **2022**, *14*, 1613–1636,
2052 doi:10.1111/raq.12665.
- 2053 51. Mohammed, H.H.; Peatman, E. Winter Kill in Intensively Stocked Channel Catfish
2054 (*Ictalurus punctatus*): Coinfection with *Aeromonas veronii*, *Streptococcus parauberis*
2055 and *Shewanella putrefaciens*. *Journal of Fish Diseases* **2018**, *41*, 1339–1347,
2056 doi:10.1111/jfd.12827.
- 2057 52. Dong, H.T.; Nguyen, V.V.; Phiwsaiya, K.; Gangnonngiw, W.; Withyachumnarnkul,
2058 B.; Rodkhum, C.; Senapin, S. Concurrent Infections of *Flavobacterium columnare*
2059 and *Edwardsiella ictaluri* in Striped Catfish, *Pangasianodon hypophthalmus* in
2060 Thailand. *Aquaculture* **2015**, *448*, 142–150, doi:10.1016/j.aquaculture.2015.05.046.
- 2061 53. Bladen, H.; Hageage, G.; Harr, R.; Pollock, F. Lysis of Certain Organisms by the
2062 Synergistic Action of Complement and Lysozyme. *J Dent Res* **1973**, *52*, 371–376,
2063 doi:10.1177/00220345730520023101.
- 2064 54. Magnadottir, B.; Lange, S.; Gudmundsdottir, S.; Bøgwald, J.; Dalmo, R.A. Ontogeny
2065 of Humoral Immune Parameters in Fish. *Fish & Shellfish Immunology* **2005**, *19*,
2066 429–439, doi:10.1016/j.fsi.2005.03.010.
- 2067 55. Wise, A.L.; LaFrentz, B.R.; Kelly, A.M.; Liles, M.R.; Griffin, M.J.; Beck, B.H.;
2068 Bruce, T.J. The Infection Dynamics of Experimental *Edwardsiella ictaluri* and
2069 *Flavobacterium covae* Coinfection in Channel Catfish (*Ictalurus Punctatus*).
2070 *Pathogens* **2023**, *12*, 462, doi:10.3390/pathogens12030462.
- 2071 56. Chen, P.; Jin, D.; Yang, S.; Yu, X.; Yi, G.; Hu, S.; Sun, Y.; Hu, Y.; Cui, J.; Rang, J.;
2072 et al. *Aeromonas veronii* Infection Remarkably Increases Expression of Lysozymes
2073 in Grass Carp (*Ctenopharyngodon idellus*) and Injection of Lysozyme Expression
2074 Cassette along with QCDC Adjuvant Significantly Upregulates Immune Factors and
2075 Decreases Cumulative Mortality. *Microb Pathog* **2022**, *169*, 105646,
2076 doi:10.1016/j.micpath.2022.105646.
- 2077 57. Xia, H.; Tang, Y.; Lu, F.; Luo, Y.; Yang, P.; Wang, W.; Jiang, J.; Li, N.; Han, Q.;
2078 Liu, F.; et al. The Effect of *Aeromonas hydrophila* Infection on the Non-Specific
2079 Immunity of Blunt Snout Bream (*Megalobrama amblycephala*). *Cent Eur J Immunol*
2080 **2017**, *42*, 239–243, doi:10.5114/ceji.2017.70965.
- 2081 58. Zhang, D.; Moreira, G.S.A.; Shoemaker, C.; Newton, J.C.; Xu, D.-H. Detection
2082 and Quantification of Virulent *Aeromonas hydrophila* in Channel Catfish Tissues
2083 Following Waterborne Challenge. *FEMS Microbiology Letters* **2016**, *363*, fnw080,
2084 doi:10.1093/femsle/fnw080.
2085
2086
2087
2088
2089
2090

2091
 2092
 2093
 2094
 2095
 2096
 2097
 2098
 2099
 2100
 2101
 2102
 2103
 2104
 2105
 2106
 2107

Tables


Table 3. Description of treatment groups, including which bacterium was administered, volume, and final dose for challenged channel catfish.

| Treatment | Inoculum | Administered | Final Dose Administered |
|----------------------------------|---|----------------|---|
| Single full dose <i>vAh</i> | virulent <i>A. hydrophila</i> | 100 mL | 2.3×10^7 CFU mL ⁻¹ |
| Single half does <i>vAh</i> | virulent <i>A. hydrophila</i> | 50 mL | 1.1×10^7 CFU mL ⁻¹ |
| Single full dose <i>F. covae</i> | <i>F. covae</i> | 100 mL | 5.2×10^7 CFU mL ⁻¹ |
| Single half does <i>F. covae</i> | <i>F. covae</i> | 50 mL | 2.6×10^7 CFU mL ⁻¹ |
| Full dose coinfection | virulent <i>A. hydrophila</i> ; <i>F. covae</i> | 100 mL; 100 mL | 2.3×10^7 CFU mL ⁻¹ ; 5.2×10^7 CFU mL ⁻¹ |
| Half dose coinfection | virulent <i>A. hydrophila</i> ; <i>F. covae</i> | 50 mL; 50 mL | 1.1×10^7 CFU mL ⁻¹ ; 2.6×10^7 CFU mL ⁻¹ |
| Controls | Phosphate-buffered saline | 100 mL | NA |

2108
 2109
 2110
 2111
 2112
 2113
 2114
 2115
 2116
 2117
 2118
 2119
 2120


2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133

Figures




2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144

Figure 11. Graphic demonstrating experimental design to assess full and half doses of single and coinfective treatment groups.




2145
 2146 Figure 12. Cumulative percent mortality due to single infections of virulent *Aeromonas*
 2147 *hydrophila* and *Flavobacterium covae* and coinfections from both pathogens throughout
 2148 the trial (96 h). Each treatment group had three tanks (n=3). Bars represent the standard
 2149 error of the mean for each day.

2150
 2151
 2152
 2153
 2154
 2155
 2156
 2157
 2158
 2159
 2160




2161
 2162 Figure 13. Lysozyme activity (mg mL^{-1}) in sera from sampled fish at 6, 12, 24, 48, and 96
 2163 hours post-challenge. Each treatment group was analyzed in triplicate ($n=3$). Capital
 2164 letters indicate significant differences in activity between treatment time periods (6, 12,
 2165 24, 48, 96 hpc), and lowercase letters represent significance within treatment groups.
 2166 Coinfected groups at 48 and 96 hpc are not included due to no surviving fish. Error bars
 2167 represent the standard error of the mean for each treatment group.
 2168
 2169
 2170
 2171
 2172
 2173
 2174
 2175
 2176
 2177



2178
 2179
 2180
 2181
 2182
 2183
 2184
 2185
 2186
 2187
 2188
 2189
 2190
 2191
 2192
 2193
 2194
 2195
 2196
 2197
 2198
 2199
 2200
 2201
 2202
 2203
 2204
 2205
 2206
 2207

Figure 14. *il1b* expression (fold-change) was quantified from RNA extractions of anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment.

2208



2209

2210

2211

2212

2213

2214

2215

2216

2217

2218

2219

2220

2221

2222

2223

2224

2225

2226

2227

2228

2229

2230

2231

2232

2233

2234


2235

2236

2237

Figure 15. *il8* expression (fold-change) was quantified from RNA extractions of anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment.


2238
2239



2240
2241
2242
2243
2244
2245
2246
2247
2248
2249
2250
2251
2252
2253
2254
2255
2256
2257
2258
2259
2260
2261
2262
2263
2264
2265
2266
2267

Figure 16. *tnfa* expression (fold-change) was quantified from RNA from anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment.

2268
2269



2270
2271
2272
2273
2274
2275
2276
2277
2278
2279
2280
2281
2282
2283
2284
2285
2286
2287
2288
2289
2290
2291
2292
2293
2294
2295
2296
2297


Figure 17. *tgfb* expression (fold-change) was quantified from RNA from anterior kidneys at 6, 12, 24, 48, and 96 hpc. Each treatment group was analyzed in triplicate (n=3). Capital letters indicate significant differences in quantity between treatment time periods, and lowercase letters represent significance within treatment groups. Bars represent the standard error of the mean for each treatment.

2298
2299



2300
2301
2302
2303
2304
2305
2306
2307

Figure 18. Images document catfish with clinical signs due to singly infected vAh: ocular hemorrhaging and hemorrhaging of all fins (A) and *F. covae*; skin discoloration, frayed fins, and damaged operculum (B).




2308
2309
2310
2311
2312
2313
2314
2315

Figure 19. Images documenting catfish with clinical signs due to coinfection with *F. covae* and vAh during early-stage infection (12 hpc). Image (A) depicts discoloration of deceased fish (saddleback lesion), and (B) depicts mild and external hemorrhaging in fins and operculum.



2316
2317
2318
2319
2320
2321
2322
2323
2324
2325
2326
2327
2328
2329
2330
2331
2332
2333
2334
2335
2336
2337
2338
2339
2340
2341
2342
2343

Figure 20. Images documenting catfish with clinical signs due to coinfection with *F. covae* and vAh during later-stage infection (36 hpc).



2344
2345

2346 Figure 21. The bacterial load (log copy number) of treatment groups challenged with *F.*
2347 *covae* (ALG-00-530) and *vAh* (ML09-119). The log of the copy number corresponds to 5
2348 ng of input DNA for each sample. Each treatment group was analyzed in triplicate (n=3).
2349 Capital letters indicate significant differences in quantity between treatment time periods,
2350 and lowercase letters represent significance within treatment groups. Bars represent the
2351 standard error of the mean for each treatment.

2352
2353
2354
2355
2356
2357
2358
2359
2360
2361
2362
2363
2364
2365
2366
2367
2368
2369
2370
2371
2372
2373

2374
2375
2376

Chapter 5:

Future Coinfection Research in Catfish

2377
2378

2379 5.1 Future Research

2380

2381 Future research is crucial in solving and avoiding the devastating impacts
2382 coinfections can create. These trials may be repeated with higher replication or pathogen
2383 variants to provide more insight. Higher replication will confirm observed trends by
2384 demonstrating more significant differences. Each treatment group only had three
2385 replicates, while typically immersion trials have at least five replicates. Observing
2386 significant differences with just the three replicates indicates a high effect coinfections
2387 have on mortality, and higher replicates will not only confirm this, but provide the ground
2388 work needed to bring light and urgency to the coinfection crisis. The trial design could
2389 also be modified to investigate how portals of entry impact the severity of infection. It is
2390 known some pathogens (*F. covae*, *Bolbophorus spp.*, *Henneguya ictaluri*) can cause
2391 lesions whether that be externally or through the gills. These exposures can allow other
2392 opportunistic pathogens to enter the host directly potentially causing more severe
2393 mortality and clinical effects. By modifying trial designs to investigate other coinfections,
2394 we broaden the scope and begin to truly unravel coinfection dynamics between not only
2395 bacterial pathogens but parasitic ones as well.

2396 A critical step to solidify and prove the deadly impact coinfections cause is
2397 evaluating coinfections in production settings to see if the same effects documented
2398 during these experimental trials still exist. Pond trials play a critical role in applying data
2399 observed in these laboratory trials to production ponds. Farmers must see the true effects
2400 of coinfections and be presented with possible solutions. Once this dynamic has been
2401 thoroughly assessed, testing antimicrobial treatments under experimental settings must be

2402 conducted to test if single infection treatment methods are just as efficacious during
2403 coinfections. This would deliver the last piece of the coinfection puzzle by providing
2404 evidence of its impact and a solution for how best to mitigate it.

2405

2406 5.2 Conclusion

2407

2408 Bacterial coinfections in channel catfish between *vAh*, *E. ictaluri*, and *F. covae*
2409 have, until now, never been assessed. Coinfections are a plague within multiple
2410 aquaculture industries, but so little is known about their infection mechanics and how the
2411 infection is to be mitigated. Bacterial diseases cause tremendous economic losses. Within
2412 the catfish industry, losses are typically associated with single pathogens and do not take
2413 into account losses due to coinfections. This leaves researchers scrambling to understand
2414 the true prevalence and interactions between pathogens during coinfections. The need for
2415 this information is crucial; with it, treatments may be more effective and efficient. At this
2416 moment, no current antibiotic treatments deemed successful to treat single pathogens
2417 have been evaluated during coinfections. However, before treatments can be assessed,
2418 infection dynamics must be evaluated. This thesis aimed to begin assessing these
2419 bacterial coinfections in channel catfish to provide evidence of the potentially deadly
2420 impact they pose in production and to stress the need for treatment evaluations.

2421 To do this, closer looks at mortality rates, innate and adaptive immune attributes,
2422 and bacterial interactions will provide a clear explanation as to what exactly is causing
2423 these investigated parameters to be augmented. Evaluating mortality between coinfecting
2424 treatments and single-exposed treatments would demonstrate the severity of coinfections.

2425 Further use of transcriptomics to map immune attributes may also be able to answer
2426 whether each coinfection causes synergistic or antagonistic effects. Understanding if the
2427 pathogens inhibit one another or work together to obtain host resources allows
2428 researchers to recognize potential pathways that could be modified to mitigate each
2429 pathogens effects. All trials documented herein demonstrated that coinfections augment
2430 mortality and the innate immune response was upregulated during days where the most
2431 mortality was occurring; however, this is the tip of the iceberg when fully understanding
2432 coinfections in production systems and should act as the foundation of future studies.